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1 Abstract 
L-Glutamate is the predominant excitatory neurotransmitter in the mammalian central 
nervous system (CNS) and involved in most physiological processes in the brain 
(106-109). Excitatory amino acid transporters (EAATs) remove glutamate from the 
synaptic cleft into neuronal and glial cells (58) and maintain low extracellular 
glutamate concentrations to prevent glutamate excitotoxicity (8, 182, 183). EAATs 
encompass eight transmembrane domains (TM) and assemble as functional trimers 
(50). Apart from functioning as secondary-active glutamate transporters, EAATs 
mediate a channel-like anion conductance (13-22, 138). Five different mammalian 
EAAT isoforms have been identified (13, 16, 136). Whereas EAAT1 and EAAT2 are 
mainly expressed in glia, EAAT3, EAAT4 and EAAT5 are neuronal glutamate 
transporters. Despite a different localization, EAAT isoforms vary in the ratio of 
transport to anion currents and are thus expected either to function primarily as 
glutamate transporters or as anion channels (16, 21, 158). 
The aspect of trimerization and the EAAT-subtype specific variations pose the 
question if certain EAAT isoforms can form heterooligomers and if hetero-
multimerization has functional consequences. Hetero-oligomerization was examined 
by studying different EAAT isoforms by using biochemical, electrophysiological and 
confocal approaches. Solely the neuronal glutamate transporters EAAT3 and EAAT4, 
but neither the glial transporters EAAT1 and EAAT2, nor EAAT2 and EAAT3, or 
EAAT2 and EAAT4 co-assemble into stable heterotrimers. Hetero-oligomerization of 
EAAT3 and EAAT4 does not affect amino acid transport or EAAT-mediated anion 
conductance, but alters epithelial sorting. In EAAT3/EAAT4 heterotrimers EAAT4 
guides EAAT3, which occupies a unique sorting signal for apical membranes, as well 
to basolateral membranes. Hetero-trimerization could alter the cellular distribution of 
transporter subtypes with a different affinity-capacitance ratio which might have a 
biological significance by tight regulation of the external glutamate concentration and 
neuronal excitability. 
Whereas the EAAT transport function and its physiological importance are well 
understood, it is less known about the molecular basis of the pore-mediated anion 
conduction and the physiological impact. EAAT anion currents have been postulated 
to be involved in the regulation of cell excitability, and are thought to be conducted 
through an anion pathway that is opened and closed in response to conformational 
changes underlying glutamate transport. A point mutation neutralizing a conserved 
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aspartate at the intracellular loop of transmembrane domain 2 (TM2) was shown to 
exert effects on both transporter properties, glutamate transport and anion channel 
function, in EAAT1 and EAAT4 (158, 160).  The interdependence of transporter and 
anion channel function was analyzed by studying the effects of the homologue point 
mutation D83A on EAAT3-associated conformational changes by the technique of 
voltage clamp fluorometry (VCF) in combination with kinetic simulations. Beside an 
enlargement of EAAT3 anion currents, a reduction of glutamate-activated anion 
currents, and coupled transport, D83A modifies the time, substrate, and voltage 
dependence of EAAT3 conformational changes by alterations of the substrate 
translocation. The direct effects of D83A on the EAAT3 transport cycle result in 
changed anion channel function which highlights the intimate interaction of the dual 
functions of EAAT glutamate transporters. 
As glutamate by itself is involved in most normal and abnormal brain activities, EAAT 
dysfunctions and resulting high external glutamate concentrations are correlated with 
diverse neurological diseases and abnormal brain activity. It was shown that a rare 
human genetic disease characterized by paroxysmal cerebellar incoordination, 
episodic ataxia type six (EA6), is caused by mutations in SLC1A3. One mutation in 
SLC1A3 - the gene encoding the glial glutamate transporter EAAT1 - predicts the 
substitution of the conserved proline 290 in the hinge of transmembrane domain 5 
(TM5) by arginine (97). With the objective to clarify the pathomechanism underlying 
EA6, the homologue mutation P259R and the effects on EAAT3-associated currents 
and conformational changes were analyzed by using electrophysiological 
approaches, VCF and kinetic simulations. P259R EAAT3 exhibits increased anion 
currents, strongly reduced uptake currents and furthermore altered sodium-
dependent conformational changes. Disturbed Na+-association represents the 
molecular basis of transporter dysfunction in episodic ataxia type 6. 
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2 Zusammenfassung 
Die Aminosäure L-Glutamat ist der vorherrschende exzitatorische Neurotransmitter 
im Zentralen Nervensystem von Säugetieren (ZNS) und beeinflusst die meisten  
physiologischen Prozesse im Gehirn (106-109). Exzitatorische 
Aminosäuretransporter (Excitatory amino acid transporters, EAATs) sind für die 
Aufnahme von Glutamat aus dem synaptischen Spalt in Neuronen und Gliazellen 
zuständig (58) und verhindern die exzitotoxische Wirkung von Glutamat durch die 
Aufrechterhaltung niedriger extrazellulärer Glutamatkonzentrationen (8, 182, 183). 
EAATs umfassen acht Transmembrandomänen (TM) und setzten sich zu 
funktionellen Trimeren zusammen (50). Neben der sekundär-aktiven 
Glutamattransportfunktion vermitteln EAATs eine kanalähnliche Anionenleitfähigkeit 
(13-22, 138). Es wurden fünf unterschiedliche Säugetier-EAATs identifiziert (13, 16, 
136). Während EAAT1 und EAAT2 hauptsächlich in Gliazellen exprimiert sind, sind 
EAAT3, EAAT4 und EAAT5 neuronale Glutamattransporter. Neben der 
unterschiedlichen Lokalisierung, variieren verschiedene EAAT-Isoformen in dem 
Verhältnis von Transport- zu Anionenstrom (16, 21, 158). Daher wird angenommen, 
dass EAATs entweder hauptsächlich als Glutamattransporter oder als Anionenkanäle 
wirken.  
Durch den Aspekt der Trimerisierung und der Variation der subtypspezifischen 
Eigenschaften entsteht die Frage, ob verschiedene EAAT-Isoformen 
Heterooligomere bilden können und ob eine Heterooligomerisierung funktionelle 
Auswirkungen hat. Die Heterooligomerisierung wurde an verschiedenen EAAT-
Isoformen mit Hilfe von biochemischen, elektrophysiologischen Techniken und 
Konfokalmikroskopie untersucht. Lediglich die neuronalen Glutamattransporter 
EAAT3 und EAAT4 bilden stabile funktionelle Heterotrimere, jedoch nicht die 
Glutamattransporter der Gliazellen, EAAT1 und EAAT2, noch EAAT2 und EAAT3 
oder EAAT2 und EAAT4. Die Heterooligomerisierung hat keinen Einfluss auf den 
Aminosäuretransport oder die EAAT-vermittelte Anionenleitfähigkeit, verändert 
allerdings die Anreicherung der Transporter in apikale oder basolaterale Membranen. 
In EAAT3/EAAT4-Heterotrimeren leitet EAAT4 den Glutamattransporter EAAT3, der 
ein einzigartiges Signal für die Anreicherung in apikale Membranen besitzt, auch in 
basolaterale Membranen. Die Heterotrimerisierung kann die zelluläre Verteilung von 
Transportersubtypen mit unterschiedlichen Affinitäts-Leitfähigkeits-Verhältnissen 
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ändern und damit eventuell eine stärkere Regulation der externen 
Glutamatkonzentration und der Zellerregbarkeit ermöglichen.  
Während die Transportfunktion der Exzitatorischen Aminosäuretransporter und deren 
physiologische Bedeutung gut verstanden sind, ist weniger über die molekulare 
Grundlage der porenvermittelten Anionenleitfähigkeit und deren physiologischer 
Bedeutung bekannt. Es wurde postuliert, dass EAAT-Anionenströme durch einen 
Anionenweg, der sich in Erwiderung auf Konformationsänderungen während des 
Glutamattransportes öffnet und schliesst, vermittelt werden. Diese 
Anionenleitfähigkeit ist eventuell in die Regulierung der zellulären Erregbarkeit 
involviert. Es wurde gezeigt, dass eine Punktmutation in EAAT1 und EAAT4, die 
einen konservierten Aspartatrest im intrazellulären Bereich der 
Transmembrandomäne 2 (TM2) neutralisiert, Auswirkungen auf beide 
Transportereigenschaften hat, den Glutamattransport sowie die Anionenleitfähigkeit 
(158, 160). Anhand der Auswirkungen der homologen Mutation D83A auf EAAT3-
assoziierte Konformationsänderungen, wurde das Zusammenwirken der Transport- 
und Anionkanal-Eigenschaft mit Hilfe der Technik der Spannungsklemmfluorometrie 
(voltage clamp fluorometry, VCF) in Kombination mit kinetischen Simulationen 
untersucht. Neben der Vergrösserung der EAAT3-Anionenströme, einer Reduktion 
der glutamataktivierten Anionenströme und des gekoppelten Transportes, verändert 
die Mutation D83A die Zeit-, Substrat- und Spannungsabhängigkeit der 
Konformationsänderungen in EAAT3 durch Änderungen der Substrat-Translokation. 
Der direkte Effekt der Punktmutation D83A auf den Transportzyklus führt zu einer 
veränderten Anionkanal-Funktion, was die enge Interaktion der dualen Funktionen 
der EAAT Glutamattransporter aufzeigt. 
Da Glutamat in die meisten normalen und abnormalen Gehirnaktivitäten involviert ist, 
stehen Fehlfunktionen Exzitatorischer Aminosäuretransporter und daraus 
resultierende hohe extrazelluläre Glutamatkonzentrationen mit einer Reihe 
neurologischer Erkrankungen und abnormer Gehirnaktivität in Zusammenhang. 
Episodische Ataxie Typ 6 (EA6) ist eine seltene genetische Erkrankung, 
charakterisiert durch paroxysmale cerebrale Koordinationsstörungen. Es wurde 
gezeigt, dass EA6 durch Mutationen in SLC1A3, dem Gen das den 
Glutamattransporter EAAT1 der Gliazellen kodiert, verursacht wird. Eine dieser 
Mutationen in SLC1A3 sagt einen Aminosäureaustausch eines konservierten Prolins 
an Position 290 im Knick der Transmembrandomäne 5 (TM5) gegen Arginin voraus 
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(97). Mit dem Ziel den der EA6 zugrundeliegenden Pathomechanismus aufzuklären, 
wurde die homologe Mutation P259R und deren Auswirkungen auf EAAT3-
assoziierte Ströme und Konformationsänderungen mittels elektrophysiologischer 
Methoden, VCF und kinetischen Simulationen untersucht. Die Mutation P259R in 
EAAT3, zeigt erhöhte Anionenströme, stark reduzierte Glutamataufnahmeströme und 
darüber hinaus veränderte natriumabhängige Konformationsänderungen. Eine 
veränderte Natriumassoziation stellt die molekulare Grundlage der 
Transporterfehlfunktion in der Erkrankung der Episodischen Ataxie Typ 6 dar. 
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3 Introduction 
3.1 Membrane Transport 
Biomembranes delimit the cytoplasm of every living cell from the extracellular 
surrounding or define enclosed compartments within a cell. Mainly, biomembranes 
consist of a lipid bilayer with embedded proteins. Biomembranes inherit several 
important functions like, cellular organization, cell-cell recognition, they have 
mechanical and elastic properties, but probably the most important feature is the 
selective permeability. Depending on the size and charge of ions and molecules the 
exchange across biomembranes is accomplished by different transport mechanisms. 
Small lipophilic molecules, e.g. CO2, O2, alcohol and urea pass the lipid bilayer via 
simple diffusion (Figure 3.1). In contrast, the transport of macromolecules, like 
proteins or polysaccharides and even other smaller cells is mediated by membrane 
transferring processes like endo-, exo- and transcytosis. The transport of ions and 
small hydrophilic molecules, like sugars, nucleotides and amino acids is enabled by 
membrane embedded proteins via passive or active transport mechanisms.  
The passive transport of solute molecules along their electrochemical gradient can 
be conducted by carriers or channels (Figure 3.1). During the passive transport by 
carriers molecules binding from the intra- or extracellular side, induce a 
conformational change which enables the passage across the membrane. Equally to 
carriers, channels are accessible from both sides of the plasma membrane and 
alleviate the movement of ions along their electrochemical gradient when the channel 
is open. Some channels possess a “gate” which opens and closes upon external 
stimuli, like chemical or electrical signals, temperature and mechanical forces. 
Transport by ion channels exhibits no fixed stoichiometry. The number of transported 
ions depends on the channel open time (1). 
Active transport mechanisms across membranes can be divided into primary- and 
secondary-active transport (Figure 3.1). In contrast to the passive transport, active 
transport necessitates diverse energy-coupling mechanisms to carry substrates 
against an electrochemical gradient. During primary-active transport energy provided 
by the hydrolysis of high-energy compounds, redox reactions or light absorption is 
directly used to pump protons and anorganic ions against their concentration gradient 
and by this generating and maintaining electrochemical ion gradients. Most common 
primary-active mechanisms are directly coupled to the binding and hydrolysis of 
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adenosine triphosphate (ATP). Secondary-active transport involves using energy to 
establish a gradient across the cell membrane, and then utilizing that gradient to 
transport a second molecule of interest up its concentration gradient, either in the 
same direction (symport) or in the opposite direction (antiport or exchange). 
 
Figure 3.1 
Membrane Transport 
 
 
 
Figure 3.1: Membrane Transport. 
Different passive and active transport mechanisms across biomembranes, as depicted in the figure. 
 
 
In summary, transporters facilitate the movement of a specific substrate, either with 
or against its concentration gradient. It is generally believed that a conformational 
change of the transporter protein is important in this transfer process. Many of these 
transporters belong to the solute-carrier (SLC) gene superfamily, including passive 
transporters, symporters and antiporters, as well as mitochondrial and vesicular 
transporters.     
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3.2 The solute-carrier 1 (SLC1) Family 
The solute-carrier (SLC) gene superfamily includes currently 362 putative functional 
protein-coding genes and is organized into 55 different families (2). Members of the 
same SLC gene family share at least 20-25 % amino acid sequence identity. 
The SLC1 family includes seven eukaryotic members, five high-affinity excitatory 
amino acid transporters (EAAT: EAAT3 (EAAC1), EAAT2 (GLT1), EAAT1 (GLAST), 
EAAT4 and EAAT5 (SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7,)) and two 
neutral amino acid transporters (ASCT1, 2 (SLC1A4, SLC1A5)) and a large number 
of bacterial amino acid and dicarboxylic acid transporters (3, 4, 5). 
The  five  high-affinity  glutamate  transporter  subtypes  share  50-60%  amino  acid  
sequence  identity  with  each  other,  30-40%  identity  with  the  neutral  amino  acid  
transporters (6),  and  around  20-30%  identity  with  bacterial  glutamate 
transporters  (7).  Between mammalian members of the glutamate transporters, the 
five isoforms are about 90% identical to the equivalent proteins of another species 
(8).  
All excitatory amino acid transporters use L-glutamate and L-aspartate as high-
affinity substrates. The high-affinity substrates for neutral amino acid transporters are 
mainly alanine, serine, cysteine and threonine, to a minor extent glutamine and 
asparagine and with a lower affinity several other amino acids (6, 9-12). Both the 
eukaryotic excitatory amino acid transporters and the neutral amino acid 
transporters, exhibit thermodynamically uncoupled ion fluxes, as substrate-
independent cation leaks and substrate-dependent chloride currents (13-22). As 
described for other neurotransmitter transporters of the SLC6 family, which 
encompasses the Na+/Cl--dependent transporters for dopamine, 5-hydroxytryptamine 
(serotonin), noradrenaline, GABA and glycine (139-147), these transporters are dual 
functional proteins which invalidates the strict distinction of channels and 
transporters. 
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3.2.1 Excitatory Amino Acid Transporters (EAATs) 
Excitatory amino acid transporters (EAATs) execute diverse cellular functions in the 
central nervous system, in sensory organs as well as in the kidney (8). EAATs are 
trimeric integral membrane proteins (50) which remove synaptically released 
glutamate from the extracellular space to ensure low resting glutamate levels and to 
prevent glutamate excitotoxicity and cell death (8, 182, 183) in the CNS. Five 
different mammalian EAAT isoforms have been identified (13, 16, 136). Glutamate 
transport by human excitatory amino acid transporters (hEAATs) is a secondary-
active transport mechanism, in which glutamate transport is coupled to the co-
transport of three sodium ions, one proton and to the counter-transport of one 
potassium ion (137). Apart from functioning as secondary-active glutamate 
transporters, EAATs mediate a less understood channel-like anion conductance (13-
22, 138).  
 
 
3.2.1.1 L-Glutamate - A neurotoxic neurotransmitter 
The amino acid L-glutamate is the predominant excitatory neurotransmitter in the 
mammalian CNS. It is involved in almost all normal brain activities, like cognition, 
memory and learning (106-109). Glutamate participates also in several aspects of the 
CNS development, e.g. in regulation of development by glutamatergic signaling (110-
114), in neuronal migration (115), in synapse elimination (116), in long-term 
potentiation and in synapse induction (117-119). Over- (112) as well as the 
understimulation (120, 121) of glutamate receptors is harmful to the developing brain. 
Glutamate acts via glutamate receptors, and most neurons and glial cells express 
glutamate receptors in their plasma membranes (127-132), but glutamate plays as 
well a signalling role in peripheral organs and tissues, like the heart (122), intestine 
(123,124), liver, kidney (123) and in endocrine cells (125, 126). For example, in 
pancreatic islets of Langerhans, glutamate is proposed to act as an intracellular 
messenger, regulating insulin secretion from β-cells (186). In pinealocytes glutamate 
was suggested to participate as chemical transmitter in a receptor mediated manner 
in melatonin synthesis (125). 
In contrast to other excitatory neurotransmitters, glutamate concentrations in the 
CNS are quite high, reaching 5-10 mmol/kg (133), whereas the concentration in the 
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extracellular solution is about 3-4 µM (134), thus creating a concentration gradient 
across the membrane of several thousands. Glutamate receptor activation requires 
just 1-10 µM glutamate; higher levels (10-100 µM) are neurotoxic (135) by glutamate 
receptor overstimulation and subsequent increased Na+- and especially Ca2+-influx 
which leads to Ca2+-dependent toxicity. Ca2+ is one of the most important secondary 
messengers and its intracellular concentration has to be tightly regulated. Calcium is 
involved in several cellular processes, e.g.: cell proliferation, gene expression, 
energy metabolism and apoptosis. Calcium-influx results in increased concentrations 
of intracellular free radicals, cytoskeletal breakdown and DNA degradation via 
activation of phospholipases, Ca2+-binding proteins, proteases and endonucleases. 
High intracellular calcium concentrations furthermore lead to mitochondrial damage, 
ATP-downregulation and to a low intracellular pH. 
Maintaining a low extracellular glutamate concentration is not just important to 
prevent the effect of excitotoxicity. It is obligatory for an effective and tight regulated 
synaptic communication on glutamatergic synapses. Furthermore, re-uptake provides 
glutamate for metabolic processes or neurotransmitter re-use. 
Synaptic release of glutamate activates ionotropic glutamate receptors as AMPA- , 
NMDA receptors and metabotropic glutamate receptors (mGluR) (Figure 3.2). Excess 
glutamate in the synaptic cleft is taken up into postsynaptic nerve terminals by the 
excitatory amino acid transporters EAAT3 and EAAT4 and into glial cells by the 
EAAT1 and EAAT2. In glial cells glutamate can be converted to glutamine by the 
glutamine synthetase (Gln). In presynaptic nerve terminals glutamine can be 
reconverted into glutamate which is transported into synaptic vesicles by a vesicular 
glutamate transporter (VGLUT) and subsequently released by exocytosis. Glutamine 
may not solely serve as a neurotransmitter precurser in the glutamine-glutamate 
cycle, but may also serve as a nutrient for neurons. Furthermore, glutamate is used 
by system Xc
- exchanging it against cystine, providing cysteine as precurser for 
glutathione. Beside excitotoxicity by glutamate receptor overstimulation, high external 
glutamate can cause cell death by blocking system Xc
- which subsequently leads to 
depletion of the antioxidant glutathione. 
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Figure 3.2 
Glutamate transporter isoforms and glutamate recirculation at an excitatory 
synapse  
 
 
Figure 3.2: Glutamate transporter isoforms and glutamate recirculation at an excitatory 
synapse. 
Synaptic release of glutamate activates ionotropic (AMPAR, NMDAR) and metabotropic glutamate 
receptors (mGluR). Glutamate in the synaptic cleft is taken up into postsynaptic nerve terminals and 
into glial cells by the excitatory amino acid transporters, EAAT3, EAAT4 and EAAT1 and EAAT2, 
respectively. In glial cells glutamate can be converted to glutamine by the glutamine (Gln) synthetase. 
In presynaptic nerve terminals glutamine is reconverted into glutamate by Glutaminase, transported 
into synaptic vesicles by a vesicular glutamate transporter (VGLUT) and released by exocytosis. 
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3.2.1.2 Localization and physiological function of EAATs in the CNS 
Five major EAAT subtypes (EAAT1-5) have been identified. EAAT subtypes differ in 
their functional characteristics and possess distinct localizations on a cellular and 
regional level. They can be roughly divided by their localization into glial and 
neuronal glutamate transporters.  
EAAT1 (GLAST) and EAAT2 (GLT-1) are primary expressed in glia cells and 
therefore considered to be glial glutamate transporters, although EAAT2 has been  
found as well in neurons and oligodendrocytes (23-25) and on presynaptic nerve 
terminals (26-27). Most synapses in the central nervous system are in close proximity 
to glia cells and glial glutamate transporters are predominantly responsible for 
glutamate clearance from the synaptic cleft. EAAT1 displays highest expression 
levels in cerebellum and lower levels in cortex and spinal cord (28-31). EAAT2 is 
highly expressed throughout the brain and spinal cord, and is responsible for > 90% 
of the total glutamate uptake (28-30).  
Besides preventing glutamate excitotoxicity, glutamate re-uptake by glial transporters 
returns glutamate to metabolic processes as the glutamate-glutamine cycle. Via 
activation of the Na+ /K+-ATPase and glucose transporters, and changes in the levels 
of ATP and lactate they also signal the energy needs of nearby neurons (32). 
Neuronal glutamate transporters, EAAT3 (EAAC1), EAAT4 (SLC1A6) (16, 33) and 
EAAT5 (SLC1A7) appear to have more specialized roles. EAAT3 is expressed at 
postsynaptic nerve terminals throughout the brain, particularly in cortex, 
hippocampus, cerebellum and basal ganglia (28, 29, 30, 33), but has like EAAT4 also 
been detected in astrocytes (34-36). EAAT4 is almost exclusively localized in soma 
and dendrites of GABAergic Purkinje cells of the cerebellum and with much lower 
expression levels in hippocampus, neocortex and other CNS regions (16, 30, 33, 37). 
EAAT5 (SLC1A7) is mainly present in rod photoreceptor and bipolar cells of the 
retina (13, 38). Weak expression levels of EAAT5 were detected furthermore in the 
liver, the heart, in muscles, and in brain tissue (13). 
Neuronal glutamate transporters assume greater significance in the selective 
modulation of glutamate signalling at particular glutamate receptors at synapses, 
especially in the cerebellum, where many peri- or extrasynaptic glutamate receptors 
are present (39). For example, signalling at metabotropic glutamate receptors 
(mGluR) on cerebellar Purkinje neurons is limited by glutamate uptake (40). At 
parallel fibre and climbing fibre synapses on Purkinje neurons, EAATs limit mGluR 
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responses under resting conditions (41). Inhibition of neuronal EAATs in the 
cerebellum facilitates mGluR-mediated long-term depression (42). Since EAAT4 
anion conductance exceeds its glutamate uptake capability, this transporter isoform 
may constitute an important regulator of neuronal excitability of neurons, 
counteracting the depolarization of neurons brought on by the postsynaptic glutamate 
receptor activation (16). 
 
 
3.2.1.3 EAAT structure and transport mechanism 
Beside biochemical and electrophysiological studies on glutamate transporters 
several crystallographic studies on a bacterial glutamate transporter homologue, 
GltPh from Pyrococcus horikoshii, deliver insights into the structure and structure-
function relationship of these transporters. GltPh shares as much as 36% amino acid 
sequence identity with the eukaryotic EAATs and exhibits even more identity in 
functional important regions (43-49) and is thus a good model for the eukaryotic 
glutamate transporter structure. 
 
3.2.1.3.1 A bacterial transporter homologue - GltPh, a model for EAAT 
structure  
Glutamate transporters are trimeric integral membrane proteins (Figure 3.3B). The 
trimer forms a bowl-shaped structure with a concave solvent-filled basin accessible 
from the extracellular solution and a peaked base directed towards the cytoplasm 
(50). The basin is 50 Å broad in diameter and 30 Å deep. The aqueous basin with its 
hydrophilic surface extends halfway across the membrane bilayer and by this allows 
aqueous, bulk solution and solutes to reach the middle of the membrane. 
Each protomer consists of eight primarily -helical transmembrane domains (TMs 1-
8) and two helical hairpins (HPs 1-2) (Figure 3.3A) (50). One protomer possesses a 
cylinder-like structure (Figure 3.3C-E). The open ends of three cylinders of a trimer 
define the outer border of the basin, whereas the cylinder tips form the bottom of the 
bowl-shaped structure, reaching the intracellular solution. 
The N-terminal part of the protein consists of the transmembrane domains TM1-6. 
The C-terminal part of the protein is buried within the N-terminal cylinder-shape and 
encompasses TM7, TM8, HP1 and HP2. 
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Figure 3.3 
Membrane topology and crystal structures of a bacterial transporter 
homologue 
 
Figure 3.3: Membrane topology and crystal structures of a bacterial transporter homologue. 
A, Membrane topology model of EAATs, deduced from crystallographic data of a bacterial transporter 
homologue from Pyrococcus horikoshii, GltPh. B-F, Ribbon representation of the trimer viewed from the 
extracellular side (B) or of the protomer viewed in the plane of the membrane in the outward facing 
open (C) (pdb-file: 2NWW), in the outward facing occluded (D) (pdb-file: 2NWX), in the inward facing 
occluded (E) (pdb-file: 3KBC) and in an intermediate state (F) (pdb-file: 3V8G) shown from the 
intracellular side with the residues S65, S74 and Y195 (light blue) flanking a proposed anion channel. 
The trimerization domain is shown in fuchsia, the transport domain in grey and the hairpins in black. 
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Early studies roughly subdivided glutamate transporters into two functional 
compartments - the N-terminal and C-terminal part - as to be responsible for 
intersubunit interactions and for substrate transport, respectively. The helical HP1 
and HP2 are composed of helix-turn-helix motifs and represent structural key 
elements of glutamate transporters (50). Whereas HP1 is buried within the N-terminal 
cylinder, beginning on the cytoplasmic surface and reaching up to the bottom of the 
extracellular basin, HP2 is mostly solvent-exposed and faces the extracellular basin. 
Following crystallographic studies revealed that the aspartate binding site (substrate 
homologue transported by GltPh instead of glutamate in eukaryotic glutamate 
transporters) is formed by the tips of HP1 and HP2, the unwound region of TM7 and 
polar residues of the amphipathic TM8 (51). The substrate binding site is thus buried 
within a polar pocket located halfway across the membrane.  GltPh’s sodium binding 
sites could be identified to be close to the aspartate binding pocket. Site 1 is 
coordinated by three carbonyl oxygens in TM7 and TM8, a carboxyl group of D405 in 
TM8 and possibly by hydroxyl oxygen of S278 in HP1 (51). The sodium site 2 is 
coordinated by carbonyl oxygens of TM7 and HP2.   
Potassium binding sites of the eukaryotic glutamate transporters are still 
controversial discussed. It was shown that the residues Y403 and E404 in rat EAAT2 
and R447 in EAAC1 are involved (52, 53, 150). The residue E404 is conserved in all 
eukaryotic glutamate transporters, but not in the bacterial or neutral-amino-acid 
transporters, which correlates with the fact that those are K+-independent. 
Furthermore, it could be shown, that HP2 acts as the extracellular gate, either in the 
open state exposing the binding sites to the extracellular solution (outward facing 
open conformation, Figure 3.3C) or in the closed state occluding the binding sites 
(outward facing occluded conformation, Figure 3.3D). HP1 was hypothesized to act 
as the corresponding intracellular gate, which - in a similar manner - by opening and 
closure allows occlusion and exposure of the substrates to the intracellular solution 
(54). A third crystal structure of GltPh, in which the transporter is fixed by cross-
linking, establishes the inward facing occluded conformation (Figure 3.3E) (54). 
The inward facing open conformation has to be proven by crystallographic studies 
and is still hypothetical. Further results suggest that GltPh can be divided into two 
functional compartments, the trimerization domain, consisting of TM1, 2, 4 and TM5 
and the transport domain, consisting of TM3, 6, 7, 8 and the two HPs (54).  
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A recent study reports on an intermediate conformation between the outward and 
inward facing states generated during substrate translocation (Figure 3.3F) (55). This 
intermediate state shows a transient cavity which is bordered by residues of TM2 and 
TM5, flanked by the polar residues S65, S74 and Y195 and supposed to be the 
pathway for the uncoupled anion conductance. Residues of TM2 were shown to 
modulate anion fluxes (158). This last crystallization study might be a starting point to 
understand the channel property of glutamate transporters.   
 
 
3.2.1.3.2 EAATs - Dual functional proteins 
Transporters and ion channels originally have been thought to function distinct and to 
have structurally different determinants. As it has been described for several other 
neurotransmitter transporters, e.g. the Na+/Cl--dependent transporters for dopamine, 
5-hydroxytryptamine (serotonin), noradrenaline, GABA and glycine (139-147), EAATs 
are dual functional proteins, melting the boundary between channels and 
transporters.  
Beside the glutamate uptake function, EAATs mediate a less understood channel-like 
anion conductance (13-22, 138). This uncoupled anion conductance requires sodium 
and glutamate binding to the transporter, but is thermodynamically independent of 
the glutamate transport (14, 16, 20, 21, 138, 149) and is distinct from a glutamate 
independent chloride leak-current (138, 151, 152). The physiological importance of 
the glutamate-dependent anion conductance is less clear than that of glutamate 
uptake. It was suggested that the anion conductance acts as voltage-clamp by 
counteracting the neuronal depolarization upon postsynaptic glutamate receptor 
activation and that it might play an important role in regulation of neuronal excitability 
(16). Neither the exact mechanism nor the structural determinants of this uncoupled 
channel-like anion conductance are defined. Up to date, several models accounting 
for the dual functions of EAATs have been proposed. Mainly, they vary in the 
assumption of a single or a dual pore for glutamate transport and anion flux (19, 21, 
153, 154). There are some mutagenesis studies which indicate rather independent 
structural determinants for both functions than a single glutamate and anion pathway 
(155-157). Recently, TM2 was suggested to form at least a part of the anion pathway 
(158). Since TM2 has a lot of polar residues and positive charges at extra- and 
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intracellular edges and is furthermore accessible for the aqueous solution it is a good 
candidate for an anion pore adjacent transmembrane domain. Mutations in TM2 were 
shown to alter anion conductance without affecting glutamate transport. Furthermore, 
a residue at the edge of TM2 - D112 in EAAT1 (S74 in GltPh, D83 in EAAT3, D117 in 
EAAT4) - can influence glutamate transport as well as anion conduction and may 
form the gate of the chloride channel. That study proposes a single pore with a 
chloride permeation pathway in close proximity to a domain that influences glutamate 
transport and that glutamate binding and/or translocation modifies the anion 
permeation properties of the transporter (158), which is in agreement with several 
other studies (159-162). In EAAT4 the homologue residue D117A  changes  unitary  
anion  current  amplitudes  and  relative  anion  selectivities  (160). The exact role of 
this region (TM2) and of flanking residues still has to be clarified and was analyzed in 
detail on the basis of D83 by voltage clamp fluorometry (VCF) (see section 10).  
Currently, a crystallization study reports on an intermediate conformation of GltPh 
between the outward and inward facing states (55) (see section 3.2.1.3.1, Figure 
3.3F). This intermediate state shows a cavity which is proposed to be the pathway for 
the uncoupled anion conductance and is bordered by residues of TM2 and TM5 and 
flanked by the two polar residues S65 and Y195. Residues of TM2 were shown to 
modulate anion fluxes (158) and S65 was formerly proposed to be involved in anion 
conduction and to be part of the selectivity filter in EAATs (148,158). The residue, 
S74 in GltPh (D83 in EAAT3, D112 in EAAT1 and D117 in EAAT4), earlier studied in 
EAAT1 and EAAT4 and analyzed within this work, exactly resides at the edge of the 
proposed anion cavity (158, 160, 161). 
This structural model could explain the substrate dependence of anion conduction, 
by transient formation of the anion pathway during substrate translocation. 
Furthermore, they hypothesized that intermediate anion states could be reached 
even if translocation to the inward facing states is prevented and by this they explain 
mutations which show abrogation of transport, whereas anion conductance is 
maintained. 
The structural characterization of GltPh gave more and more insights into the 
structure-function relationship and enables to establish a transport scheme for 
glutamate transporters. 
 
 
Introduction 
 
28 
 
3.2.1.3.3 EAAT transport mechanism 
Currently, it is believed that the glutamate transport cycle is composed of 17 
reactions (56, 57) (Figure 3.4A) and structural fulfilled by isomerization between four 
major conformations (54) (Figure 3.4B).  
 
Figure 3.4 
Uptake cycle and transport scheme of glutamate transporters 
 
 
 
Figure 3.4: Uptake cycle and transport scheme of glutamate transporters. 
A, shows a 15-state model of the uptake cycle of eukaryotic glutamate transporters consisting of 17 
reactions (adapted from (57)). B, illustrates a schematic transport mechanism (modified from (54)). 
Shown is a single protomer. The isomerization between the outward and inward facing occluded 
states occurs upon movement of the whole transport domain (grey), relative to the trimerization 
domain (fuchsia). The inward facing open state has not been structurally characterized and is 
hypothetical. 
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The empty transporter resides in an outward facing state, the extracellular gate - HP2 
- is open and the substrate binding sites are exposed to the extracellular space (ToK, 
To). Eukaryotic glutamate uptake is initiated by association of three sodium ions, one 
proton and one glutamate. Association of these substrate causes closure of HP2 
(ToNa1, ToNa2, ToNa2G, ToNa2H, ToNa2GH, ToNa3GH), and the isomerization 
between outward and inward facing conformations which involves a rotation and a 
large piston-like movement of the whole transport domain results in the inward-facing 
occluded conformation (TiNa3GH, TiNa2GH, TiNa2G, TiNa2, TiNa1). Opening of the 
intracellular gate - HP1 - is followed by substrate release and exposure of the binding 
sites to the intracellular solution (Ti, TiK) (54), the inward facing open conformation is 
reached. 
The trimerization domain is fixed in the membrane and acts by this as a 
counterbalance to the movements of the transport domain. The 2-3 loop and the 5-6 
loop connect the corresponding transmembrane domains to the trimerization domain 
and enable the large inward movement. Retranslocation after association of internal 
K+ completes the uptake cycle. 
 
 
3.2.1.4 EAAT involvement in pathogenicity 
A low extracellular glutamate concentration is important to ensure an appropriate 
signal-to-noise ratio and to prevent over-excitation of glutamate receptors and 
resulting cell death, which is known as glutamate excitotoxicity. The neurotoxic effect 
of glutamate was first shown 1957 by Lucas and Newhouse by systemic glutamate 
application which caused retina-degeneration in mice.  
EAATs remove glutamate from the synaptic cleft into neuronal and glial cells (58) and 
by this they exhibit a neuroprotective role. EAAT dysfunctions and resulting high 
external glutamate concentrations are correlated with diverse neurological diseases 
and abnormal brain activity. An increased extracellular glutamate concentration has 
been associated with a wide range of chronic neurodegenerative disorders, e.g. 
amyotrophic lateral sclerosis, Huntington’s and Alzheimer’s disease, multiple 
sclerosis (59-64) and with neuropsychiatric disorders like schizophrenia (65). 
Additionally, glutamate provokes severe damages in acute insults as stroke or 
traumatic injury, ischemia, anoxia end epilepsy (66-72). Glutamate excitotoxicity and 
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oxidative stress have furthermore impact on retinal diseases, e.g. retinal ischemia, 
glaucoma, diabetic retinopathy and age-related macular degeneration (73-75). 
This wide variety of involvement of EAAT dysfunctions in diverse diseases made 
them an attractive target from a therapeutic perspective. Surprisingly, the medicinal 
chemistry attempt in the glutamate field focused almost only on glutamate receptors 
(76-78) while EAATs attract minor attention. A better understanding of glutamate 
transporters, their regulation, expression and structure-function relationship might be 
beneficial in creating new therapies and pharmaceutical products against e.g. 
neurodegenerative diseases. In this work, attention is in particular turned to one 
neurological disorder - episodic ataxia (EA) - which has its seeds in mutations in 
SLC1A3, the gene encoding EAAT1.   
 
3.2.1.4.1 The role of EAAT1 in episodic ataxia  
Episodic ataxias (EAs) are rare autosomal dominant channelopathies that manifest 
as imbalance and paroxysmal cerebellar incoordination associated with additional 
other neurological symptoms, which are mainly cerebellar in origin.  
So far, six episodic ataxia syndromes have been identified, differing in the genetic 
origin and clinical features (79). The genetic origin of EA3 and EA4 is unknown. 
Whereas EA1 (mutated gene: KCNAI, mutant protein: Kv1.1) (80-90), EA2 (mutated 
gene: CACNAIA, mutant protein: Cav2.1) (91-95) and EA5 (mutated gene: CACNB4, 
mutant protein: Cav2.1) (96) are caused by mutations in genes encoding voltage-
gated cation channels, episodic ataxia type 6 is caused by mutations in SLC1A3, the 
gene encoding EAAT1 the major glutamate transporter in cerebellar Bergmann glia 
(97, 98). 
In contrast to the other types of episodic ataxia, EA6 is characterized by long 
duration of attacks, epilepsy and absent myokymia, nystagm, and tinnitus (79). So 
far, EA6 has been reported in two families with two distinct disease-causing SLC1A3 
mutations. One mutation predicts a substitution of cysteine in TM4 by serine (C186S 
EAAT1) (98). File studies of a ten-year-old boy suffering from episodic ataxia type 6 
determined another mutation, on which this work partly focused on, and which 
predicts a substitution of a highly conserved proline by arginine at position 290 in 
EAAT1 (97). Both mutations have been reported to reduce glutamate uptake (97-99). 
Ongoing studies showed that P290R reduces EAAT1 expression levels and surface 
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membrane insertion, diminishes individual glutamate transport rates and increases 
EAAT1-associated anion currents (99). As antisense knockdown of EAAT1 was 
shown to cause excitotoxicity in in-vivo and in-vitro models (100) and EAAT1 deletion 
results in increased susceptibility to seizures and cerebellar injury after traumata 
(101), EAAT1 plays a crucial role in glutamate clearance and reduced glutamate 
uptake by the disease-causing mutation was suggested to contribute to neuronal 
hyperexcitability and seizures, hemiplegia, and episodic ataxia (97). 
The role of the anion conductance in the pathomechanism of EA6 is controversial, 
since hEAAT1 is almost exclusively expressed in Bergmann glia cells in the 
cerebellum which exhibit a negligible anion conductance (102). GABAA-mediated 
excitation is caused by high internal chloride concentrations (103-105). And it was 
suggested that an activated channel property of EAAT1 by P290R and resulting low 
intracellular chloride concentrations might impair GABAergic astrocyte excitation 
(99). EAAT1 anion currents may attenuate GABAA- and GABAB-mediated synaptic 
transmission by stimulating GABA re-uptake by GABA transporters which are 
coupled to Cl- movement (99) and expressed in Bergmann glia. 
The exact mechanism and physiological impact still has to be clarified. To get further 
insights into the molecular pathophysiology of EA6 and to define particular steps on 
the transport cycle affected by this disease-associated mutation, voltage clamp 
fluorometry (VCF) was employed (see section 11).  
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4 Aims of this thesis 
Although several biochemical, electrophysiological and crystallographic studies 
expand the knowledge of glutamate transporters, their localization, physiological 
importance, pathogenicity, structure and their transport mechanism, the details of 
structure-function relationship are still covered.  
Among a minor project dealing with hetero-oligomerization studied by biochemical 
and electrophysiological and confocal approaches, the principal objective was to 
employ the technique of voltage clamp fluorometry (VCF) to analyze EAAT-
associated conformational changes and by this gaining detailed insights into the 
structure-function relationship of human glutamate transporters. The technique of 
VCF enables simultaneous measurements of whole-cell currents and detection of 
fluorescence changes of fluorescently labeled proteins. Thereby fluorophores are 
attached to moving parts of the protein. Since the emission of a fluorophore is 
sensitive to the local environment, a conformational change in response to a 
stimulus, (e.g., a change in membrane potential or changing substrate 
concentrations), resulting in an environmental change of the fluorophore, could be 
either reported as an increase or decrease of the fluorescence signal. Prior VCF-
studies on EAAT3 already revealed several positions for fluorophore attachment and 
demonstrated that the technique is applicable to detect EAAT-associated 
conformational changes during glutamate uptake (163, 164).   
Beside biomolecular, biochemical and electrophysiological approaches, voltage-
dependent conformational changes of hEAATs and altered conformational changes 
of mutant hEAATs heterologously expressed in Xenopus laevis oocytes should be 
analyzed via VCF. Thereby the focus was set primary on two mutations. One 
mutation, D83A in EAAT3, was shown to exert effects on both transporter functions 
and was therefore a good target to investigate the interdependence of transporter 
and anion channel function. Analyzing the conformational changes of P259R EAAT3, 
the homologue mutation shown to cause episodic ataxia type 6 in EAAT1, should 
clarify the disease underlying pathomechanism. 
 
 
 
 
 
 
Discussion 
 
33 
 
5 Discussion 
5.1 Independent-acting subunits in heterotrimers of neuronal 
glutamate transporters EAAT3 and EAAT4  
Different EAAT isoforms can be roughly subdivided by their localization as being 
either glial (EAAT1, EAAT2) or neuronal (EAAT3, EAAT4, EAAT5) glutamate 
transporters. Furthermore, EAAT isoforms vary in the ratio of transport to anion 
currents and are thus expected either to function primarily as glutamate transporter 
or as anion channels (16, 21, 158). As it is already known, functional EAATs 
assemble as trimers and it is interesting if certain EAAT isoforms can form 
heterooligomers and if hetero-multimerization has functional consequences on the 
heterotrimeric assembly. 
To study whether EAAT isoforms assemble into heterotrimeric complexes, different 
EAAT isoforms were co-expressed in mammalian cells, either as YFP fusion protein 
or as a His fusion protein and analyzed by SDS- or BN-PAGE by their different 
molecular masses added by the distinct tags. The glial transporters EAAT1 and 
EAAT2, or EAAT2 and EAAT3, or EAAT2 and EAAT4, do not co-assemble. Solely 
the two neuronal transporters EAAT3 and EAAT4 form heterotrimers (see section 
9.4.1, Figure 9.1).  
As EAAT3 and EAAT4 exhibit different unitary glutamate transport rates (165) and 
display isoform-specific time and voltage dependences of macroscopic anion 
currents (168), heterotrimers of these isoforms provide an excellent possibility to 
study intersubunit interactions. By introducing a mutation which changes the 
substrate sensitivity from glutamate to serine (150, 167), EAAT3- and EAAT4-
currents can be distinguished. Co-expression of EAAT3 and EAAT4 in Xenopus 
laevis oocytes revealed no changes of the apparent dissociation constants for 
glutamate, serine or sodium. Employing expression in mammalian cells and rapid 
application of glutamate with subsequent analysis of the time constants of the 
transport- and anion-associated currents showed no effect by co-expression. 
Individual subunits within heterotrimeric complexes act independently of each other 
(see section 9.4.2 and 9.4.3, Figure 9.2-4). 
EAAT3 is polarized to the apical surface in epithelial cells and localized to 
hippocampal neuronal dendrites by a unique sorting signal (166). Epithelial sorting 
was analyzed by co-expression of fluorescent protein-tagged EAAT3 and EAAT4 in 
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Madin-Darby canine kidney (MDCK) cells, confocal imaging and surface biotinylation. 
Confocal imaging and surface biotinylation revealed an altered epithelial sorting of 
EAAT3/EAAT4-heterotrimers (see section 9.4.4, Figure 9.5 and Figure 9.6). 
Summarizing this, it could be shown that the neuronal glutamate transporters EAAT3 
and EAAT4 co-assemble into stable heterotrimers (see section 9). Hetero-
oligomerization of EAAT3 and EAAT4 has no effects on amino acid transport or on 
EAAT-mediated anion conductance, but alters epithelial sorting. 
The observation of fully independent-acting subunits in terms of substrate transport 
and anion conduction is in agreement with other studies of co-expressed WT and 
mutant EAATs (167, 169, 170). The physiological importance of the glutamate-
dependent anion conductance is less clear than that of glutamate uptake, but it was 
suggested that it acts as voltage-clamp and that is has an important role in regulation 
of neuronal excitability (16). The result that the anion conductance is as well rather 
mediated independently than cooperatively, may play a role for its physiological 
impact. At low glutamate concentrations, the anion conductance will be effective 
activated in independently working subunits. In contrast, cooperative intersubunit 
interactions would require higher glutamate concentrations for a same effective 
activation. Furthermore, the advantage of the trimeric nature of the transporter with 
fully independently acting subunits might be founded in the large aqueous bowl-
shaped basin in a multimeric structure, which plays a functional role by facilitation of 
the transport of charged substrates across the membrane dielectric. An additional 
function of the central basin in a trimeric structure in modifying ligand diffusion was 
suggested by the kinetics of β-2-fluorenyl-aspartylamide (2-FAA) interactions with 
EAAT3 (185). By steric effects of the aqueous cavity itself, it might present a 
significant diffusion barrier which would not slow the microscopic subunit unbinding 
rate but would result in a kinetic advantage by slowing the effective loss of substrate 
to the bulk space. This could provide a mechanism to modulate the buffering kinetics 
at low substrate concentrations.  
Hetero-trimerization, as reported here, is not a common feature of different EAAT 
isoforms. It is special for EAAT3 and EAAT4, which were selectively enriched in 
Purkinje cell bodies, dendrites, and spines (29, 33). Heterotrimeric assemblies of 
EAAT3 and EAAT4 might be a native appearance in these regions. The presence of 
both, EAAT3 and EAAT4, facilitates rapid glutamate binding, and may have a role in 
shaping the amplitude of postsynaptic responses in Purkinje cells (171,172) and 
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could modulate the metabolism of GABA (173). Different targeting signals in native 
heterotrimers might result in a changed insertion of heterotrimers on a cellular level 
than that of homotrimers. Hetero-trimerization of a low affinity/high capacity (EAAT3) 
and a high affinity/low capacity (EAAT4) transporter (165), may serve as tight 
regulation of the external glutamate concentration and as fine modulation of neuronal 
excitability by EAAT-associated anion channels (174, 175). 
 
 
5.2 Interdependence of transport and anion channel function 
EAATs act as dual functional proteins. Beside the secondary-active glutamate 
transport, they exhibit a pore-mediated anion conduction. EAATs occupy a 
neuroprotective role by their glutamate uptake ability and might be involved in the 
regulation of cell excitability by their anion channel property. Gating of EAAT anion 
channels is tightly coupled to transitions within the glutamate uptake cycle, resulting 
in Na+- and glutamate-dependent anion currents. These anion currents are thought to 
be conducted through an anion pathway that is opened and closed in response to 
conformational changes underlying glutamate transport. The exact molecular 
determinants of the anion conduction or of the interconnection of both functions are 
poorly understood. In a systematic screen of TM2 for mutations affecting EAAT1 
anion channel function, a highly conserved aspartate (D112) at the intracellular loop 
of TM2 was found to have serious effects on both transporter functions. Neutralizing 
D112 in EAAT1 abolishes the glutamate dependence of anion currents and reduces 
glutamate uptake rates by about 40% (158). Continuing studies revealed that the 
corresponding mutation D117A changes unitary anion current amplitudes and 
relative anion selectivities of EAAT4 anion channels (160). By these effects, 
aspartate 112, respectively 117, was suggested to be localized in close proximity to a 
domain influencing substrate transport, and furthermore to flank the anion channel of 
EAATs and to possess gating properties. 
Investigating the effects of the homologue point mutation D83A on EAAT3 
conformational changes by VCF promised insights into the interaction of transporter 
and anion channel function of EAAT glutamate transporters. To permit site-directed 
fluorescence labeling of EAAT3, different single cysteines for fluorophore attachment 
localized in different parts of the transporter, V120C (3-4 loop), M205C (TM4c) and 
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A430C (7-8 loop) were introduced into hEAAT3 (see section 10.4.1, Figure 10.1). To 
study conformational changes, WT, cysteine-substituted or D83A EAAT3 was 
expressed in Xenopus laevis oocytes. It could be ensured by two-electrode voltage 
clamp measurements that cysteine insertions do not modify basic features of EAAT3, 
since voltage-dependent currents, composed of a mixture of anion and uptake 
currents, as wells as pure uptake currents resemble those of WT EAAT3 (see section 
10.4.1, Figure 10.1). Uninjected oocytes or oocytes expressing EAAT3 lacking 
cysteines for fluorophore attachment do not exceed background fluorescence, in 
contrast to each of the reporter mutants (see section 10.8, Suppl. Figure 10.9), 
indicating an EAAT3-specific fluorescence labeling.  
V120C, M205C and A430C EAAT3 display pronounced voltage-dependent 
fluorescence changes which mirror conformational changes during transport or anion 
conduction. Fluorescence amplitudes can be modified by transporter substrates, 
such as Na+ and glutamate. The EAAT-specific blocker, threo-β-benzyloxyaspartate 
(TBOA) is known to prevent substrate-binding by locking EAATs into an outward 
facing conformation with HP2 open (51). TBOA blocks the observed fluorescence 
changes by about 90 % (see section 10.4.1, Figure 10.2 and section 10.8, Suppl. 
Figure 10.9), supporting the notion that fluorescence changes are strictly associated 
with conformational changes of EAAT3. Further experiments revealed that 
conformational changes are not affected by total substitution of external anions (see 
section 10.8, Suppl. Figure 10.10). Moreover, observed fluorescence changes are 
time-dependent and time courses differ for different fluorophore attachment sites and 
are therefore thought to depend not only on global conformational changes of the 
EAAT proteins, but also reflect additional distinct micro-environmental changes. 
A special observation was made for M205C EAAT3 fluorescence time courses. 
M205C EAAT3 discovers an ultra slow voltage- and glutamate-dependent process 
(single time constants 4 s and 7 s) (see section 10.4.2, Figure 10.3). There are 
several possibilities what kind of process might be reflected by this slow 
conformational change: a) a process occurring within the uptake cycle, b) a 
branching process outside the uptake cycle to another conformational state with 
reciprocal dependence and c) a branching process outside the uptake cycle to 
another conformational state with partial dependence. As EAAT3 turnover rates are 
determined to be above 10/s (165), and glutamate transport currents do not change 
with the same time constants as the fluorescence, possibility a) and b) are excluded. 
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This conformational change might reflect a process that occurs from certain states of 
EAAT3 and does not interfere with the uptake cycle, but depends on substrates as 
sodium and glutamate. A possible explanation of these slow processes might be a 
large collective motion, recently reported by Jiang and colleagues (176). These large 
collective motions are described as processes which are functionally important for 
substrate transport, but not for the substrate-gated anion conductance and which are 
coupled to the inward movement of the transport domain. This might explain why the 
slow conformational changes observed in this study are anion-independent, but 
altered by glutamate. Alternatively, the slow fluorescence changes correspond to a 
slow gating process within the EAAT anion channel, initially described in EAAT4, but 
also observed in EAAT3 (unpublished observation). This gating process slowly 
changes the anion to cation selectivity upon membrane depolarization with 
resembling time and voltage dependences (175). Further studies have to uncover the 
exact underlying process of this ultra slow conformational change. 
Recapitulatory, fluorescence changes of fluorophores added to V120C, M205C and 
A430C report on conformational changes that require external Na+, are changed by 
glutamate, are blocked by TBOA, but are independent of the anion composition. 
These results indicate that the reported fluorescence changes rather reflect 
conformational changes during the transport cycle than conformational changes 
initiated by anion flux. 
Expression of cysteine-substituted D83A EAAT3 revealed strongly reduced 
glutamate uptake, reduced glutamate-activated and increased anion currents (see 
section 10.4.3, Figure 10.4) resembling earlier results on this mutation (158, 160). 
Furthermore, D83A changes the voltage and substrate sensitivity of conformational 
changes for each fluorophore attachment site (see section 10.4.3, Figure 10.5). The 
observed fluorescence changes are still sodium- and glutamate-dependent and 
anion-independent (see section 10.8, Suppl. Figure 10.10).  
Employing kinetic simulation of observed current and fluorescence data enables to 
determine the concrete steps/reactions and or transitions within the EAAT uptake 
cycle disturbed by neutralizing aspartate 83. The voltage and substrate dependence 
of EAAT3 fluorescence signals can be well described by a kinetic model that is based 
on the glutamate transport cycle, composed of 17 reactions (56, 57) and structurally 
fulfilled by isomerization between four major conformations (54) assigned to different 
fluorescence amplitudes. To account for the anion channel ability, branching open 
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channel states from certain states of the uptake cycle were added (see section 
10.4.4, Figure 10.6). In this scheme the empty transporter resides in an outward 
facing state, with HP2 being open and the substrate binding sites exposed to the 
extracellular space (Foopen: ToK, To). Glutamate uptake is initiated by association of 
three Na+, one H+ and one glutamate. Association of these substrate causes closure 
of HP2 (Fooccluded: ToNa1, ToNa2, ToNa2G, ToNa2H, ToNa2GH, ToNa3GH), and a 
large piston-like movement of the transport domain results in the inward-facing 
conformation (Fioccluded: TiNa3GH, TiNa2GH, TiNa2G, TiNa2, TiNa1). Opening of HP1 
is followed by substrate release and exposure of the binding sites to the intracellular 
solution (Fiopen: Ti, TiK).  Association of internal K
+ and subsequent retranslocation 
completes the uptake cycle. WT EAAT3 rate constants within the uptake were 
adopted from a previous VCF study on EAAT3 (163). The anion channel open 
probabilities were determined by fitting the model to the experimentally observed 
fluorescence and current data of V120C, M205C and A430C EAAT3. The resulting 
simulation demonstrates a good agreement of the simulated and observed 
fluorescence-voltage relationship under different substrate conditions and could 
reproduce current characteristics of EAAT3 (see section 10.4.4, Figure 10.7), but it 
fails to reproduce as high transport rates of EAAT3 for reverse transport at high 
external K+ as published (177). As all experimentally data were obtained by 
measurements in the absence of external K+ this limitation of the kinetic simulation 
was accepted. 
By unrestricting distinct reactions, groups of reactions and or transitions within the 
EAAT uptake cycle or anion channel open probabilities, kinetic simulation revealed 
that D83A modifies translocation rates between outward and inward facing states 
(reaction 8, 15, 17). Modifying these transitions enables to accurately describe all 
existing data, glutamate transport, anion currents and fluorescence data (see section 
10.4.4, Figure 10.7). This result is in partial disagreement with a recently performed 
analysis of the effects of D117A on EAAT4 anion currents (160). There it was 
suggested that D117 is in close proximity to the anion conduction pathway and that 
neutralizing this residue alters anion channel open probabilities by direct and 
exclusive modification of the anion channel. EAAT3 and EAAT4 anion channel 
properties are very well conserved (168) in contrast to glutamate transport rates 
(165). EAAT4 is a high-affinity/low capacity transporter, contrariwise EAAT3. The 
glutamate uptake as serious effect of D117 was disregarded in that study, although 
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first reports on D112 in EAAT1 report on about 40% reduced glutamate uptake (158). 
D83A reduced EAAT3 uptake current amplitudes to values between 30% - 50% in full 
agreement with Ryan et. al.. Especially this parameter seems to be crucial for a 
correct determination of the disruption underlying the effects of neutralizing aspartate 
83, 112 and 117, respectively.  
The large movement of the transport domain is enabled by the membrane-fixed 
trimerization domain acting as counterbalance (see section 3.2.1.3.3). During the 
movement of the transport domain TM3 is shifted relative to TM2, resulting in an 
altered orientation of the 2-3 loop. Crystal structures of GltPh place the homologous 
residue of D83/D112/D117 to the 2-3 loop between the trimerization and the 
transport domain (Figure 5.1). Homology models of EAAT to GltPh structures predict a 
rotational movement of the residue upon transition from the outward to the inward-
facing conformation (160). Altered translocation by D83A might occur by changing 
the hinge function of the 2-3 loop connecting the trimerization and the transport 
domain and by this D83A might affect the isomerisation between inward and outward 
facing conformations.  
 
Figure 5.1 
Localization of S74 in GltPh, the homologue residue of D83 in EAAT3 
 
Figure 5.1: Localization of S74 in GltPh, the homologue residue of D83 in EAAT3. 
Ribbon representation of a GltPh monomer viewed from the intracellular side (pdb-file: 3KBC) with the 
residue S74 (light blue), the homologue residue of D83 in EAAT3, localized in the 2-3 loop connecting 
the trimerization domain (fuchsia) with the transport domain (grey). 
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This study primarily shows that conformational changes in EAAT3 are anion-
independent. It seems rather unlikely that anion-dependent conformational changes 
were just invisible, since the anion independence of conformational changes was 
observed for different fluorophore attachment sites, localized in the 3-4 loop, in TM4c 
and in the 7-8 loop. Moreover, a mutation previously suggested to exert its effects on 
transport and anion channel-mediated currents by solely affecting the anion pathway 
by itself, was here shown to modify the transition between inward and outward facing 
states. By a changed translocation, D83A directly impairs glutamate uptake which 
leads to changed anion channel properties of EAATs, providing further evidence for 
the intimate interaction of both transporter functions. 
 
 
 
5.3 Disturbed sodium association as underlying 
pathomechanism of EA6 - Another example for the intimate 
interdependence of glutamate uptake ability and anion 
channel function of EAATs 
EAAT dysfunctions and resulting high external glutamate concentrations are 
correlated with diverse neurological diseases and abnormal brain activity (see 
section 3.2.1.4). Investigating EAAT-associated diseases might assist to gain insights 
into the pathomechanisms of certain rare human diseases and might be beneficial in 
creating new strategies against them. Further, it will help to understand the 
physiological impact of the impaired transporters and to permit additional knowledge 
of the structure-function relationship of EAATs.  
In terms of defining EAAT-associated pathomechanisms, this work focuses on one 
neurological disorder - episodic ataxia type 6 (EA6) - which has its seeds in 
mutations in SLC1A3, the gene encoding the glial glutamate transporter EAAT1. 
Episodic ataxias (EAs) are rare autosomal dominant channelopathies that manifest 
as imbalance and paroxysmal cerebellar incoordination associated with additional 
other neurological symptoms, which are mainly cerebellar in origin. In contrast to 
other types of EAs, EA6 is characterized by long duration of attacks, epilepsy and 
absent myokymia, nystagm, and tinnitus (79). In a systematic genetic screen for 
polymorphisms in SLC1A3 two mutations were found in patients suffering from EA6. 
 
Discussion 
 
41 
 
One of these mutations predicts the substitution of a highly conserved proline 290 in 
the hinge of transmembrane domain 5 (TM5) by arginine (97). Former studies 
showed that P290R reduces EAAT1 expression levels and surface membrane 
insertion, diminishes glutamate uptake and increases EAAT1-associated anion 
currents (97, 99). EAAT1 plays a crucial role in glutamate clearance and in one of the 
studies reduced glutamate uptake by P290R was suggested to be the major cause of 
EA6-symptoms (97). The other study paid more attention on the disturbed anion 
channel function and proposed it to be the EA6-underlying pathomechanism (99). 
The exact mechanism and physiological impact is controversial and still has to be 
clarified. To get further insights into the molecular pathophysiology of EA6 and to 
define particular steps on the transport cycle affected by this disease-associated 
mutation, voltage clamp fluorometry (VCF) was employed (see section 11). Since 
P290R affects both transporter functions, as D83A (see section 10), the technique of 
VCF may expose another example for the intimate interdependence of glutamate 
uptake ability and anion channel function of EAATs. 
To enable cysteine-specific fluorophore attachment for subsequent VCF analysis, a 
cysteine was introduced at position 238 in P290R EAAT1. This mutation is localized 
in TM4c and the homologue mutation in EAAT3 was shown to report on pronounced 
EAAT3-specific conformational changes, without affecting basic features of the 
transporter (161, 164). 
As V238C P290R hEAAT1 did not express at levels sufficiently high to allow current 
and fluorescence measurements in Xenopus laevis oocytes, a related isoform, 
hEAAT3 was chosen to study the effects of the homologue mutation P259R. To 
ensure that mutation of the conserved proline exerts similar effects in both EAAT 
isoforms, P259R was expressed in mammalian cells, electrophysiologically analyzed 
and compared to P290R EAAT1 measurements. P259R alters hEAAT3 current 
characteristics similar as P290R hEAAT1, i.e. increases anion currents and displays 
similar voltage-dependent time courses (see section 11, Figure 11.1 and Suppl. 
Figure 11.5) (99). Two-electrode voltage clamp measurements furthermore showed 
similar effects in oocytes expressing P259R EAAT3 or P290R EAAT1 and could 
confirm drastically reduced glutamate uptake currents (see section 11, Figure 11.1 
and Suppl. Figure 11.5). As exchanging the conserved proline by arginine exerts 
similar effects in both EAAT isoforms after expression in oocytes as well as in 
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mammalian cells, EAAT3 is an appropriate model-isoform to study the disease-
causing mutation. 
To permit site-directed fluorescence labeling of EAAT3, an established cysteine 
mutation for fluorophore attachment localized in TM4c (M205C) was introduced into 
hEAAT3 (see Figure 11.1) and combined with P259R. Earlier work on M205C EAAT3 
revealed that this mutation reports on pronounced fluorescence changes specific for 
EAAT3 and furthermore does not change basic features of WT EAAT3 (161, 164). 
EAAT3 carrying the fluorescence attachment site M205C displays voltage-, 
substrate- and time-dependent conformational changes (see Figure 11.2, left 
column). These conformational changes are altered by substrates such as sodium 
and glutamate. P259R profoundly changes the voltage, substrate and time 
dependences of M205C EAAT3 conformational changes. P259R inverts the voltage 
dependence, alters the glutamate-induced fluorescence change and decelerates the 
time dependence of these signals (see Figure 11.2, right column).  
Extensive studies and kinetic simulations on M205C (161) demonstrated that 
fluorescence changes mirror conformational changes during the EAAT uptake cycle. 
The EAAT uptake cycle is elaborately composed of 17 different reactions and 
structural accomplished by isomerization between four major conformational states 
(see section 3.2.1.3.3), i.e.: the outward facing open and occluded and the inward 
facing open and occluded states. Calculations of the steady-state distribution identify 
fluorescence changes upon hyperpolarization in the absence of glutamate to reflect 
primary sodium-binding events to the empty transporter (To) (see Suppl. Figure 
11.7). P259R shows most severe alterations on M205C hEAAT3 fluorescence under 
the conditions causing the transitions from To to ToNa2H, indicating a disturbed 
sodium association. Sodium dependence VCF measurements adduce evidence of a 
modified Na+-association, represented in a decreased sodium affinity and extremely 
decelerated time constants of sodium-binding and unbinding induced conformational 
changes. Furthermore, P259R fluorescence signals upon sodium binding occupy a 
changed voltage dependence. An additional effect on the third sodium-binding which 
occurs under saturating glutamate concentrations could be excluded as P259R 
resembles WT and M205C EAAT3 KD’s as well as published data on EAAT3 (see 
Suppl. Figure 11.6) (181).  
Employing kinetic simulation of observed current and fluorescence data enables to 
discover individual reactions or transitions within the EAAT uptake cycle which are 
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disturbed by P529R. An earlier developed kinetic scheme to describe fluorescence 
signals as well as transport and anion currents of M205C hEAAT3 was used to 
confirm or to invalidate a disturbed sodium association (see section 10, 11) (161). In 
fact, random alterations revealed that modifying reactions 1, 2, 12 and 13 that report 
on Na+-association/-dissociation to the transporter in the outward or in the inward 
facing state and the additional increase of the voltage dependence of reaction 1 and 
the adjustment of the voltage dependence of reaction 2, could simulate almost all 
functional alterations by P259R (see Figure 11.4). The simulation predicts the 
voltage, substrate and [Na+] dependence of fluorescence signals of mutant 
transporters correctly. The decreased glutamate uptake currents and increased anion 
currents in the absence of glutamate were as well calculated in agreement with the 
measurements (see Figure 11.4). Furthermore, the kinetic model for P259R could 
support the extremely decelerated time dependence as binding and unbinding of the 
first and second sodium is calculated to be around 100 times slower (Table 11.2). 
Time-dependent simulations of current and fluorescence responses qualitatively 
resemble the deceleration by P259R. Calculations of the steady-state distribution 
show that P259R is mostly trapped in the outward facing open states (To and 
ToNa2H) (see Suppl. Figure 11.7) in the absence of glutamate. Application of 
glutamate just slightly changes the residence probability of P259R EAAT3 by 
increasing the probability to reside in glutamate-bound outward facing states and in 
TiNa1. Appropriate glutamate uptake and fulfilling the complete transport cycle 
necessarily requires binding of the first and second sodium prior to glutamate. The 
shift of the steady-state distribution by P259R illustrative demonstrates the 
consequence of an enervated sodium binding. 
The disease-causing mutation, either in EAAT1 or EAAT3, leads to an extremely 
reduced glutamate uptake capability and increased anion currents on a slow time 
course by a slowed Na+-association to the mutant transporters. Recently, a study on 
EAAT5 (186) identified slow Na+-association as basis for a slow activation time 
course of anion currents and very low glutamate transport. The result that the high 
capacity glutamate transporters EAAT1 or EAAT3 carrying a disease-causing 
mutation functionally resemble the low capacity glutamate transporter EAAT5 further 
support the results presented in this work and illustrates the importance of the 
evolutionary optimization of EAAT isoform with distinct functional properties. 
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However, the predictions by the established kinetic model fail to correctly describe 
the increased anion currents calculated by the prediction of open probabilities of 
P259R EAAT3 in the presence of glutamate (Figure 11.4). P290R EAAT1 was shown 
to increase anion currents while surface membrane insertion was reduced (99). 
Noise analysis measurements revealed an incompatible high absolute open 
probability for WT EAAT1. Under saturating glutamate concentrations EAAT3 
absolute anion channel open probabilities were defined to be around 0.9. Assuming 
that these values are correctly determined, a fourfold increase of EAAT3 glutamate-
induced anion currents by P259R has to result in open probabilities larger than 1. 
Therefore, noise analysis might underestimate the number of active WT EAAT anion 
channels. A similar disagreement was found analyzing ClC-4 (184). ClC-4 acts like 
EAATs as dual functional channel and transporter. Noise analysis revealed that 
changing the external chloride concentration, changes the apparent number of ClC-4 
proteins without affecting the surface membrane density. It was suggested that ClC-4 
can switch in an anion-dependent manner between its two functional states. As anion 
binding and unbinding is rapid compared to the transition to the channel mode, ClC-4 
equilibrates into a semi-equilibrium distribution between the two transport modes. 
Noise analysis will only report on opening and closing transitions of the anion 
channels and in such a mechanism underestimate the number of active anion 
channels and overestimate the open probability. Na+-association is likewise fast for 
WT hEAAT3 and noise analysis might provide as well incorrect high absolute open 
probabilities of hEAAT3 anion channels via a similar mechanism.  
Nevertheless, kinetic simulation could correctly describe all other functional 
alterations by P259R by a disturbed sodium association to EAAT3. This raises the 
question how exchanging proline by arginine can cause the described effects on 
sodium binding and unbinding. Is there a direct effect on the binding site causing 
enfeebled sodium coordination by a sterical barrier or does P259R disturb a 
conformational change associated with sodium binding or might there be global 
structural change?  
On the first view crystal structures of the bacterial transporter homologue GltPh show 
no indication for a direct influence on the sodium binding sites by P259R (Figure 5.2). 
Sodium binding sites of EAAT3 have been identified as the aspartate residues at 
position D368 (TM7), D440 and D455 (TM8) (51, 178-180). The episodic ataxia 
causing mutation P259R is not in close proximity to these residues (C-distances in 
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the outward facing open conformation from P259 to: D368 = 26.3, D440 = 21.2, D455 
= 24.4 Å) (Figure 5.2).  
 
Figure 5.2 
C-distances distances in the outward facing open conformation from P259 to 
the different sodium binding sites 
 
 
Figure 5.2: C-distances distances in the outward facing open conformation from P259 to the 
different sodium binding sites. 
Ribbon representation of a GltPh monomer viewed from the side of the membrane (pdb-file: 2NWW) 
with the residue P259 (light blue), localized in TM5 (fuchsia), the three sodium binding sites (black) 
and parts of the transport domain (grey). Given are C-distances in the outward facing open 
conformation from P259 to: D368 = 26.3, D440 = 21.2, D455 = 24.4 Å. For simplification parts of the 
protein were removed from the crystal structure and residue numbers of EAAT3 are used. 
 
 
Furthermore, cation association is assumed to be a fast diffusion-controlled process 
and a dramatic effect of a 100-fold reduction of reaction rates seems rather unlikely. 
The structural basis for altered sodium binding to P259R hEAAT3 seems to be rather 
an effect on sodium associated conformational changes or a global structural change 
than a direct effect of P259R on the sodium binding sites. 
The influence on a process associated with sodium binding, possibly a 
conformational change, is supported by the sodium-dependent saturating time 
constants of M205C or M205C-P259R EAAT3 fluorescence changes (Figure 11.3). 
Inverse time constants saturates at high sodium concentrations, implicating that rapid 
sodium binding is followed by a slower step, that becomes independent of sodium 
concentration once all binding sites are occupied. Since sodium site 2 is coupled to 
 
Discussion 
 
46 
 
opening and closure of HP2, P259R might affect these particular movements. Proline 
by itself functions as structural disruptor of -helices and -sheets and might be the 
structural determinant of the kinked shape of TM5 and exchanging proline by 
arginine might result in an overall structural change. Such an overall structural 
change could impair sodium-binding and subsequent induced conformational 
changes including translocation to the inward facing conformation of EAAT. It might 
be that P259 comes in close proximity to the sodium binding sites by such a global 
change. A possible scenario of a global structural change might be an altered 
orientation of the transport domain to the trimerization domain by a loss of the kinked 
shape of TM5 in P259R. A resulting changed coordination of the transport domain in 
the membrane dielectric might result in a changed electric field in the environment of 
moving protein parts upon sodium binding. Moreover, the position of Na+ binding 
sites within the electric field could be altered. This interpretation could explain the 
inversed voltage dependence of conformational changes (Figure 11.2) and the 
increased electrical distances simulated for sodium binding (Table 11.2). 
Furthermore, a global structural change might as well explain the increased anion 
conduction by structural induced alterations of anion-conducting states and/or of the 
anion pathway by itself. 
Recapitulatory, the effects of the EA6-causing mutation on the transport capability 
and anion channel function of EAATs are molecular founded in an impaired sodium-
binding which might be triggered by a structural change influencing sodium 
associated conformational changes or by a global structural change induced by a 
disruption of the kinked shape of TM5. By direct intervention in the uptake cycle 
P259R exerts dual effects and sets another example for the intimate interaction of 
transporter and anion channel function. 
The physiological relevance of the EAAT1 mutation found in patients suffering from 
EA6 might have its seeds in both EAAT functions: the impaired uptake ability and 
resulting high extracellular glutamate concentrations contributing to neuronal 
hyperexcitability and the increased anion channel function might impair GABAergic 
astrocyte excitation. 
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5.4 Observations made by an intermediate structure of GltPh 
Finally, the results presented in this work, the independence of individual subunits in 
heterotrimers, the tight interaction of substrate transport and anion channel function 
discovered by two different mutations are in full agreement with a recently proposed 
structural model (55).  
In this study a crystal structure of an asymmetric trimer of GltPh with two protomers in 
inward facing states and the third in an intermediate conformation between the 
outward and inward facing states is presented. In the asymmetric structure, single 
protomers show similar state-independent transport activities, supporting the 
observation of individual-acting subunits in EAAT-trimers.  
The intermediate conformation furthermore shows a transient cavity which is 
proposed to be the pathway for the uncoupled anion conductance and is bordered by 
residues of TM2 and TM5. This intermediate conformation could be reached even if 
translocation to the inward facing states is prevented and by this the structural model 
can explain abrogation of transport, whereas anion conductance is maintained. The 
mutation D83A, localized at the edge of TM2 and the disease-causing mutation 
P259R, localized in the kink of TM5, reside exactly in the region described as 
transient cavity and the flank of it. Both mutations were shown to nearly abolish 
substrate transport, whereas anion conduction was maintained or even increased.  
D83A exerts its effects on both transporter functions by modulation of the three 
translocation reactions (reaction 8, 15, 17). Theoretically, this altered translocation by 
D83A might occur by changing the hinge function of 2-3 loop and by this D83A might 
affect the isomerisation between inward and outward facing conformations, as 
discussed above (see section 5.2). It is also possible that D83A earlier intervenes in 
the uptake cycle by disturbing the isomerization to one of the intermediate states. By 
changing the translocation trajectory, D83A could not only affect substrate 
translocation and anion channel opening/closing, but also the anion conduction 
pathway itself. 
Interestingly, the crystal structure of this intermediate state discovers a reduction of 
one of the C-distances from P259 (P206 in GltPh) to one of the sodium binding sites. 
The C-distance between P259 to D440 is reduced from 21.2 to 12.9 Å (Figure 5.3) 
which is possibly close enough to exert effects on the sodium binding site in a direct 
way. Although isomerization from the outward facing to the intermediate state 
requires sodium and glutamate binding in the proposed structural model (55), one 
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might speculate about a possible stepwise isomerization from and to several 
conducting states so that first a conformation is captured which develops a reduced 
distance between P259 and D440. In the currently accepted glutamate uptake cycle, 
isomerization is as well possible prior to glutamate binding (reaction 17), even if the 
reaction rates for this translocation are low compared to the translocation rates after 
glutamate binding. One might speculate about a further translocation possibility 
between ToNa1 and TiNa1. 
 
 
 
Figure 5.3 
C-distances distances in the intermediate conformation from P259 to the 
sodium binding site D440 
 
 
Figure 5.3: C-distances distances in the intermediate conformation from P259 to the sodium 
binding site D440. 
Ribbon representation of a GltPh monomer viewed from the side of the membrane (pdb-file: 3V8G) with 
the residue P259 (light blue), localized in TM5 (fuchsia), the three sodium binding sites (black) and 
parts of the transport domain (grey). For simplification parts of the protein were removed from the 
crystal structure, residue numbers of EAAT3 are used and solely one C-distance in the intermediate 
conformation from P259 to D440 = 12.9 Å is given in the picture. 
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5.5 Continuative questions and research  
Although this work provides novel insights in terms of cooperativity between 
individual subunits in heterotrimeric EAAT complexes, the effects of two mutations 
residing in the region of the proposed anion cavity and the interconnection of 
transport and anion conduction by itself, there are still a lot of open questions, e.g.:  
“Is heterotrimerization of the neuronal glutamate transporters EAAT3 and EAAT4 a 
native state?” and “What are the regulation mechanisms and physiological 
consequences of heterotrimerization and the changed epithelial sorting?” 
“What is the structural background of the ultra slow conformational changes 
observed in EAAT3?” - As discussed above, these conformational changes might 
represent large collective motions, which are coupled to the inward movement of the 
transport domain. It is planned in a future project to test for such large collective 
motions by VCF experiments of co-expressed fluorescently stainable (M205C 
EAAT3) and serine-sensitive mutants of EAAT3 (R447E EAAT3). Application of 
serine should result in an inward movement of the serine-sensitive monomer, but not 
in a fluorescence change by itself. In case of fluorescence changes which reflect 
same time constants as the ultra-slow fluorescence changes, but do not exactly 
mimic the fluorescence changes induced in homotrimeric M205C EAAT3 by 
glutamate, one could support the suggestion of somehow cooperative large collective 
movements without inconsistency with non-cooperatively acting subunits.   
Further posed questions are: 
 “What is the exact localization of the anion pathway?”, “Which residues are 
important for the correct development of the pathway and mandatory for the gating 
mechanism?” and “What is the definite physiological role of the anion conductance 
mediated by glutamate transporters?” Answering and investigating these questions 
necessitates more crystallographic evidence of the localization of the anion channel 
and might be adduced by a systematic screen of residues flanking the proposed 
anion channel and by combining molecular dynamics simulations and 
electrophysiological experiments on mutations of those residues. It is suggested that 
the anion channel is transiently formed by isomerization between inward and outward 
facing states. Mutations which avoid this movement and in consequence abrogate 
anion conduction, but do not directly interfere with substrate-binding (to exclude the 
possibility that the inward movement is avoided by a disturbed substrate-binding) 
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would expand the chance to understand anion conduction in EAATs. Studies in this 
direction have already started.  
Furthermore, such a mutation on an EAAT isoform, which rather mediates anion flux 
than glutamate uptake (EAAT4) and which has less influence on the total glutamate 
uptake ability, could be studied in a mouse model and probably discover the 
physiological impact of the anion channel activity. 
Concerning the project analyzing the episodic ataxia causing mutation, there are as 
well some unsettled questions: 
“Is the impaired Na+-association to P259R the result of an overall structural change 
of the transporter caused by a modification of the kinked shape of TM5?” or “Might 
there exist another conformation in which a direct modulation of sodium binding by 
P259R is possible?” Ongoing work in our institute targets crystallization of the 
homologous mutation P206R in the bacterial glutamate transporter GltPh and 
hopefully will provide structural access to the P206R-mediated alterations. One could 
as well use Photo-induced electron transfer (PET) between tryptophane and bimane 
fluorescence, a short distance-dependent quenching method, introduced in GltPh to 
prove whether this residue gets into close contact with the suggested sodium binding 
sites and therefore could influence them directly. To improve the understanding of 
what exactly happens in patients suffering from episodic ataxias, a P290R EAAT1 
knock-in mouse model will be studied in detail in a future project. 
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6 Conclusions 
This work essentially deals with detailed investigations of the structure-function 
relationship in human excitatory amino acid transporters. It could be shown that 
individual subunits within EAAT heterotrimers act independently of each other. 
Furthermore, analyzing the interdependence of glutamate transport and the feature 
of anion conductance on the basis of two different mutations, shown to exert effects 
on both transporter functions, permits deeper insights concerning this particular 
question. The project analyzing aspartate 83 demonstrates that sole modification of 
the isomerization between outward and inward facing transporter states is effectual 
enough not only to constrict the transport function but also to modify anion channel 
conduction. Analyzing an episodic ataxia causing mutation could clarify the 
constitutive steps within the glutamate uptake cycle underlying the EA6 
pathomechanism and furthermore revealed that both effects on EAAT function, i.e. 
on glutamate uptake and anion conduction could be triggered by a modified sodium-
binding. The results on hetero-multimerization, on D83 and on P259 are in full 
agreement with a recently proposed model on the basis of a crystal-structure, in 
which the anion cavity is transiently established during the movement of the transport 
domain. 
Primary, this structure-function analysis was achieved by investigations of 
conformational changes via voltage clamp fluorometry and kinetic simulations. By 
this means, this work demonstrates an alternative experimental access to determine 
particular details of structure-function relationship. 
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9.1 Abstract 
Excitatory amino acid transporters (EAATs) mediate the uptake of glutamate into 
neuronal and glial cells of the mammalian central nervous system. Two transporters 
expressed primarily in glia, EAAT1 and EAAT2, are crucial for glutamate 
homeostasis in the adult mammalian brain. Three neuronal transporters (EAAT3, 
EAAT4, and EAAT5) appear to have additional functions in regulating and processing 
cellular excitability. EAATs are assembled as trimers, and the existence of multiple 
isoforms raises the question of whether certain isoforms can form heterooligomers. 
Co-expression and pull-down experiments of various glutamate transporters showed 
that EAAT3 and EAAT4, but neither EAAT1 and EAAT2, nor EAAT2 and EAAT3 are 
capable of co-assembling into heterotrimers. To study the functional consequences 
of hetero-oligomerization, we co-expressed EAAT3 and the serine-dependent mutant 
R501C EAAT4 in HEK293 cells and Xenopus laevis oocytes and studied 
glutamate/serine transport and anion conduction using electrophysiological methods. 
Individual subunits transport glutamate independently of each other. Apparent 
substrate affinities are not affected by hetero-oligomerization. However, polarized 
localization in Madin-Darby canine kidney cells was different for homo- and 
heterooligomers. EAAT3 inserts exclusively into apical membranes of Madin-Darby 
canine kidney cells when expressed alone. Co-expression with EAAT4 results in 
additional appearance of basolateral EAAT3. Our results demonstrate the existence 
of heterotrimeric glutamate transporters and provide novel information about the 
physiological impact of EAAT oligomerization. 
 
 
9.2 Introduction 
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous 
system. After its release from glutamatergic nerve terminals, glutamate is quickly 
taken up into glial and neuronal cells by glutamate transporters belonging to the 
“excitatory amino acid transporter” (EAAT)4 family (1, 2). Five different mammalian 
EAAT isoforms have been identified. Two of those, EAAT1 and EAAT2, are 
expressed mainly in glia, whereas EAAT3, EAAT4, and EAAT5 are considered to be 
neuronal transporters. All EAAT glutamate transporters sustain two fundamentally 
distinct transport mechanisms. They function as stoichiometrically coupled co-
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transporters of one glutamate, three sodium ions, and one proton, while one 
potassium ion is countertransported (3, 4). In addition, all EAATs are capable of 
functioning as anion channels (5). Different EAAT isoforms differ in the relative 
contribution of anion currents to the total transporter-mediated current (5–8). These 
differences have been interpreted as an indication that some EAATs play a 
physiological role as glutamate transporters (9, 10) and others as glutamate-gated 
anion channels involved in the regulation of cellular excitability (2, 11, 12).  
EAAT glutamate transporters are assembled as trimers (13–16). At present, it is not 
clear whether distinct isoforms can form heterotrimers, and moreover, whether 
subunits might acquire new functions within heterotrimeric assemblies. We here use 
biochemical and electrophysiological approaches to study co-assembly of different 
EAATs and possible functional consequences of hetero-multimerization. 
 
 
9.3 Experimental Procedures 
9.3.1 Heterologous Expression of EAATs 
Coding regions of rat EAAT1, human EAAT2, rat and human EAAT3, rat EAAT4, and 
human SLC26A9 were subcloned into pcDNA3.1 or pRcCMV using PCR-based 
strategies. YFP, GFP, CFP, and His fusion proteins were generated by PCR-based 
techniques. All constructs were verified by restriction analysis and DNA sequencing. 
For each construct, two independent recombinants from the same transformation 
were examined and shown to exhibit indistinguishable functional properties. 
Transient transfection of tsA201 and MDCKII cells using the Ca3(PO4)2 technique or 
Lipofectamine (Invitrogen) was performed as described previously (8). 
 
 
9.3.2 Purification and Gel Electrophoresis of EAAT Fusion Proteins 
EAAT fusion proteins were purified from tsA201 cells as described (22). For PAGE 
under denaturing conditions, proteins were denatured for 15 min at 56 °C with SDS 
sample buffer containing 20 mM dithiothreitol (DTT) and electrophoresed on linear 
SDS-polyacrylamide gels. Blue native (BN)-PAGE was performed immediately after 
protein purification as described (22, 23). YFP-tagged proteins were visualized by 
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scanning the wet polyacrylamide gels with a fluorescence scanner (Typhoon 9400; 
GE Healthcare). Each experiment was at least performed three times and illustrated 
as representative result. 
 
 
9.3.3 Electrophysiology 
For expression in oocytes, cRNA was synthesized from MluI-linearized pTLN2-
hEAAT3 (24) or from NheI-linearized pGEMHE-R501C rEAAT4 (20) templates 
through use of MESSAGE machine kits (Ambion, Austin, TX). Injection and handling 
of oocytes were performed as described elsewhere (25). Current recordings from 
oocytes expressing hEAAT3 were usually performed 1 day after injection. To account 
for differences in expression levels, this period was increased to 4-5 days for R501C 
rEAAT4. For coexpression experiments in oocytes, hEAAT3 and R501C rEAAT4 
RNAs were injected at a 1:5 ratio unless otherwise stated. 
EAAT-associated currents were recorded by two-electrode voltage clamp using a 
CA1 amplifier (Dagan, Minneapolis, MN). Oocytes were held at 0 mV, and currents 
elicited by 200-ms voltage steps between -120 mV and +80 mV were filtered at 2 kHz 
(-3d B) and digitized with a sampling rate of 10 kHz, using either a Digidata AD/DA 
converter (Molecular Devices, Sunnyvale, CA) or an ITC-18 Computer Interface 
(Instrutech Corporation). The external solution contained 96 mM NaNO3 , 4 mM KCl, 
0.3 mM CaCl2 , 1 mM MgCl2 , 5 mM HEPES, pH 7.4, either with or without 500 µM L-
glutamate or L-serine. 
After each experiment with substrate application, the substrate was washed out by 
perfusion with substrate-free solution and consequently at least once applied again. 
Cells were only incorporated into the analysis if current amplitudes measured at 
different times with the same substrate concentration perfectly superimpose. For the 
experiment shown in Figure 9.2E-G, the application order was changed from 
experiment to experiment. 
 
 
9.3.4 Laser Pulse Photolysis 
Transient transfection of subconfluent human embryonic kidney cell cultures with the 
calcium phosphate-mediated transfection method and laser pulse photolysis 
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experiments were performed as described previously (26). Electrophysiological 
recordings were performed 24 h after the transfection for 3 days. 
In these experiments, the extracellular solution contained 140 mM NaMES, 2 mM 
CaMES2, 2 mM MgMES2, and 30 mM HEPES (pH 7.4/NaOH). The pipette solution 
contained 140 mM NaMES (exchange transport current)/NaSCN (exchange anion 
current), 2 mM MgMES2, 10 mM EGTA, 10 mM glutamate and serine, and 10 mM 
HEPES (pH 7.4/NaOH). 
Briefly, glutamate or 4-methoxy-7-nitroindolinyl-caged glutamate (Tocris Bioscience, 
Ellisville, MO) was applied to cells by means of a small quartz tube (350-µm 
diameter) with a mean velocity of 5 cm/s and a time resolution of 20-30 ms (10–90% 
rise time with whole cells). Photolysis of caged glutamate was initiated with a light 
flash (355 nm, 5 ns, frequency-tripled NdYag laser; Continuum, Santa Clara, CA), 
which was delivered to the cell with an optical fiber (350-µm diameter). Laser 
energies were varied in the range of 50–450 mJ/cm2 with neutral density filters. To 
estimate the concentration of photolytically released glutamate, a standard glutamate 
concentration of 100 µM was applied to the cells by rapid perfusion before and after 
photolysis experiments, and the steady-state current amplitude was used to calculate 
the free glutamate concentration from the dose-response curve (26). Current 
responses to the laser pulse were low pass-filtered at 3 kHz (100-µs time resolution) 
and recorded with a 100-kHz sampling rate. 
 
 
9.3.5 Data Analysis 
Data were analyzed with a combination of pClamp9 (Molecular Devices) and 
SigmaPlot (Jandel Scientific, San Rafael, CA) programs. Current amplitudes were 
used without applying a subtraction procedure. Current-voltage relationships at 
various substrate concentrations were constructed by plotting isochronal current 
amplitudes determined 1 ms after the voltage step versus the membrane potential. 
To obtain the concentration dependence of anion channel activation by Na+ and 
glutamate, isochronal anion current amplitudes were measured at various 
concentrations at a given test potential. The so-obtained substrate dependences 
were normalized to the maximum current amplitude, fit with Hill equations, 
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                                               (Eq. 1) 
 
and averaged after normalization to the maximum current amplitude (Imax + I0). All 
data are given as means  S.E.. For statistic evaluation the Student’s t test was used. 
 
 
9.3.6 Confocal Microscopy 
MDCKII cells were transiently transfected with mCFP-hEAAT3, mYFP-rEAAT4, 
barttin-YFP, or hSLC26A9-mYFP and grown on Ibidi glass-bottom dishes. 
Additionally, co-transfections of CFP-hEAAT3/YFP-rEAAT4 and GFP-
hEAAT3/mCherry-hEAAT2 were performed (see Figure 9.5). Confocal imaging was 
carried out on living cells with a TCS SP2 AOBS scan head and an inverted Leica 
DM IRB. CFP was excited at 405 nm, and the emission was detected after filtering 
with a 450-505 nm bandpass filter. YFP/GFP/mCherry were excited at 514 nm/488 
nm/514 nm, and the emission was detected after filtering with 520–580 nm/500-535 
nm/555-700 nm bandpass filters, respectively. 
 
 
9.3.7 Surface Biotinylation and Western Blotting 
Cell surface expression of hEAAT3 was assayed with a modification of cell surface 
biotinylation methods described previously (27, 28). In these experiments, hEAAT3 
was expressed as a GFP fusion protein because the fluorescence scanner 
(Typhoon) had preferable imaging capabilities for GFP. GFP-hEAAT3 alone or GFP-
tagged hEAAT3 together with untagged rEAAT4 or hEAAT2 was expressed in 
MDCKII cells, grown until 70% confluence on filters (see Figure 9.6), and incubated 
with 2 mg/ml biotin (sulfo-NHS-SS-biotin; Pierce) in triethanolamine buffer (2 mM 
CaCl2, 150 mM NaCl, 10 mM C6H15NO3, pH 7.5) for 1-2 h, either added to the apical 
or to the basolateral side. The membrane domain that was not treated with biotin was 
incubated with biotinylation buffer only. The reaction was quenched by repeated 
washing with quenching buffer (100 mM glycine in PBS). After washing with PBS, the 
cells were scraped in lysis buffer (150 mM NaCl, 1% Triton X-100, and 5 mM EDTA 
with 50 mM Tris, pH 7.5) and transferred to a tube. After 15 min on ice, they were 
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centrifuged at 14,000 × g for 10 min at 4 °C, and the cell lysate was collected. Cell 
lysates were incubated with Ultralink immobilized NeutrAvidin beads (Pierce) for 2 h. 
After washing with either lysis buffer or high salt wash buffer (0.1% Triton, 500 mM 
NaCl, 5 mM EDTA, 50 mM Tris, pH 7.5), proteins on the beads were released by 
incubation with SDS loading buffer containing 200 mM DTT and 4.1% SDS. The 
proteins were separated on 10% polyacrylamide gradient gels. Fluorescence 
intensities of apical/basolateral channels were determined by fluorescence scanning 
and given as fraction of the total surface transporter fluorescence, obtained by 
adding apical and basolateral fluorescence intensities. Gels were blotted onto 
polyvinylidene (Bio-Rad), and actin was visualized with rabbit anti-actin antibody 
(Sigma-Aldrich) and anti-rabbit Cy5 antibody (GE Healthcare). Results were used 
only from experiments in which no actin was detected in purified membrane fractions. 
We used heterologously expressed hSLC26A9-YFP as apical (29) and endogenous 
Na+,K+-ATPase as basolateral markers (27). Biotinylated hSLC26A9-YFP was 
quantified using fluorescent scanning, but we used antibodies (Abcam) and Western 
blotting for endogenous Na+,K+-ATPases. 
 
 
9.4 Results 
9.4.1 EAAT3 and EAAT4 Form Hetero-oligomeric Transporters 
To study whether different EAAT isoforms assemble into heterotrimeric complexes, 
we co-expressed two different EAAT isoforms in mammalian cells, one as a YFP 
fusion protein and the other as a His fusion protein. The tested mammalian EAATs 
acquire different molecular masses by the distinct added tags and can, thus, be 
distinguished by gel electrophoresis (Figure 9.1A). Transporters were either purified 
in their native multimeric state by Ni2+-nitrilotriacetic acid-based affinity 
chromatography before gel electrophoresis (eluate fractions) or resolved as full 
lysates by denaturing SDS- or BN-PAGE (homogenate fractions). YFP-tagged 
proteins were then visualized by scanning the wet polyacrylamide gels with a 
fluorescence scanner. 
Figure 9.1B shows a BN-PAGE from cells co-expressing His-hEAAT3 and YFP-
rEAAT4 (lanes 3 and 4) and from cells expressing each transporter alone (lanes 1 
and 2). Because His-hEAAT3 homotrimers are not fluorescent, we verified 
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expression of His-hEAAT3 by Western blotting. BN-PAGE of full lysates from cells 
expressing YFP-rEAAT4 resulted in two different fluorescent bands that correlate to 
non- or core-glycosylated and complex-glycosylated forms of homotrimers (Figure 
9.1B, lane 2) (14). The full homogenate of cells co-transfected with both transporters 
also contains homotrimeric YFP-rEAAT4 (Figure 9.1B, lane 3). After Ni2+-
nitrilotriacetic acid-based affinity chromatography, homotrimeric YFP-rEAAT4, which 
lacks an affinity tag, is absent from the retained fraction. The protein fraction with the 
highest molecular mass must represent heterotrimers because it contains the His 
tag, which is only present in His-hEAAT3, exhibits fluorescence from YFP-rEAAT4, 
and is of a smaller molecular mass than the YFP-rEAAT4 homotrimer (Figure 9.1B, 
lane 4, Eluate). 
 
Figure 9.1 
Co-assembly of EAAT3 and EAAT4 
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Figure 9.1: Co-assembly of EAAT3 and EAAT4.  
A, YFP and His fusion proteins differ in size, allowing distinction of homo- and heterotrimeric proteins 
by gel electrophoresis. B, BN-PAGE of homogenates and eluates from Ni
2+
-affinity chromatography 
from cells co-expressing His-EAAT3 and YFP-EAAT4 (lane 3 and 4). The trimeric membrane protein 
P2X1 was used as size standard (lane 5). C, SDS-PAGE from various fractions obtained by a pull-
down assay using Ni
2+
-affinity chromatography. D, BN-PAGE of lysates and eluted proteins after Ni
2+
-
affinity chromatography from cells expressing YFP-hEAAT2 (third and fourth lanes) or cells co-
expressing His-rEAAT1 and YFP-hEAAT2 (fifth and sixth lanes) as well as His-hEAAT3 and YFP-
hEAAT2 (seventh and eighth lanes). Eluates were concentrated 8-fold. E, SDS-PAGE from various 
fractions obtained by Ni
2+
-
 
affinity chromatography from cells co-expressing His-rEAAT1 and YFP-
hEAAT2, His-hEAAT2 and GFP-hEAAT3. 
 
 
Figure 9.1C shows a SDS-PAGE of various fractions isolated from affinity 
chromatography. Homotrimeric YFP-rEAAT4 does not bind the Ni2+ resin and 
appears completely in the flow-through (lanes 1-3). In contrast, hetero-trimerization of 
hEAAT3 and rEAAT4 allows pulldown of YFP-rEAAT4 together with His-hEAAT3 by 
metal affinity chromatography (Figure 9.1C, lanes 4-6). We used human EAAT3 and 
rat EAAT4 for these experiments because functional properties of these isoforms 
were recently studied and compared by our group (25). Although human and rat 
EAAT3 are highly conserved, they do not exhibit complete sequence identity. To 
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demonstrate that EAAT3/EAAT4 hetero-oligomerization also occurs with isoforms 
from the same species, we repeated coexpression and pulldown experiments with 
His-rEAAT3 and YFP-rEAAT4. The outcome of these experiments closely resembled 
those with hEAAT3 and rEAAT4 (data not shown). YFP-rEAAT4 and His-rEAAT3 
form heterotrimers. 
We conclude that EAAT3 and EAAT4 can co-assemble into heteromultimers. Other 
isoforms fail to co-assemble (Figure 9.1D and E). Neither BN-PAGE analysis (Figure 
9.1D) nor pull-down assays (Figure 9.1E) revealed any indication for hetero-
oligomerization for three other EAAT isoform combinations, the two glial transporters 
EAAT1 and EAAT2 as well as for EAAT2 and EAAT3. 
 
 
9.4.2 Co-expression of EAAT3 and EAAT4 in Xenopus Oocytes 
hEAAT3 and rEAAT4 differ in the unitary glutamate transport rate (30) but not in the 
unitary anion current (25). Moreover, macroscopic anion currents display isoform-
specific time and voltage dependences (25). hEAAT3/rEAAT4 heterotrimers 
therefore provide an excellent possibility to study potential intersubunit interactions. 
To separate currents conducted by hEAAT3 or rEAAT4 subunits, we mutated 
rEAAT4 at position 501 (R501C) to modify the substrate binding pocket in a way that 
glutamate cannot bind anymore, but serine or cysteine can bind instead (17, 20, 31). 
Figure 9.2 shows current recordings from Xenopus oocytes expressing either WT 
hEAAT3 or R501C rEAAT4 alone, or co-expressing both isoforms. In the presence of 
extracellular NO3
- these currents are dominated at positive membrane potentials by 
the anion component (8, 32, 33). When the membrane potential is stepped to more 
positive values, WT hEAAT3 currents display time- and voltage-dependent increases 
(Figure 9.2A, arrow), likely due to channel activation (25).  
In contrast R501C rEAAT4, like WT rEAAT4, is inactivated by positive voltages 
(Figure 9.2B) (8, 20, 25), resulting in decreased channel open probabilities and time-
dependent current amplitude reductions (arrow) (8, 25, 34). WT hEAAT3 currents are 
greatly increased in the presence of extracellular glutamate, but are not responsive to 
serine (Figure 9.2A). In contrast, R501C rEAAT4 currents are not significantly 
affected by glutamate, but they are augmented by application of extracellular serine 
(Fig. 9.2B).  
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Figure 9.2C and D, shows the time course of the development of glutamate- and 
serine-dependent currents with time after mRNA injection. Serine-dependent anion 
currents are larger in oocytes co-expressing WT hEAAT3 and R501C rEAAT4 than in 
those expressing R501C rEAAT4 alone (Figure 9.2D), indicating that hEAAT3 
stimulates the insertion of rEAAT4 subunits into the surface membrane. Confocal 
images from oocytes expressing YFP-rEAAT4 alone or co-expressing YFP-rEAAT4 
and untagged hEAAT3 revealed increased surface insertion of YFP-rEAAT4 in the 
presence of hEAAT3 (data not shown). In contrast, expression of R501C rEAAT4 did 
not increase glutamate-dependent hEAAT3 anion currents, but rather decrease this 
current amplitude at certain time intervals (Figure 9.2C). 
 
 
Figure 9.2 
EAAT3 modifies membrane surface insertion and function of EAAT4 
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Figure 9.2: EAAT3 modifies membrane surface insertion and function of EAAT4.  
A and B, representative recordings and current-voltage relationships from oocytes expressing WT 
EAAT3 (A) or R501C EAAT4 (B) in the following conditions, 96 mM NaNO3 (filled circles), 96 mM 
NaNO3 + 500 µM L-glutamate (upward triangles), and 96 mM NaNO3 + 500 µM L-serine (downward 
triangles). Mean  S.E. from 6-7 experiments is shown. C and D, dependences of the glutamate-
induced (C) and serine-induced (D) currents on the time after mRNA injection for oocytes expressing 
WT EAAT3 (n = 8 for each time point), R501C EAAT4 (5  n  10), and oocytes co-expressing WT 
EAAT3 and R501C EAAT4 (5  n  10) at different ratios. E, representative recordings from an oocyte 
co-expressing hEAAT3 and R501C rEAAT4 without substrate (I1) in the presence of 96 mM NaNO3 + 
500 µM L-serine (I2) or 500 µM L-glutamate (I3), or after application of both (I4). F, current-voltage 
relationship for serine-activated (IA = I2 - I1) and glutamate-activated (IB = I3 - I1) currents as well as of 
currents activated in the simultaneous presence of serine and glutamate (IC = I4 - I1) from the example 
shown in E. The solid line gives the sum of serine- and glutamate-activated current amplitudes. G, 
averaged normalized current-voltage relationship for different substrate-sensitive current components 
(n = 6, *, p  0.05; **, p  0.01). 
 
 
Figure 9.2E shows representative recordings from a single co-injected oocyte and 
the corresponding analysis. Currents were measured in the absence as well as in the 
presence of glutamate and serine. For the application of each substrate alone as well 
as for the simultaneous application of both, we determined substrate-dependent 
current amplitudes for various voltages and constructed current-voltage relationships 
from these data (Figure 9.2F). Current increases elicited by the simultaneous 
presence of glutamate and serine were slightly smaller than the sums of the current 
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amplitudes induced by only one substrate at positive potentials (Figure 9.2G). At 
negative potentials, where current amplitudes are dominated by coupled transport 
currents, no difference between the two amplitudes could be observed (Figure 9.2G). 
 
 
9.4.3 Individual Subunits Transport Substrates Independently of Each Other 
WT hEAAT3 and R501C rEAAT4 differ in the apparent dissociation constants for 
glutamate/serine and sodium (25, 30). To test whether binding of an amino acid 
substrate/cation to one subunit is affected by the neighboring subunit, we determined 
glutamate concentration dependences of hEAAT3 anion currents when expressed 
alone or co-expressed together with R501C rEAAT4 in oocytes (Figure 9.3A), or 
serine concentration dependences of R501C rEAAT4 currents either expressed 
alone or co-expressed with WT hEAAT3 (Figure 9.3B).  
 
Figure 9.3 
Substrates bind independently to individual subunits 
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Figure 9.3: Substrates bind independently to individual subunits. 
A, glutamate dependence of isochronal current amplitudes measured at +60 mV from oocytes 
expressing WT EAAT3 (filled circles, n = 3, KD = 23.4  1.2 µM) and oocytes co-expressing WT 
EAAT3 and R501C EAAT4 (open triangles, n = 6, KD = 26.0  2.4 µM) in the absence of serine. B, 
serine dependence of isochronal current amplitudes from oocytes expressing R501C EAAT4 (filled 
circles, n = 3, KD = 6.1  0.1 µM) or co-expressing WT EAAT3 and R501C EAAT4 (open triangles, n = 
6, KD = 4.6  0.7 µM) in the absence of glutamate. C, comparison of the serine dependence of 
isochronal current amplitudes from oocytes expressing R501C EAAT4 (shown in B) with the serine 
dependence from oocytes co-expressing WT EAAT3 and R501C EAAT4 in the presence of 500 µM 
glutamate (open triangles, n = 5, KD = 4.6  0.2 µM). D, serine dependence of substrate-dependent 
anion current amplitudes. Data from C were scaled by setting the minimum values to 0 and the 
maximum values to 1. E, sodium dependence of isochronal current amplitudes from oocytes 
expressing WT EAAT3 (filled circles, n = 5, KD = 38.2  0.8 mM) and oocytes co-expressing WT 
EAAT3 and R501C EAAT4 (open triangles, n = 8, KD = 42.5  0.5 mM) in the presence of 500 µM L-
glutamate. F, sodium dependence of the isochronal current amplitude from oocytes expressing R501C 
EAAT4 (closed circles, n = 6, KD = 6.4  1.4 mM) or co-expressing WT EAAT3 and R501C EAAT4 
(open triangles, n = 4, KD = 5.5  0.5 mM) in the presence of 500 µM L-serine. 
 
 
No differences in the apparent dissociation constants were observed. Moreover, the 
serine concentration dependence was not affected when co-applied with a saturating 
concentration of glutamate (Figure 9.3C and D), a condition in which the hEAAT3 is 
expected to be predominantly in the inward-facing, but not in the outward-facing 
configuration. At saturating glutamate (Figure 9.3E) or serine concentrations (Figure 
9.3F), WT hEAAT3 and R501C rEAAT4 differ significantly in the apparent 
dissociation constants for sodium, with R501C rEAAT4 showing significantly higher 
apparent affinity. However, co-expression of the two transporters does not modify 
sodium binding (Figure 9.3E and F). 
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Figure 9.4 
Substrate translocation occurs independently by individual subunits 
 
Figure 9.4: Substrate translocation occurs independently by individual subunits. 
A, typical exchange transport current recordings (in the absence of permeating anions) after laser 
pulse photolytic release of glutamate at t = 0 with cells expressing WT EAAT3 alone or co-expressing 
WT EAAT3 and R501C EAAT4 (internal solution contained 140 mM NaMES and 10 mM glutamate 
and serine, exchange mode). The presence of R501C EAAT4 was tested by applying a saturating 
serine concentration in the anion-conducting mode. The decay of the transport current is biphasic in 
both cases and could be fit with a sum of two exponentials, yielding two time constants. B, 
quantification of the time constants associated with the rapidly and slowly decaying phases of the 
exchange transport current for WT EAAT3-expressing cells (black, n = 3) and R501C EAAT4 + WT 
EAAT3-expressing cells (grey, n = 3). C and D, typical anion current recordings (inward current 
caused predominantly by outflow of the highly permeant anion SCN
-
) after laser pulse photolytic 
release of glutamate at t = 0 with cells expressing WT EAAT3 alone or co-expressing WT EAAT3 and 
R501C EAAT4 in the absence (grey traces) and presence (black traces) of serine (internal solution 
contained 140 mM NaSCN and 10 mM glutamate and serine, exchange mode). In C, the baseline 
current of the black trace is increased due to the continuous presence of serine, preactivating R501C 
EAAT4. In the absence of R501C EAAT4, serine had no effect. The rise of the current was fit with a 
sum of two exponentials, yielding two time constants. E and F, quantification of the time constants 
associated with the rapidly (open bars) and slowly (gray bars) rising phases of the exchange anion 
current for R501C EAAT4 + WT EAAT3-expressing cells (E, n = 3) and WT EAAT3-expressing cells 
(F, n = 3) in the presence and absence of extracellular serine. Error bars, S.D. 
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To test for potential subunit interactions during coupled substrate transport, we 
employed heterologous expression in mammalian cells and rapid application of 
glutamate with subsequent analysis of the relaxation of the transport-associated 
currents. This approach allows the resolution of early conformational changes in 
glutamate transporters (Figure 9.4). Because homotrimeric R501C rEAAT4s are 
insensitive to glutamate, differences in current responses of cells co-expressing WT 
hEAAT3 and R501C rEAAT4 from cells expressing hEAAT3 alone will indicate 
modification of the function of hEAAT3 by adjacent rEAAT4 subunits. We performed 
these experiments under two different intracellular ionic conditions, i.e. with MES- or 
with SCN- as the predominant intracellular anion. In both types of experiments, 
intracellular K+ was replaced by Na+, eliminating the relocation of the K+-bound 
transporter. With internal MES-, there are no contributions of EAAT anion channels, 
and currents reflect conformational changes in the Na+/glutamate homoexchange 
mode (33) (Figure 9.4A and B). SCN- represents the anion with highest permeability 
through the EAAT anion pore (8, 25, 32), and in cells dialyzed with internal SCN-, 
currents at negative potentials are dominated by EAAT-mediated anion currents. 
Two kinetic components of the current signal in response to glutamate application 
are observed in hEAAT3-expressing cells, a fast component due to Na+ binding and 
a conformational change subsequent to the association of glutamate with the 
transporter (35) and a slow component representing the translocation of Na+ and 
glutamate (26). Homo- and heterotrimeric transporters display identical time 
constants and relative amplitudes of the two kinetic components (Figure 9.4B). The 
two kinetic processes can also be observed in the presence of internal SCN-. In this 
case, sudden increases of the external glutamate concentration result in a 
biexponential activation of hEAAT3 anion channels with the same time constants as 
observed in the absence of permeant anions (Figure 9.4C and D). Serine activates 
R501C rEAAT4 anion channels and thus increases the current amplitude in cells 
expressing heterotrimers in the presence of internal SCN-. However, the rate 
constants of current activation were not affected by the co-expression of R501C 
rEAAT4, either in the absence or in the presence of serine (Figure 9.4E and F). We 
conclude that, within heterotrimeric assemblies, individual EAAT subunits bind and 
transport amino acid substrates and sodium ions independently of each other. 
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9.4.4 Targeting of Heterotrimeric Transporters in Polarized Epithelial Cells 
EAAT3 exhibits a unique sorting signal that targets transporters to the apical 
membrane of epithelial cells and into neuronal dendrites (27). EAAT1, EAAT2, and 
EAAT4 lack this signal and are therefore distributed differently in MDCK cells than 
hEAAT3 (27). We used co-expression of fluorescent protein-tagged hEAAT3 and 
rEAAT4, confocal imaging (Figure 9.5) and surface biotinylation (Figure 9.6) to study 
whether hetero-trimerization affects epithelial sorting.  
 
Figure 9.5  
Epithelial sorting of homo- and heterotrimeric EAATs observed by confocal 
imaging 
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Figure 9.5: Epithelial sorting of homo- and heterotrimeric EAATs observed by confocal 
imaging.  
A-D, confocal images of MDCK cells that transiently express CFP-hEAAT3 (A), YFP-rEAAT4 (B), 
barttin-YFP (C), or hSLC26A9-YFP (D). E, co-expression of CFP-EAAT3 and YFP-rEAAT4. CFP is 
shown in green, and YFP is shown in red. This color code results in an orange coloring of regions 
where both proteins overlap. Individual YFP and CFP fluorescences are added to demonstrate co-
localization of hEAAT3 and rEAAT4. F, co-expression of GFP-hEAAT3 and mCherry-hEAAT2. GFP is 
shown in green, and mCherry is shown in red. GFP and mCherry fluorescences are added to 
demonstrate co-localization of hEAAT3 and hEAAT2. Arrows indicate basolateral membranes. x-y 
projections (front view) are given in the upper part, x-z projections (side view) in the lower part. Scale 
bar, 5 µm. 
 
 
We first performed confocal imaging in confluent monolayers to study alteration of 
epithelial sorting (Figure 9.5). Whereas CFP-hEAAT3 alone is predominantly inserted 
into the apical dome (Figure 9.5A), YFP-rEAAT4 is visible in the apical and in the 
basolateral membranes (Figure 9.5B). We used barttin as basolateral (28, 36) (Fig. 
9.5C) and SLC26A9 as apical marker (Figure 9.5D) (29). Co-transfection of CFP-
hEAAT3 and YFP-rEAAT4 results in the appearance of hEAAT3 and rEAAT4 in 
apical as well as in basolateral (arrows) domains (Figure 9.5E). As expected for 
hetero-oligomerizing subunits, YFP and CFP fluorescence co-localizes. In contrast, 
co-transfection of GFP-hEAAT3 with mCherry-hEAAT2 that does not result in the 
formation of heterotrimers (Figure 9.1) fails to route hEAAT3 to the basolateral 
domain (Figure 9.5F, arrows). 
To quantify this alteration of epithelial sorting, we performed surface biotinylation in 
confluent monolayers of MDCK cells grown on filters (Figure 9.6). Figure 9.6A 
displays the fluorescent scan of a SDS-polyacrylamide gel with purified membrane-
inserted GFP-hEAAT3 after biotin application to the apical or the basolateral site of 
 
Hetero-oligomerization of neuronal glutamate transporters 
82 
 
cells expressing GFP-hEAAT3 alone or co-expressing GFP-hEAAT3 and rEAAT4 or 
hEAAT2.  
Figure 9.6  
Epithelial sorting of homo- and heterotrimeric EAATs studied by cell surface 
biotinylation 
 
 
Figure 9.6: Epithelial sorting of homo- and heterotrimeric EAATs studied by cell surface 
biotinylation. 
A, fluorescent scans of SDS-PAGE of GFP-hEAAT3 purified by surface biotinylation from basolateral 
and apical membranes of MDCK cells expressing GFP-hEAAT3 alone or together with untagged 
rEAAT4 or hEAAT2. Control blots show that Na
+
,K
+
-ATPase is detected at the basolateral but not the 
apical cell surface fraction, whereas heterologously expressed SLC26A9-mYFP is predominantly 
present in the apical membrane. Actin was only detected in the intracellular fraction. B and C, relative 
amounts of EAAT3 protein in the apical and the basolateral membrane when expressed alone or 
together with rEAAT4 (B) or hEAAT2 (C). GFP-EAAT3 was surface-biotinylated from the apical or the 
basolateral membrane, quantified by GFP fluorescence, and given as relative amount of the total 
surface fluorescence. Data represent means  S.E. (error bars) from three experiments. Level of 
significance: *, p  0.05; **, p  0.01. Solid lines give the proportion of the apical marker protein 
hSLC26A9 in basolateral or apical fractions. 
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In all cases, the majority of biotinylated EAAT3 protein is complex-glycosylated. 
Endogenous Na+,K+-ATPase and hSLC26A9-YFP were used as basolateral or apical 
controls. 
Figure 9.6B shows the relative amounts of biotinylated GFP-hEAAT3 after biotin 
application to the apical or the basolateral site, when expressed alone or co-
expressed with nonfluorescent rEAAT4. Whereas hEAAT3 homotrimers preferentially 
inserts into the apical membrane, hetero-trimerization results in equal distribution of 
hEAAT3 in the apical and the basolateral membrane. Co-expression with hEAAT2 
does not modify the polarized expression of hEAAT3 (Figure 9.6C). We conclude that 
hEAAT3 is targeted to distinct regions as homotrimer or as a hEAAT3/rEAAT4 
heterotrimer. 
 
 
 
9.5 Discussion 
We here demonstrate that EAAT3 and EAAT4, but neither EAAT1 and EAAT2 nor 
EAAT2 and EAAT3, co-assemble into stable heterotrimers in heterologous 
expression systems. EAAT3 and EAAT4 co-express in several cell types of the 
mammalian brain (37, 38), and heterotrimers might, thus, represent a significant 
portion of the native transporters. BN-PAGE demonstrates the existence of stable 
heterotrimers, providing compelling evidence for a direct interaction of EAAT3 and 
EAAT4 (Figure 9.1). There are no indications for dimers and monomers or for higher 
order oligomers, i.e. the linkage of two trimers via interacting proteins. 
Recent reports have demonstrated that co-expression of WT and mutant EAAT 
subunits results in a superposition of WT and mutant glutamate transport and anion 
currents, in full agreement with functionally independent subunits (17–19). We 
extended these studies by measuring substrate dependences (Figure 9.3) as well as 
early conformational changes (Figure 9.4) in heterotrimeric glutamate transporters. 
Our results support the idea that individual subunits function independently within the 
hetero-oligomeric assembly. The substrate concentration dependences of hEAAT3 
and R501C rEAAT4 anion currents are similar in homo- and in heterotrimeric 
assemblies (Figure 9.3). Pre-steady-state kinetics of hEAAT3 are unaffected by the 
presence of R501C rEAAT4 in the heteromultimer (Figure 9.4). Co-expression of 
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hEAAT3 and serine-sensitive R501C rEAAT4 results in uptake currents that are 
identical to the superposition of currents mediated by hEAAT3 and R501C rEAAT4 
(Figure 9.2G). For EAAT-associated anion currents, we observed slight deviations 
from the expectations of complete independence of individual subunits (Figure 9.2G). 
Structural evidence from the bacterial EAAT homolog GltPh (39) suggested that 
substrate transport requires a major conformational change. Comparison of high 
resolution structures of GltPh in the outward-facing (15) and in the inward-facing 
conformation (39) demonstrated a largely immobile “trimerization domain” (containing 
TM1, TM2, TM4, and TM5) and a “transport domain” undergoing substantial 
movements during the glutamate transport process (39). This transport mechanism 
requires trimerization for normal transport and suggests that monomeric GltPh 
subunits might be unable to transport, in contrast to other multimeric transporter 
families (40). The apparent independence of EAAT subunits indicates that any 
transmission of conformational changes to other subunits through the trimerization 
domain may be minor. 
Neither the glial transporters EAAT1 and EAAT2 nor EAAT2 and EAAT3 or EAAT2 
and EAAT4 have the ability to co-assemble (Figure 9.1). Hetero-trimerization is, 
therefore, not a common feature of different EAAT isoforms. At present, we can only 
speculate about the biological significance of the hetero-oligomerization of EAAT3 
and EAAT4. EAAT3 and EAAT4 are co-expressed in certain neurons of the central 
nervous system. Cooperation of different targeting signals might result in the 
insertion of heteromultimers in cell regions that exclude homotrimers. Hetero-
trimerization results in close proximity of low affinity/high capacity (EAAT3) and high 
affinity/low capacity (EAAT4) transporter (30), allowing tight regulation of the external 
glutamate concentration. Because EAAT anion channels possibly modulate neuronal 
excitability (2, 11), relative expression levels of EAAT3 and EAAT4 will result in 
distinct pattern of neuronal excitability and its regulation by glutamate. 
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Background: Neutralizing a conserved aspartate between TM2 and TM3 affects 
gating of EAAT anion channels.  
Results: Voltage clamp fluorometry demonstrates that the analogous mutation alters 
EAAT3 substrate translocation. 
Conclusion: Altered substrate translocation is sufficient to explain anion channel 
gating in D83A EAAT3.  
Significance: Dissection of transport and anion channel gating defines an intimate 
relationship between these two EAAT transport functions. 
 
 
 
10.1 Abstract 
Excitatory amino acid transporters (EAATs) terminate glutamatergic synaptic 
transmission by removing glutamate from the synaptic cleft into neuronal and glial 
cells. EAATs are not only secondary-active glutamate transporters, but also function 
as anion channels. Gating of EAAT anion channels is tightly coupled to transitions 
within the glutamate uptake cycle, resulting in Na+- and glutamate-dependent anion 
currents. A point mutation neutralizing a conserved aspartic acid within the 
intracellular loop close to the end of transmembrane domain 2 (TM2) was recently 
shown to modify the substrate dependence of EAAT anion currents. To distinguish 
whether this mutation affects transitions within the uptake cycle, or directly modifies 
opening/closing of the anion channel, we employed voltage clamp fluorometry. Using 
three different sites for fluorophore attachment, V120C, M205C and A430C, we 
observed time-, voltage- and substrate-dependent alterations of EAAT3 fluorescence 
intensities. The voltage and substrate dependence of fluorescence intensities can be 
described by a 15-state model of the transport cycle in which several states are 
connected to branching anion channel states. D83A-mediated changes of 
fluorescence intensities, anion currents and secondary-active transport can be 
explained by exclusive modifications of substrate translocation rates. In contrast, sole 
modification of anion channel opening and closing is insufficient to account for all 
experimental data. We conclude that D83A has direct effects on the glutamate 
transport cycle, and that these effects result in changed anion channel function. 
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10.2 Introduction 
Excitatory amino acid transporters (EAATs) are secondary-active transporters that 
mediate the stoichiometrically coupled transport of one glutamate, three sodium ions 
and one proton while one potassium ion is counter-transported (1; 2). They are 
necessary for termination of glutamatergic synaptic transmission and for 
maintenance of low resting glutamate levels (3-5). There are five different mammalian 
EAATs with distinct physiological roles. Genetic removal of mouse EAAT2 results in 
pronounced hyperexcitability and neurodegeneration (6) demonstrating the crucial 
role of this isoform for glutamate homeostasis in the central nervous system. Mouse 
models that lack other EAATs exhibit much milder phenotypes with certain 
impairment of motor coordination, behavioural abnormalities, or age-dependent 
neurodegeneration (7-10). EAAT3 is not only expressed in the central nervous tissue, 
but also mediates glutamate and aspartate reabsorption in the renal proximal tubule 
(8). Naturally occurring mutations in the gene encoding EAAT3 cause human 
dicarboxylic aminoaciduria (11). 
EAATs are not only glutamate transporters, but also conduct a pore-mediated anion 
current (12-15). EAAT anion currents have been postulated to be involved in the 
regulation of cell excitability (16; 17), but so far, the physiological importance of this 
transport function is not sufficiently understood. EAAT anion currents are thought to 
be conducted through an anion pathway that is opened and closed in response to 
conformational changes underlying glutamate transport (18; 19). However, how this 
anion pore is formed and how opening and closing occur is unclear. In a systematic 
screen for mutations affecting EAAT1 anion channel function, D112A was found to 
abolish the glutamate dependence of EAAT1 anion currents (20). The corresponding 
mutation D117A was later shown to change unitary anion current amplitudes and 
relative anion selectivities of EAAT4 anion channels (19), suggesting close proximity 
of this residue to the EAAT4 anion conduction pathway. In addition to modifying 
EAAT1 anion currents, D112A reduces EAAT1 glutamate uptake rates by 40%.  
So far, anion permeation through EAATs was thought not to affect glutamate 
transport (13). A mutation that changes anion conduction and coupled glutamate 
transport thus promises insights into the interdependence of the two EAAT transport 
functions, and thus, we decided to further study this mutation using voltage clamp 
fluorometry. Voltage clamp fluorometry combines electrophysiological and 
fluorescence measurements and has been used to monitor conformational changes 
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in diverse transport proteins (21-23). We inserted the homologous mutation D83A 
into EAAT3 and applied voltage clamp fluorometry to separate the effects on coupled 
transport and on anion channel function. EAAT3 has already been studied using 
voltage clamp fluorometry, permitting detection of conformational rearrangements 
during coupled transport (23-26). Moreover, EAAT3 effectively transports glutamate 
(12; 27), thus permitting additional direct insights into the effects of neutralizing D83 
on coupled transport.  
We found that D83A changes the time, substrate and voltage dependence of EAAT3 
fluorescence signals. Moreover, similar to earlier data on D112A EAAT1 and D117A 
EAAT4, D83A enlarges EAAT3 anion currents in the absence of glutamate, but 
reduces glutamate-sensitive current amplitudes. It reduces coupled transport by 
about 50%. The data on fluorescence amplitudes and transport function can be 
described by a kinetic scheme in which only transitions within the uptake cycle are 
modified by the mutation, whereas the likelihood of anion channel opening was not 
changed in mutant transporters. 
 
 
 
10.3 Experimental Procedures 
10.3.1 Expression of WT and mutant hEAAT3 transporters in Xenopus laevis 
oocytes 
Point mutations were introduced into pTLN2-hEAAT3 (28; 29) (kindly provided by Dr. 
Matthias Hediger (University of Bern, Switzerland)) using the QuikChange 
mutagenesis kit (Stratagene, La Jolla, CA, USA). Capped cRNA was synthesized 
from MluI-/NheI-linearized pTLN2-hEAAT3 through use of MESSAGE machine kits 
(Ambion, Austin, TX, USA). Collagenase-treated, defolliculated stage IV-V oocytes 
were microinjected with 10 ng of RNA (Nanoliter 2000, World Precision Instruments, 
Sarasota, FL, USA) and incubated at 18°C in ND96 (in mM: 96 NaCl, 2 KCl, 1.8 
CaCl2, 1 MgCl2, 5 Hepes, pH 7.6, supplemented with 2.5 sodium pyruvate and 50 
µg/ml gentamycine sulfate). Experiments were performed 3-7 days after injection.  
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10.3.2 Electrophysiology 
Currents were recorded through two-electrode voltage clamp using a CA-1B amplifier 
(Dagan Corporation, Minneapolis, MN, USA) and digitized at 5 kHz using an ITC-18 
Computer Interface in combination with Patchmaster (HEKA Elektronik, Lambrecht, 
Germany) (30). Experiments were performed under constant perfusion  using a PF-8 
8-Channel Perfusion System (Abimek-Zech electronic, Göttingen, Germany) with 
Ringer’s solution (in mM: 98.5 Choline-Cl or NaCl/NO3/gluconate, 1.8 
CaCl2/gluconate, and 1 MgCl2/gluconate, 5 Hepes pH 7.5,  1 glutamate). Oocytes 
were held at 0 mV for at least 2 s between voltage steps. 
 
 
10.3.3 Voltage clamp fluorometry 
For fluorescence experiments, oocytes were labeled for 2-3 h with 10 µM of the 
fluorescent maleimide probe, AlexaFluor546 (Life Technologies Corporation, 
Invitrogen, Carlsbad, CA, USA). A short arc mercury lamp (HBO 103W/2, Osram, 
München, Germany) combined with a Uniblitz shutter (VS25S2ZMOR1-24 shutter, 
VCM-D1 shutter driver, Uniblitz, Vincent Associates, Rochester, NY, USA) was used 
as light source. Fluorescence was monitored under voltage clamp by a photodiode 
(PIN020-A, AMS Technologies AG, Martinsried, Germany) and a rhodamine filter 
cube (HQ535/50x, Q565LP,  HQ610/75m, Chroma Technology Corp., Bellows Falls, 
VT, USA) attached to an inverted fluorescence microscope (IX71, Olympus, 
Hamburg, Germany). Fluorescence signals were amplified with a DLPCA-200 
amplifier (Femto Messtechnik, Berlin, Germany) and low pass-filtered at 2 kHz (LPF-
8, Low Pass Bessel Filter, Warner Instruments, Hamden, CT, USA). Representative 
fluorescence recordings were obtained by averaging ten consecutive measurements. 
 
 
10.3.4 Data analysis 
Electrophysiological and fluorescence data were analyzed with a combination of 
Patchmaster (HEKA Elektronik, Lambrecht,), pClamp10 (Molecular Devices, 
Sunnyvale, CA, USA), MATLAB (The MathWorks, Natick, MA, USA) and SigmaPlot 
(Jandel Scientific, San Rafael, CA, USA). For statistical evaluations, Student’s t-test 
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and paired t-test with p ≤ 0.05 (*) as the level of significance were used (p ≤ 0.01 (**), 
p ≤ 0.001 (***)). The data are given as means ± S.E.. 
 
10.3.5 Kinetic modeling 
Voltage and substrate dependence of EAAT3 fluorescence was simulated by solving 
differential equations at steady-state according to a previously developed 15-state 
model of EAAT2 extended by channel states branching from the uptake cycle (19; 
23; 31). Rate constants of the uptake cycle were adopted from earlier work on 
cysteine-substituted EAAT3 (23). Anion channel open probabilities were estimated by 
optimizing the model against cysteine-substituted WT steady-state fluorescence data 
using the genetic algorithm as implemented in MATLAB (The MathWorks, Natick, 
MA, USA). The overall fluorescence was calculated as sum of the products of relative 
fluorescence and probability of occupation for every state. This model was then 
adapted to D83A EAAT3 - either by modifying translocation rates (reactions 8, 15, 
17) or anion channel open probabilities. In all cases, detailed balance was preserved, 
and fitting parameters were simultaneously optimized against experimentally 
determined relative glutamate uptake and anion current amplitudes. For kinetic 
modeling we assumed intracellular concentrations of [Na+] = 10 mM, [K+] = 70 mM, 
[glu] = 12 mM and a pH = 7.3 (1), extracellular concentrations were set to 
experimental conditions. 
 
 
 
10.4 Results 
10.4.1 Time, substrate and voltage dependence of EAAT-associated currents 
and fluorescence signals 
To permit site-directed fluorescence labeling of EAAT3 we introduced single 
cysteines into human EAAT3 and expressed WT and cysteine-substituted 
transporters in Xenopus oocytes (Figure 10.1). We chose three reporter mutations 
localized in different parts of the transporter, V120C (3-4 loop), M205C (TM4c) and 
A430C (7-8 loop) (Figure 10.1A) to observe fluorescence changes due to 
conformational changes in more than one protein region. M205C and A430C has 
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already been used in earlier studies (23; 25), whereas V120C has not been reported 
to date. Since the fluorophore attachment site Cys120 is localized nearby an 
accessible endogenous cysteine, we additionally mutated Cys158 to serine in all our 
constructs, to prevent possible modifications by fluorophore application.  
For each reporter mutation, the time course of fluorescence labeling was tested to 
define incubation times sufficient for maximum labeling (Suppl. Figure 10.8). V120C, 
M205C and A430C EAAT3 injected oocytes exhibit higher levels of fluorescence 
intensities as uninjected oocytes or oocytes expressing C158S EAAT3 (data not 
shown). Moreover,  oocytes expressing V120C, M205C or A430C EAAT3 displayed 
fluorescence changes upon voltage or substrate alterations (Suppl. Figure 10.9) that 
were absent in uninjected oocytes or those expressing C158S EAAT3, indicating that 
cysteine-substituted EAAT3 are specifically labeled with the fluorescent dye.  
 
 
Figure 10.1  
Reporter mutations do not affect the function of EAAT3 associated currents 
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Figure 10.1: Reporter mutations do not affect the function of EAAT3 associated currents. 
A, localization of the fluorescence reporter mutations, V120C, M205C and A430C on the 
transmembrane topology model of EAAT3. The trimerization domain is shown in grey, the transport 
domain and the hairpins are in black. B, representative current traces recorded from X. laevis oocytes 
expressing WT, V120C, M205C or A430C EAAT3. C, averaged absolute current amplitudes at ±100 
mV (top) and averaged uptake current amplitudes at -100 mV (bottom) calculated by the difference of 
measurements in sodium gluconate with and without glutamate. n.s.: not significantly different p  
0.05, ***, p ≤ 0.001. Data are given as means ± S.E.; n ≥ 7.Int, internal; Ext, external; glu, glutamate. 
 
 
To test whether cysteine insertions change glutamate transport or anion conduction 
we studied WT and cysteine-substituted EAAT3 currents using two-electrode voltage 
clamp (Figure 10.1B). Application of glutamate resulted in a pronounced increase of 
current amplitudes at negative as well as at positive voltages. In the absence as well 
as in the presence of glutamate, current amplitudes in oocytes expressing V120C, 
M205C, or A430C EAAT3 were not statistically different from those of WT EAAT3, 
illustrating comparable expression levels. EAAT3 currents consist of two 
components, glutamate uptake currents due to electrogenic transport and EAAT3-
associated anion currents. Glutamate uptake current can be separated from anion 
currents after substituting permeant anions with impermeant gluconate and 
measured as the difference of currents in the presence and in the absence of 
glutamate (2; 13; 33). Glutamate uptake is strongly voltage-dependent and 
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decreases to values around zero at positive potentials (2). Thus, currents at positive 
voltages predominantly represent anion currents. The use of NO3
- as main external 
anion results in EAAT3 currents that are significantly larger than endogenous 
currents of uninjected oocytes and permit accurate measurements of EAAT3 anion 
currents (Figure 10.1B) (33). For all tested constructs, glutamate uptake currents and 
anion currents at saturating glutamate concentrations were not statistically different 
from WT values, illustrating that none of the cysteine substitutions modify functional 
properties of EAAT3 (23;25) (Figure 10.1B and C). 
Figure 10.2 shows representative fluorescence recordings from V120C, M205C or 
A430C EAAT3 in the absence (top) or in the presence (bottom) of 1 mM L-glutamate. 
Oocytes were held at 0 mV, and voltage steps between -150 mV and +150 mV were 
applied in 50 mV intervals. In the absence of glutamate hyperpolarizing voltage steps 
caused a slow reduction of V120C EAAT3 fluorescence that could be fit with a 
monoexponential function ((-150 mV) = 46.7 ± 4.3 ms, n = 3) (Figure 10.2A). M205C 
and A430C EAAT3 exhibited fluorescence amplitudes that, in the absence of 
glutamate, increased upon membrane depolarization and decreased upon 
hyperpolarization (Figure 10.2B and C). The time course of these voltage-dependent 
changes was significantly faster than for V120C ((M205C,-150/+150mV) = 4.3 ± 0.4/7.1 ± 
0.9 ms, n = 3; (A430C,-150/+150mV) = 10.5 ± 0.6/8 ± 1.2 ms, n = 3). For M205C EAAT3, 
the initial rise upon membrane depolarization was followed by a much slower decay 
(Figure 10.2).  
Application of glutamate increased fluorescence intensities of V120C EAAT3 and 
decreased these values for M205C and A430C EAAT3. Glutamate modified the 
voltage dependences of fluorescence signals for all cysteine-substituted EAAT3 
(Figure 10.2). Application of L-glutamate accelerated the time course of fluorescence 
change ((+150 mV) = 16 ± 0.5 ms, n = 3) and modified its voltage dependence for 
V120C EAAT3 (Figure 10.2A). For M205C and A430C EAAT3 (Figure 10.2B and C), 
fluorescence showed lowest intensity around 0 mV and increased upon positive as 
well as negative membrane potentials. In the presence of glutamate, fluorescence 
increased on a slow time course upon depolarization as well as upon 
hyperpolarization ((M205C,+150mV) = 87.2 ± 3.2 ms, n = 3; (A430C,+150mV) = 59.2 ± 4.2 ms, 
n = 2). 
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Figure 10.2 
Voltage- and substrate-dependent conformational changes of EAAT3 
 
 
 
 
Figure 10.2: Voltage- and substrate-dependent conformational changes of EAAT3. 
Representative fluorescence traces (left column) recorded from X. laevis oocytes expressing V120C 
(A), M205C (B) and A430C EAAT3 (C) and averaged voltage dependence of late (arrow) relative 
ﬂuorescence changes (right column) in the presence of different substrates are shown. Fluorescence 
signals were measured in NaCl Ringer’s solution during 200-ms voltage steps between +150 mV and -
150 mV. Fluorescence amplitudes were normalized to the fluorescence generated at +150 mV in NaCl 
solution. Measurements in NaCl at voltages above 0 mV are shown in red, 0 mV is in dark red, and 
negative voltages in the absence of 1 mM glutamate are shown in light grey and in the presence of 1 
mM glutamate are shown in black. Fluorescence data from at least six oocytes are reported as means 
± S.E.. F, fluorescence; glu, glutamate. 
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EAAT-mediated glutamate transport is based on a series of substrate association 
steps and related conformational changes. Three Na+ ions, one H+ and one 
glutamate associate with the outward facing transporter with an open extracellular 
gate (hairpin 2; HP2). After closure of HP2 and movement of the translocation 
domain to the inside (34), Na+, H+ and glutamate are released by opening of the 
intracellular gate (hairpin 1; HP1), and the uptake cycle is completed by 
retranslocation after association of K+ or Na+. Modification of the uptake cycle by 
removal of certain substrates or application of EAAT-specific blockers allows testing 
of the specificity of the observed signals. For all constructs, substitution of Na+ by 
choline+ abolished the voltage dependence of fluorescence signals and changed the 
fluorescence intensity (Figure 10.2). A specific blocker of EAAT transporters, DL-
threo-benzyloxyaspartate (35; 36) inhibited fluorescence changes in the absence and 
in the presence of glutamate by about 90%, supporting the notion that fluorescence 
changes are due to conformational rearrangements in the glutamate transporter 
(Suppl. Figure 10.9).  
EAAT4 anion channel gating depends on anion concentrations on both membrane 
sites (19; 33). To test whether EAAT3 fluorescence intensities undergo anion-
dependent alterations, we studied all cysteine-substituted EAAT3 constructs after 
substitution of the external anion by gluconate. Chloride removal did not change the 
intensity or voltage dependence of fluorescence signals (Suppl. Figure 10.10A-C). 
We conclude that fluorescence changes of fluorophores added to V120C, M205C 
and A430C report on conformational changes within the EAAT3 uptake cycle that 
require external Na+ but do not depend on the anion composition. 
To test whether EAAT3 
 
 
10.4.2 Voltage clamp fluorometry reveals additional slow conformational 
changes 
In addition to the initial rise upon depolarization, fluorescence intensities of M205C 
EAAT3 exhibited voltage-dependent changes with very slow time course. Figure 10.3 
shows such current and fluorescence recordings of M205C EAAT3 on an extended 
time scale. In the absence of glutamate, a depolarizing voltage step to +50 mV 
caused a very slow fluorescence decay ((+50mV) = 6.7 ± 1.2 s, n = 6). This process is 
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not due to bleaching, since we observed slow fluorescence recovery upon return to 
the holding potential of 0 mV (Figure 10.3A). Application of glutamate shifted the 
voltage dependence of these slow processes so that relaxation of these signals was 
observed upon voltage steps to -100 mV ((-100mV) = 4.0 ± 1.2 s, n = 11) (Figure 
10.3A).  
 
Figure 10.3  
Slow conformational changes in EAAT3 
 
 
Figure 10.3: Slow conformational changes in EAAT3. 
A, representative current and fluorescence traces recorded from X. laevis oocytes expressing M205C 
EAAT3 in response to long voltage steps to +50 mV in the absence of glutamate (light grey, top) or to -
100 mV in the presence of glutamate (black, bottom) and the recovery back to the holding potential of 
0 mV. B, current responses to voltage steps to +60 mV of increasing durations followed by ﬁxed test 
steps to -120 mV in the absence of glutamate (light grey, top) and in the presence of glutamate (black, 
middle). Averaged current amplitudes (bottom) are given as means ± S.E.; n = 4. glu, glutamate; 
NaGluc, sodium gluconate. 
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These fluorescence changes are too slow to represent transitions within the uptake 
cycle. However, we did not observe slow fluorescence changes in the absence of 
transport substrates or in the presence of DL-threo-benzyloxyaspartate (Suppl. 
Figure 10.9), suggesting that the slow fluorescence signal also reflects 
conformational changes coupled to the uptake cycle. A possible explanation might be 
a conformational change occurring from certain states of the uptake cycle. Such a 
kinetic scheme predicts that occupation of this novel state will prevent progress of the 
uptake cycle and thus result in concomitant slow alterations of transport rates. We 
tested for slow voltage-dependent changes of glutamate transport rates by studying 
glutamate uptake currents after prepulses to positive voltages. These experiments 
were performed in external gluconate after incubation of oocytes in Cl--free solution 
(13). For various pulse protocols, we did not observe any time- or voltage-dependent 
changes in transport current amplitudes (Figure 10.3B). These data indicate that slow 
fluorescence changes cannot be represented as transitions branching from the 
uptake cycle. 
 
 
10.4.3 D83A modifies EAAT3 glutamate transport, anion currents and 
fluorescence amplitudes  
We next inserted the D83A mutation into each cysteine-substituted EAAT3 construct 
and studied the functional effects of this mutation using voltage clamp analysis. D83 
is localized between TM2 and TM3 and is highly conserved among mammalian 
EAATs (Figure 10.4A). Because homologous mutations in EAAT1 (20) and EAAT4 
(19) alter glutamate transport and anion conduction, D83A might allow insights into 
how conformational changes underlying coupled transport open and close the anion 
channel. 
At positive membrane potentials in the absence of glutamate, D83A EAAT3 currents 
were statistically larger than WT or cysteine-substituted EAAT3 currents (Figure 
10.4B and C) (WT (3.7 ± 0.2 µA) compared to V120C-D83A (7.7 ± 0.3 µA): p < 0.001, 
compared to M205C-D83A (6.1 ± 0.5 µA): p = 0.006, and compared to A430C-D83A 
(9.5 ± 0.5 µA): p < 0.001; n  10). The glutamate-induced current increase was less 
pronounced in D83A EAAT3 than in WT EAAT3 (Figure 10.4C, top). This is due to 
virtually glutamate-independent anion current amplitudes (Figure 10.4C, middle). 
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Moreover, D83A reduced uptake current amplitudes to values between 30% and 
50% for all reporter mutations (Figure 10.4C, bottom). 
Voltage clamp fluorometry revealed D83A-induced changes in the voltage and 
substrate sensitivity of the fluorescence signals for each fluorophore attachment site 
(Figure 10.5). V120C-D83A and A430C-D83A EAAT3 fluorescence signals increased 
during depolarization and decreased during hyperpolarization (Figure 10.5A and C). 
However, D83A modified the time course of hyperpolarization-induced fluorescence 
decreases (((V120C-D83A,-150mV) = 18.2 ± 2.6 ms, n = 2; (A430C-D83A,-150/+150mV) = 12.7 ± 
2.6/11.5 ± 2.8 ms, n = 4). The voltage dependence of M205C EAAT3 fluorescence 
was dramatically altered by D83A. Without external glutamate, D83A EAAT3 
fluorescence amplitudes displayed minimum levels around +50 mV and increased 
with depolarization and hyperpolarization to nearly the same intensity as in sodium-
free conditions (Figure 10.5B).  
 
Figure 10.4  
D83A changes substrate dependence of EAAT3 current amplitudes 
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Figure 10.4: D83A changes substrate dependence of EAAT3 current amplitudes. 
A, Localization of the mutation D83A in the transmembrane topology model. The trimerization domain 
is shown in grey, the transport domain is shown in black. The amino acid sequence alignment of GltPh 
and EAAT1-5 shows the TM2-3 region. D83 of EAAT3 is highlighted in black. B, representative current 
traces recorded from X. laevis oocytes expressing V120C-, M205C- or A430C-D83A EAAT3. C, 
averaged absolute current amplitudes at 100 mV with and without glutamate (top), averaged relative 
glutamate-induced current increase at +100 mV (middle) calculated by division of the current in 
presence by the current absence of glutamate, and averaged uptake current amplitudes at -100 mV 
(bottom) calculated by the difference of currents in sodium gluconate with and without glutamate from 
oocytes expressing WT or mutant EAAT3. n.s.: not significant different p  0.05; *, p ≤ 0.05 **, p ≤ 
0.01; ***, p ≤ 0.001. Data are given as means ± S.E.; n ≥ 10. Int, internal; Ext, external; glu, glutamate. 
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Figure 10.5 
Voltage- and substrate-dependent conformational changes of D83A EAAT3 
 
 
Figure 10.5: Voltage- and substrate-dependent conformational changes of D83A EAAT3. 
Representative fluorescence traces (left column) recorded from X. laevis oocytes expressing V120C- 
(A), M205C- (B) and A430C-D83A EAAT3 (C) and averaged voltage dependence of late (arrow) 
relative ﬂuorescence changes (right column) in the presence of different substrates are shown. 
Fluorescence signals were measured in NaCl Ringer’s solution during 200-ms voltage steps between 
+150 mV and -150 mV and. Fluorescence amplitudes were normalized to the fluorescence generated 
at +150 mV in NaCl solution. Measurements in NaCl at voltages above 0 mV are shown in red, 0 mV 
is shown in dark red, and negative voltages in the absence of 1 mM glutamate are shown in light grey 
and in the presence of 1 mM glutamate are shown in black. Fluorescence data from at least 6 oocytes 
are reported as means ± S.E.. F, fluorescence; glu, glutamate. 
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Furthermore, the maximum change of fluorescence intensity by applying different 
membrane potentials was less pronounced than for M205C EAAT3 (5% instead of 
10%). Glutamate decreased fluorescence intensity of V120C-D83A and M205C-
D83A EAAT3 and modified their voltage dependences (Figure 10.5A and B). 
Whereas fluorescence signals of V120C-D83A and M205C-D83A EAAT3 require 
external Na+, A430C-D83A EAAT3 voltage-dependent fluorescence changes 
seemed to be less substrate-dependent (Figure 10.5C). Removal of external 
permeant anions did not affect the intensity or the voltage dependence of 
fluorescence signals of D83A EAAT3 (Suppl. Figure 10.10D-F), similar to our results 
on EAAT3 with an aspartate at position 83. 
 
 
10.4.4 Kinetic modeling reveals changes in the glutamate uptake cycle in 
D83A EAAT3 
Glutamate transport by EAATs can be described with a kinetic scheme that 
encompasses subsequent substrate association/dissociation and translocation steps 
between inward and outward facing conformations (14; 31; 37) (Figure 10.6). Anion 
channel gating is tightly coupled to these transitions and can be represented by 
adding branching open anion channel states (19; 38; 39). Because the transport 
cycle can only proceed from closed channel states (19; 38), opening of EAAT anion 
channels prevents progression of the uptake cycle. Changes in the distribution 
between open and closed anion channel states will therefore affect the uptake cycle.  
D83A could alter EAAT3 function by directly modifying substrate 
association/dissociation or transporter translocation rates. Alternatively, D83A might 
modify apparent transitions within the uptake cycle by changing anion channel 
opening and closing transitions. To distinguish between the two possibilities, sole 
modification of transitions within the uptake cycle or modification by changed anion 
channel open probabilities, we modeled voltage-dependent fluorescence data from 
WT and D83A EAAT3 with a kinetic model that is based on a scheme developed to 
describe EAAT3 fluorescence data (23).  
We modified this model by increasing the number of different fluorescence levels for 
each fluorescently labeled transporter from three to four. The four fluorescence levels 
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of our kinetic scheme correspond to four structurally distinct conformations (Figure 
10.6).  
 
Figure 10.6 
Kinetic model and transport scheme of wildtype and mutant EAAT3 
 
Figure 10.6: Kinetic model and transport scheme of wildtype and mutant EAAT3. 
A, modiﬁed 15-state model extended by anion channel states branching from state 2-12 and state 14 
(grey circles) (16; 28) used to simulate the ﬂuorescence data. B, schematic transport mechanism. 
Shown is a single protomer. The isomerization between the outward and inward facing occluded 
states occurs upon movement of the whole transport domain (dark grey) relative to the trimerization 
domain (light grey). The inward facing open state has not been structurally characterized and is 
hypothetical. (modified from Reyes et al. (34)). 
 
 
The empty transporter resides in an outward facing state with HP2 open and the 
substrate binding sites exposed to the extracellular space (Foopen: ToK, To). 
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Glutamate uptake is initiated by association of three Na+ ions, one H+ and one 
glutamate. Association of these substrate causes closure of HP2 (Fooccluded: ToNa1, 
ToNa2, ToNa2G, ToNa2H, ToNa2GH, ToNa3GH), and a large piston-like movement 
of the “translocation domain” results in the inward-facing conformation (Fioccluded: 
TiNa3GH, TiNa2GH, TiNa2G, TiNa2, TiNa1) (26). Opening of HP1 is followed 
substrate release and exposure of the binding sites to the intracellular solution (Fiopen: 
Ti, TiK) (23).  Retranslocation after association of internal K+ completes the uptake 
cycle. The Gating of EAAT anion channels can be represented by adding branching 
open channel states from the uptake cycle (Figure 10.6A and B) (19; 38). Anion 
channel opening and closing are assumed to be fast compared with transitions in the 
uptake cycle, and therefore, we only use probabilities of anion channel opening from 
a particular state. These state-specific open probabilities are the ratio of the number 
of transporters in one transporter state with an open anion channel to the number of 
transporters in this particular state with either open or closed states. 
To obtain a kinetic scheme describing fluorescence values, anion currents and 
uptake currents for WT EAAT3 we used the same rate constants of the uptake cycle 
as determined in earlier work on cysteine-substituted EAAT3 (23). We determined 
anion channel open probabilities by fitting the model to the experimentally observed 
fluorescence of V120C, M205C and A430C EAAT3. The parameters were 
constrained to correctly describe experimentally determined relative glutamate-
induced current amplitudes at +100 mV and to preserve detailed balance (Figure 
10.7G). The so-obtained fitting parameters (Table 10.1, 2 and 3) demonstrated a 
good agreement of the simulated and observed fluorescence-voltage relationship 
under different substrate conditions (Figure 10.7A-C). However, they predicted a 
transport rate of about 4 transported glutamate per second at -100 mV (Figure 
10.7H), which is lower than in previously published data relating to EAAT1, -2 or -3 
(27; 40). We did not succeed in modifying fit parameters in order to increase 
transport rates. All attempts impaired the compatibility with the experimentally 
observed voltage dependence of fluorescence. Because unitary transport currents 
are extremely difficult to measure directly, we accepted this deviation between 
published and predicted results and only used the relative decrease of glutamate 
uptake currents by D83A in the optimization procedure.  
We then modified the thus established kinetic model to account for the fluorescence 
signals and transport properties of D83A EAAT3. We initially tested whether 
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modifying reactions in certain parts of the uptake cycle can qualitatively account for 
the observed D83A-mediated changes in fluorescence. There were two processes 
that resulted in such alterations, changes in anion channel open probability or 
changes in translocation rates. We first optimized all anion channel opening/closing 
reactions simultaneously against fluorescence intensities for all three reporter 
mutations combined with D83A. Glutamate-induced increases of anion current 
amplitudes at +100 mV, relative glutamate uptake currents at -100 mV, and detailed 
balance were again used as constraints.  
 
 
Figure 10.7 
Simulated voltage- and substrate-dependent conformational changes, open 
probabilities and transport currents of cysteine-substituted and D83A EAAT3 
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Figure 10.7: Simulated voltage- and substrate-dependent conformational changes, open 
probabilities and transport currents of cysteine-substituted and D83A EAAT3. 
A-F, averaged voltage dependence of measured late ﬂuorescence changes (fluorescence-voltage 
relationship) (circles) and simulated ﬂuorescence changes (solid lines) in the absence (grey) or in the 
presence of 1 mM glutamate (black). Fluorescence amplitudes were normalized to the fluorescence 
generated at +150 mV in NaCl solution. G and H, simulated open probabilities (G) at +100 mV of 
cysteine-substituted WT and D83A EAAT3 without (grey) and in the presence of glutamate (black) and  
simulated transport currents (H) at -100 mV from the data given in Table 10.1 and 10.3. I and J, 
simulated residence probability of cysteine-substituted WT (I) and D83A EAAT3 (J) calculated from the 
data given in Table 10.1 without (grey) and in the presence of glutamate (black) for three different 
voltages, +150 mV (solid line), 0 mV (dashed line) and +150 mV (dotted line). glu, glutamate; F, 
fluorescence. 
 
 
During optimization of opening and closing rates of anion channels, global fitting 
yielded a set of parameters that well reproduced the fluorescence-voltage 
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relationship of D83A EAAT3 under different ionic conditions. However, these 
changes always predicted reduction of glutamate transport rates to negligible values. 
Therefore, we evaluated whether alterations of translocation rates within the uptake 
cycle can account for D83A fluorescence and function. In these fitting procedures, 
only the three translocation reactions were adjusted. The fitting procedure revealed 
altered translocation rates of the K+-bound (reaction 15), the Na+-bound (reaction 17) 
and the Na+- and glutamate-bound transporter (reaction 8). Whereas inward 
translocation from ToNa3GH to TiNa3GH was promoted, D83A stimulated the 
outward translocation for the two other processes (Table 10.1-3). These alterations 
resulted in predicted fluorescence data that resemble experimental data on D83A 
EAAT3 (Figure 10.7D-F) (Table 10.1-3). 
The kinetic model permits prediction of the steady-state probability that the 
transporter resides in a given state of the transport cycle. We next calculated the 
residence probability of each states of the uptake cycle under steady-state conditions 
for the cysteine-substituted WT (Figure 10.7I) or D83A EAAT3 (Figure 10.7J). In the 
presence as well as in the absence of glutamate, D83A EAAT3 was predicted to 
reside with higher likelihood in the inward facing conformation than cysteine-
substituted EAAT3. 
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Table 10.1 
Parameters of the EAAT3 model 
 
    changed parameters for D83A 
reaction forward backward z forward backward 
 
1 
 
1.00 10
+04 
M
-1
s
-1
 
 
2.50 10
+03
 s
-1
 
 
0.20 
  
2 1.00 10
+04
 M
-1
s
-1
 2.50 10
+03
 s
-1
 0.20   
3 6.80 10
+06
 M
-1
s
-1
 3.00 10
+02
 s
-1
  -0.40   
4 6.00 10
+11
 M
-1
s
-1
 7.00 10
+02
 s
-1
    
5 6.00 10
+11
 M
-1
s
-1
 7.00 10
+02
 s
-1
 0.40   
6 6.80 10
+06
 M
-1
s
-1
 3.00 10
+02
 s
-1
    
7 1.00 10
+04
 M
-1
s
-1
 1.00 10
+03
 s
-1
 0.55   
8 5.50 10
+02
 s
-1
 5.00 10
+02
 s
-1
  1.00 10
+05
 s
-1
 6.59 s
-1
 
9 8.00 10
+02
 s
-1
 4.00 10
+04
 M
-1
s
-1
 0.45   
10 6.00 10
+03
 s
-1
 9.00 10
+10
 M
-1
s
-1
    
11 3.00 10
+03
 s
-1
 4.00 10
+05
 M
-1
s
-1
    
12 5.00 10
+02
 s
-1
 2.00 10
+05
 M
-1
s
-1
    
13 4.00 10
+03
 s
-1
 1.00 10
+06
 M
-1
s
-1
 0.20   
14 1.00 10
+06
 M
-1
s
-1
 1.00 10
+03
 s
-1
    
15 50 s
-1
 5.00 s
-1
 0.40 131.45 s
-1
 1.00 10
+05
 s
-1
 
16 8.00 10
+02
 s
-1
 1.00 10
+04
 M
-1
s
-1
    
17 0.80 s
-1
 1.00 10
-02
 s
-1
  0.11 s
-1
 19.19 s
-1
 
Table 10.1: Parameters of the EAAT3 model. 
Rate constants of the transport process and channel opening/closing at -70 mV are shown. 
Electrogenic reactions are defined by z values, which correspond to the product of the charge and 
the fraction of the electric field the charge is moved across the membrane. Clockwise transitions in the 
model scheme are denoted as “forward reactions”.  
 
 
 
 
Table 10.2 
Fluorescence intensities used for simulations of cysteine-substituted wildtype 
and mutant EAAT3 fluorescence voltage relationships 
 
fluorescence 
state 
V120C M205C A430C V120C-D83A M205C-D83A A430C-D83A 
 
Foopen 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Fooccluded 0.98 0.89 0.96 0.97 0.92 0.96 
Fioccluded 1.32 0.29 0.79 0.98 0.88 0.97 
Fiopen 0.52 2.44 1.25 0.97 0.88 0.93 
Table 10.2: Fluorescence intensities used for simulations of cysteine-substituted wildtype and 
mutant EAAT3 fluorescence voltage relationships. 
Fluorescence intensities of fluorescence states Foopen/occluded and Fiopen/occluded of cysteine-substituted 
and D83A EAAT3 used to simulate the overall fluorescence-voltage relationship were normalized to 
the fluorescence intensity of Foopen. 
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Table 10.3 
State-specific open probabilities for channel opening from the respective state 
used in the kinetic modeling of cysteine-substituted wildtype and mutant 
EAAT3 
 
anion channel state 
branching from: 
open 
probability 
 
ToNa1 
 
0.722 
ToNa2 9.999 10
-05
 
ToNa2G 9.999 10
-05
 
ToNa2H 9.999 10
-05
 
ToNa2GH 1.321 10
-04
 
ToNa3GH 0.988 
TiNa3GH 0.826 
TiNa2GH 0.713 
TiNa2G 1.275 10
-04
 
TiNa2 1.008 10
-04
 
TiNa1 0.765 
TiK 1.357 10
-04
 
Table 10.3: State-specific open probabilities for channel opening from the respective state 
used in the kinetic modeling of cysteine-substituted wildtype and mutant EAAT3. 
 
 
 
10.5 Discussion 
Here, we studied the functional consequences of neutralizing a conserved aspartate 
at position 83 in EAAT3. Homologous mutations have already been studied in EAAT1 
and EAAT4 (19; 20) and were reported to result in dramatic alterations of EAAT 
anion channel opening and closing for both isoforms. Investigating the effects of this 
point mutation on conformational changes promised insights into the interaction of 
transporter and anion channel function of EAAT glutamate transporters. 
In our experiments transporter proteins were labeled with fluorophores, and 
fluorescence intensities were measured upon changes in membrane voltages or in 
substrate concentrations (22; 41). We used three different cysteine substitutions, 
V120C, M205C and A430C for these experiments. Labeling of cysteine-substituted 
EAAT3 was specific because the same procedures on oocytes expressing EAAT3 
that lack cysteines for fluorophore attachment resulted in background fluorescence 
levels (Suppl. Figure 10.8 and Suppl. Figure 10.9). For each reporter mutant, voltage 
steps caused changes in fluorescence amplitudes that were modified by 
concentrations of transporter substrates, such as Na+ and glutamate (Figure 10.2). 
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Moreover, application of DL-threo-benzyloxyaspartate abolished our observed 
fluorescence changes (Suppl. Figure 10.9). Because DL-threo-benzyloxyaspartate is 
known to lock EAATs into an outward facing conformation with HP2 open (35) and 
thus to prevent substrate-binding and subsequent voltage-dependent conformational 
changes, this result further supports the notion that fluorescence signals arise from 
conformational changes of the EAAT3 transporter. 
Because EAATs are dual function proteins, the observed fluorescence changes 
might report on transitions within the uptake cycle or on anion channel opening and 
closing. We found that the voltage and substrate dependence of EAAT3 fluorescence 
signals can be well described by a kinetic model that is based on the glutamate 
transport cycle and in which opening and closing transitions of anion channels are 
voltage-independent (Figure 10.6) (5; 23; 34). Moreover, fluorescence is modified by 
transport substrates that affect the transport cycle, but do not directly affect the anion 
channel opening and closing (42). Taken together, these results indicate that the 
observed fluorescence changes are not directly linked to opening and closing of the 
anion channel.  
Time courses of fluorescence changes are therefore expected to reflect rate 
constants of transitions between individual states of the uptake cycle. However, we 
observed different kinetics but very similar voltage dependences of fluorescence 
changes of M205C and A430C (Figure 10.2B and C). The time dependences of 
fluorescence amplitudes obviously depend not only on global conformational 
changes of the EAAT proteins but also on additional region-specific changes of the 
environment. We therefore did not use the time dependence of fluorescence 
amplitudes to deduce information about rate constants within the uptake cycle. 
For M205C EAAT3, we observed very slow changes in the fluorescence amplitude 
upon depolarizing voltage steps in the absence of external glutamate and upon 
membrane hyperpolarization after application of glutamate (Figure 10.3). The time 
dependence of this process can be well described with a single time constant of 
around 7 s without glutamate, and around 4 s in the presence of the substrate. 
Turnover rates of individual EAAT3 have been determined to be well above 10/s (27), 
and such slow time constants thus indicate a conformational change outside the 
transport cycle. Because ultraslow fluorescence changes are voltage-dependent 
(Figure 10.3A) and because glutamate modifies this voltage dependence, one might 
speculate about the existence of a branching connection from one of the states of the 
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uptake cycle. After entering such a branching state, the transport cycle is interrupted 
and can only resume after having left this particular long-lasting state. We tested the 
existence of such branching connection by measuring time-dependent changes in 
glutamate transport currents. The existence of long-lasting branching states requires 
that glutamate transport rates are changed with the same time constant as the 
fluorescence signal. However, we did not observe any time- or voltage-dependent 
changes in the glutamate-dependent current, indicating that there are no branching 
connections from one of the uptake cycle states of the transporter (Figure 10.3). Slow 
fluorescence changes are thus due to conformational changes that occur in certain 
states of EAAT3 but do not interfere with the uptake cycle. At present, we can only 
speculate about the molecular basis and functional consequences of this finding. A 
possible explanation of these slow processes might be large collective motions as 
recently reported by Jiang et al. (43). An alternative assumption is that these very 
slow fluorescence changes correspond to a slow gating process within the EAAT 
anion channel. This gating process has been initially described in EAAT4 where slow 
changes in the anion to cation selectivity occur upon membrane depolarization. We 
also observed similar processes for EAAT3 (unpublished observation) and the time 
and voltage dependence of these gating processes resemble the observed slow 
changes of the fluorescence signals (17).  
Due to the slow changes of fluorescence amplitudes, it was impossible to obtain and 
to interpret steady-state fluorescence values. We therefore determined fluorescence 
values at the end of a 200-ms pulse. After this time period, all processes within the 
uptake cycle will have reached steady-state conditions. Moreover, the additional slow 
processes that occur outside the uptake cycle and thus should not contribute to the 
measured fluorescence values will not have caused major alterations of the 
fluorescence levels.  
We recently performed a detailed analysis of the effects of D117A on EAAT4 anion 
currents (19). Noise analysis demonstrated reduced unitary current amplitudes of 
D117A EAAT4 anion channels, and reversal potential measurements under bionic 
conditions indicated altered anion selectivity. These functional alterations supported 
direct modification of the EAAT4 anion conduction pathway by D117A. We reasoned 
that D117 is in close proximity to the anion conduction pathway and that D117A 
alters anion channel open probabilities by directly modifying opening and closing 
transitions. We optimized rate constants in the kinetic scheme that is closely similar 
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to the one shown in Figure 10.6 against experimentally determined absolute open 
probabilities for WT and D117A EAAT4 at different voltages. This procedure revealed 
that the effect of D117A on EAAT4 gating can be well reproduced by exclusive 
modification of anion channel open probabilities.  
We now studied the effects of the homologous mutation on EAAT3 using voltage 
clamp fluorometry. The use of EAAT3 permits direct measurements of glutamate 
uptake currents, and this parameter turned out to be crucial for our interpretation of 
the effects of D83A. Cysteine-substituted EAAT3 fluorescence, glutamate transport 
and anion currents can be well represented by a kinetic scheme that is based on a 
model developed in a recent voltage clamp fluorometry study (23). We optimized this 
scheme by inserting anion channel states branching from certain states of the 
glutamate transport cycle. For WT EAAT3, rate constants within the uptake cycle 
were not modified. The glutamate transport cycle consists of many different steps, 
and some of them are outside the temporal resolution of our system. Moreover, the 
kinetic scheme encompasses too many rate constants to be accurately determined in 
separation. The resulting scheme is in good agreement with all our experimental data 
on WT. However, there is one published feature of EAAT3 the kinetic model fails to 
account for. It is not capable to correctly predict the high transport rates of EAAT3 for 
reverse transport at high external K+ (44). Since our experiments were performed in 
the absence of external K+, we accepted this limitation of the kinetic scheme. 
The effects of D83A on fluorescence and anion current could be explained by 
modifying anion channel gating. However, these alterations predicted a reduction of 
the glutamate uptake rates to very low values and are thus in disagreement with 
experimental data (Figure 10.4). Only by modification of translocation rates in the 
uptake cycle were we able to accurately describe all existing data, glutamate 
transport, anion currents, and fluorescence data. Our data thus indicate that D83A 
modifies translocation rates. These changes in translocation are supported by 
available crystal structures that place the homologous residue of D83/D117 to the 
TM2-TM3 loop between the trimerization and the transport domains. By altering the 
hinge function of this region (19; 34; 45) D83A/D117 might affect the isomerisation 
between inward and outward facing conformations.  
The different outcome of the two studies on EAAT3 and EAAT4 is most likely not due 
to isoform-specific differences in anion channel function but rather caused by the 
separate experimental approaches. Anion channel properties are very well conserved 
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between EAAT3 and EAAT4 with closely similar unitary conductance, selectivity and 
open probabilities (33). EAAT4 differs from EAAT3 in very low glutamate transport 
rates (27). Changes in translocation processes might have less influence on anion 
channel gating in EAAT4 than in EAAT3. D83A is thus expected to exert effects on 
EAAT3 anion channels similar to those of D117A on EAAT4 anion channels. We 
conclude that D83A/D117A modifies substrate translocation and anion channel 
opening as well as anion conduction by EAAT3/EAAT4.  
At present, the molecular basis of anion conduction in EAAT glutamate transporters 
is insufficiently understood. So far, only one point mutation, D117A, has been shown 
to modify unitary anion conduction rates in the outward (35) as well as in the inward 
facing conformation (34). S74, the GltPh residue homologous to D83/D117, projects 
into surrounding lipids rather than into possible conduction pathways. Moreover, 
D117A reduces unitary current amplitudes of EAAT4 anion channels by removing a 
negative charge. These two findings argue against a direct effect of D83A/D117A on 
anion conduction. A possible scenario that accounts for the effects of D83A on 
substrate translocation in EAAT3 and of D117A on anion conduction in EAAT4 is that 
anion channel formation is closely related to translocation. One might speculate that 
the anion pore opens upon moving the translocation domain between outward to 
inward facing conformations. Indeed, a recently reported high resolution structure of 
an intermediate conformation of GltPh revealed an aqueous conduction pathway that 
might permit permeation of anions (32). By altering the translocation trajectory, 
D83A/D117A could not only affect substrate translocation and anion channel 
opening/closing, but also the anion conduction pathway itself. 
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10.8 Supplemental Figures 
 
 
 
Suppl. Figure 10.8 
Time course of fluorescence labeling of cysteine-substituted EAAT3 
 
 
Suppl. Figure 10.8: Time course of fluorescence labeling of cysteine-substituted EAAT3. 
Averaged time-dependent fluorescence change of Xenopus laevis oocytes expressing V120C, M205C 
or A430C EAAT3 from at least 5 oocytes is reported as means ± S.E.. 
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Suppl. Figure 10.9 
Voltage-dependent conformational changes are due to EAAT3 and are blocked 
by TBOA 
 
 
 
Suppl. Figure 10.9: Voltage-dependent conformational changes are due to EAAT3 and are 
blocked by TBOA. 
Representative fluorescence traces recorded from Xenopus laevis oocytes, either uninjected or 
expressing C158S, and M205C EAAT3. Fluorescence recordings were generated by 0.3 – 0.6 s 
voltage steps between +150 mV and -150 mV and measured in NaCl Ringer´s solution in the absence 
of 1 mM glutamate (grey) or in the presence of 1 mM glutamate (black). The block by application of 
100 µM TBOA was the same oocyte as shown above. 
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Suppl. Figure 10.10 
Anion independence of cysteine-substituted WT and D83A EAAT3 
 
Suppl. Figure 10.10: Anion independence of cysteine-substituted WT and D83A EAAT3. 
Averaged voltage dependence of late relative ﬂuorescence changes of cysteine-substituted WT (A-C) 
and D83A EAAT3 (D-F) in the presence of different substrates. Fluorescence signals were measured 
during 200 ms voltage steps between +150 mV and -150 mV. Fluorescence amplitudes are 
normalized to the fluorescence measured at +150 mV in NaCl solution. Measurements were done 
either in NaCl (solid lines) or in anion-substituted NaGluconate solution (circles) in the absence of 1 
mM glutamate (grey) or in the presence of 1 mM glutamate (black). Fluorescence data from at least 6 
oocytes are reported as means ± S.E.. 
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11.1 Abstract 
The episodic ataxias (EA) are inherited human syndromes characterized by 
paroxysmal cerebellar incoordination. One type, episodic ataxia type 6, is associated 
with mutations in SLC1A3 - the gene encoding the glial glutamate transporter 
hEAAT1. We here use voltage clamp fluorometry to functionally evaluate one EA6-
associated mutation that predicts the substitution of a conserved proline in the hinge 
of transmembrane domain 5 (TM5) by arginine, P290R. Since P290R hEAAT1 did 
not express at sufficient levels to permit fluorescence measurements, we studied the 
homologous mutation P259R in another EAAT transporter, hEAAT3. P259R inverts 
the voltage dependence, changes the sodium dependence and drastically 
decelerates the kinetics of EAAT3 fluorescence signals. Analysis of these results and 
kinetic modelling defined altered sodium-binding to mutant transporters as molecular 
basis of reduced glutamate uptake and increased anion conduction of EAAT 
transporters in episodic ataxia type 6. 
 
 
11.2 Introduction 
Episodic ataxia (EA) is a rare autosomal dominant human disease characterized by 
imbalance and paroxysmal cerebellar incoordination associated with additional other 
neurological symptoms. There are six episodic ataxia syndromes with distinct clinical 
features and underlying genetic origins1. Episodic ataxia type 6 differs from other 
forms of episodic ataxia in long duration of attacks, epilepsy and absent myokymia, 
nystagm, and tinnitus1. It is caused by mutations in SLC1A3, the gene encoding 
EAAT1, the major glutamate transporter in cerebellar Bergmann glia2, 3. So far, two 
disease-associated mutations have been reported, and one of them predicts a 
substitution of a highly conserved proline by arginine at position 290 in EAAT12. 
P290R reduces EAAT1 expression levels and surface membrane insertion2 and also 
modifies transport functions of EAAT14.  
EAATs are secondary-active glutamate transporter, coupling glutamate transport to 
the co-transport of three sodium ions, one proton and to the countertransport of one 
potassium ion. The effective glutamate transport by EAATs ensures tightly regulated 
synaptic communication and is the basis of low extracellular glutamate 
concentrations in the synaptic cleft that are necessary to prevent glutamate 
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excitotoxicity. Furthermore, EAATs mediate a glutamate-activated anion flux which is 
thought to be conducted through an anion pathway transiently generated during 
conformational changes coupled to glutamate transport5-8. EAAT anion currents have 
been suggested to regulate neuronal excitability, but so far, the physiological 
importance of this transport function is not sufficiently understood. P290R was shown 
to exert distinct effects on both EAAT functions. It diminishes individual glutamate 
transport rates and increases EAAT1-associated anion currents4.  
We here employed “voltage clamp fluorometry” (VCF) to define which particular steps 
in the transport cycle are affected by this disease-associated mutation. Voltage 
clamp fluorometry combines current recordings with fluorescence measurements 
under voltage clamp and permits insights into the substrate and voltage 
dependences of various conformational changes underlying EAAT function. Using 
the related isoform EAAT39-13, we demonstrate that alteration of Na+-association and 
dissociation prior to glutamate-binding to the outward facing transporter and to the 
inward facing transporter represents the molecular basis of transporter dysfunction in 
episodic ataxia type 6.   
 
 
 
 
11.3 Results 
11.4 P259R EAAT3 is a reliable model to study transport 
dysfunction of P290R EAAT1  
To permit cysteine-specific fluorescence labeling for subsequent fluorescence 
analysis we inserted the mutation V238C into WT and P290R hEAAT1 and 
expressed both constructs in Xenopus oocytes. V238C hEAAT1 is homologous to 
M205C hEAAT3 (Figure 11.1A), a reporter mutation that results in prominent 
changes of fluorescence amplitudes with substrate concentration and voltage when 
labeled with the cysteine-specific dye AlexaFluor54611, 13. Unfortunately, oocytes 
expressing V238C-P290R hEAAT1 did not show fluorescence signals of sufficient 
amplitude to permit quantitative analysis. The low fluorescence amplitude levels of 
V238C-P290R hEAAT1 are consistent with earlier reports that P290R reduces the 
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surface density of hEAAT12, 4. Since P290 is highly conserved within the whole EAAT 
family, we studied the functional effects of the disease-associated mutation in the 
related glutamate transporter EAAT3. EAAT3 expresses robustly in oocytes14 and 
has already been successfully analyzed using voltage clamp fluorometry9, 12, 13. We 
initially tested the suitability of P259R hEAAT3 as model for P290R hEAAT1 by 
measuring P259R hEAAT3 glutamate transport and anion currents after expression 
in Xenopus oocytes or in mammalian cells and comparing the results to those on 
P290R hEAAT1.  
To quantify WT and mutant hEAAT1/3 glutamate transport oocytes expressing WT, 
M205C, or M205C-P259R hEAAT3 and WT or P290R hEAAT1 were incubated in Cl--
free medium, and differences in current amplitudes before and after glutamate 
application were measured (Figure 11.1B and Suppl. Figure 11.5B). The thus 
determined current amplitudes reveal comparably reduced uptake currents for 
P259R hEAAT3 (WT: Iuptake = -1.17 ± 0.14 µA ; M205C: Iuptake = -1.07 ± 0.13 µA; 
M205C-P259R: Iuptake = -0.18 ± 0.04 µA; n ≥ 13; pWT:P259R ≤ 0.001) as well as for 
P290R hEAAT1 (WT: Iuptake = -0.75 ± 0.07 µA ; P290R: Iuptake = -0.11 ± 0.03 µA; n ≥ 
8; p WT:P290R ≤ 0.001) (Suppl. Figure 11.5B). Lyotropic anions such as NO3
- or SCN- 
greatly increase EAAT anion currents and permit observation of these current 
components without significant contaminations with glutamate uptake currents8, 15. 
However, oocytes expressing P259R hEAAT3 mediated large anion currents that are 
neither TBOA nor Na+-dependent and thus represent endogenous anion currents. 
We therefore studied the effect of P259R on hEAAT3 anion currents through whole-
cell patch clamp measurements in transfected mammalian cells (Figure 11.1C and 
D). In these experiments, cells were internally dialyzed with high [K+] to permit all 
physiologically occurring transitions in the glutamate uptake cycle5. In the absence as 
well as in the presence of glutamate, cells expressing P259R hEAAT3 display 
significantly larger current amplitudes in the negative voltage range when compared 
to WT. P259R did not only modify EAAT3 anion current amplitudes, but also the 
voltage and time dependence of these currents. Upon hyperpolarizing voltage steps 
P259R hEAAT3 currents display time-dependent increases that are more 
pronounced in the presence of glutamate than in its absence. The novel gating 
results in inwardly rectifying currents associated with mutant hEAAT3.  
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Figure 11.1 
P259R changes EAAT1- and EAAT3-associated anion- and uptake currents 
 
 
Figure 11.1: P259R changes EAAT1- and EAAT3-associated anion- and uptake currents. 
A, Localization of M205C and P259R on the transmembrane topology model of EAAT3 and on the 
monomeric structure shown in a ribbon representation viewed in the plane of the membrane. B, 
averaged glutamate uptake currents at -100 mV of oocytes expressing WT, M205C- or M205C-P259R 
EAAT3. Uptake currents were calculated as difference of current amplitudes with and without 
glutamate measured in a chloride-free solution. Student’s t-test and paired t-test with p ≤ 0.05 (*) as 
the level of significance were used (p ≤ 0.01 (**), p ≤ 0.001 (***)). The data are given as the means ± 
S.E.; n ≥ 13. C, representative current recordings from tsA201 cells expressing WT or P259R EAAT3 
with standard KNO3-based internal solution and a NaNO3-based external solution before (light grey) 
and after application of 1mM glutamate (black) and the corresponding I-V plot (D) with WT-data 
(circles), either in the absence (white) or in the presence of glutamate (black) and P259R EAAT3 data 
(triangles), either in the absence (yellow) or in the presence of glutamate (red); n ≥ 4. 
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Under similar experimental conditions, WT hEAAT3 anion currents display 
comparable anion conductances at positive and at negative voltages with only minor 
time-dependent relaxations. The effects of P259R on hEAAT3 anion current 
amplitudes resemble those of P290R on hEAAT1 (Suppl. Figure 11.5A). P259R 
hEAAT3 and P290R hEAAT1, both open upon negative membrane potentials on a 
slow time course (Suppl. Figure 11.5A). Since openings and closings of EAAT anion 
channels are tightly coupled to transitions within the uptake cycle6, 16, 17, these 
similarity in gating indicates that P290R and P259R cause comparable changes in 
the glutamate uptake cycle of hEAAT1 and hEAAT3. We conclude that P259R 
hEAAT3 represent a reliable model protein to study the effects of the disease-
associated mutation P290R on hEAAT1 function. 
 
 
11.4.1 P259R modifies conformational changes of M205C hEAAT3 
We used M205C for fluorophore attachment to P259R hEAAT3 (Figure 11.1A). This 
reporter mutation is known to preserve functional properties of hEAAT3 and to 
generate fluorescence signals that report on EAAT3-specific conformational 
changes11, 13.Figure 11.2A shows representative fluorescence recordings of M205C 
or M205C-P259R EAAT3 in absence (top) and in the presence of glutamate 
(bottom). Oocytes were held at 0 mV, and voltage steps between -150 mV and +150 
mV were applied in 50 mV intervals. EAAT3 carrying only the fluorophore attachment 
site M205C displays pronounced voltage- and substrate-dependent fluorescence 
signals (Figure 11.2, left column). Application of glutamate decreases fluorescence 
intensity of M205C EAAT3 over the whole tested voltage-range and furthermore 
changes the voltage dependence of the fluorescence signal (Figure 11.2B, left 
column)13. P259R inverts the voltage dependence and modifies the substrate 
dependence of these fluorescence signals (Figure 11.2A and B, right column). 
M205C-P259R hEAAT3 fluorescence intensities increase upon membrane 
hyperpolarization, and positive membrane potentials lead to slight decreases. 
Glutamate decreases fluorescence intensities at negative voltages and leaves them 
unaffected at positive potentials (Figure 11.2B, right column).  
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Figure 11.2 
Voltage-, substrate- and time-dependent conformational changes of M205C and 
M205C-P259R EAAT3 
 
 
Figure 11.2: Voltage-, substrate- and time-dependent conformational changes of M205C and 
M205C-P259R EAAT3. 
A, fluorescence recordings of M205C (left column) or M205C-P259R EAAT3 (right column) expressing 
oocytes. B, averaged voltage dependence of ﬂuorescence changes. Voltages above 0 mV were 
shown in red, 0 mV in dark red and negative voltages without (light grey) or with glutamate (black). 
Fluorescence amplitudes are normalized to the fluorescence generated at +150 mV in NaCl solution. 
C, averaged time constants determined from monoexponential fits of the fluorescence change at a 
voltage jump from 0 mV to -150 mV (black) of fluorescence traces of M205C (left column) or M205C-
P259R EAAT3 (right column) expressing oocytes shown as insets. Fluorescence amplitudes are 
normalized to the fluorescence generated at 0 mV. n ≥ 4 in B and n ≥ 3 in C. Fluorescence data are 
reported as means ± S.E.. 
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P259R does not only modify the voltage dependence of M205C hEAAT3 
fluorescence signals, but also their time course. Hyperpolarizing voltage steps cause 
fast reductions of M205C EAAT3 fluorescence that can be fit with monoexponential 
functions resulting in time constants of around 3 ms (Figure 11.2C, left column). For 
M205C-P259R EAAT3, time constants of fluorescence increases upon 
hyperpolarization are between 170 and 370 ms (Figure 11.2C, right column), 
changing upon the voltage, whereas M205C EAAT3 values change only little within 
the tested voltage-range. 
 
 
11.4.2 P259R alters the sodium dependence of M205C hEAAT3 conformational 
changes 
M205C EAAT3 fluorescence changes report on sodium-binding in absence of 
glutamate11, 13 and the pronounced effects of P259R on these signals suggest that 
the disease-associated mutation modifies these particular substrate association 
steps within the EAAT transport cycle. Figure 11.3A gives the voltage dependence of 
averaged fluorescence intensities of M205C EAAT3 at various external [Na+]. 
Reduction of external sodium results in larger fluorescence amplitudes at negative 
voltages, whereas values at positive potentials were unaffected. Complete 
substitution of Na+ by choline+ nearly abolishes the voltage dependence of 
fluorescence signals. We next fitted the sodium dependences of fluorescence 
amplitudes at certain membrane potentials with Hill equations (Figure 11.3A, inset) to 
obtain apparent dissociation constants (KD) and Hill coefficients (nH) for sodium-
binding and subsequent protein movements. M205C hEAAT3 exhibits apparent 
dissociation constants in the range of 11 - 14 mM (Table 11.1). P259R increases 
apparent KD’s about fivefold (Table 11.1). Even doubling of [Na
+] to 197 mM was 
insufficient to reach saturation for M205C-P259R hEAAT3 (Figure 11.3A, right 
column). For M205C and for M205C-P259R hEAAT3, apparent KD’s decrease slightly 
with hyperpolarizing voltages. For WT as well as for P259R hEAAT3, Hill coefficients 
are above one (Table 11.1) - in agreement with the notion that two Na+ associate 
prior to glutamate5, 12, 18. 
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Figure 11.3 
Sodium dependence of M205C and M205C-P259R EAAT3 conformational 
changes 
 
 
Figure 11.3: Sodium dependence of M205C and M205C-P259R EAAT3 conformational changes. 
A, averaged voltage dependence of ﬂuorescence changes of M205C (left column) or M205C-P259R 
EAAT3 (right column) measured at different [Na
+
] (197, 98.5, 49.25, 24.625, 10, 0 mM) and 
corresponding dose-response curves were shown as insets. Fluorescence amplitudes are normalized 
to the fluorescence generated at +150 mV. B, fluorescence traces of M205C (left column) or M205C-
P259R EAAT3 (right column) expressing oocytes at different [Na
+
] (197, 98.5, 49.25, 24.625, 10 mM) 
with monoexponential fits of the fluorescence change at a voltage jump from 0mV to -150 mV (black) 
and from -150 mV to 0 mV (red). Fluorescence amplitudes are normalized to the fluorescence 
generated at 0 mV. C, corresponding averaged time constants. n ≥ 4. Fluorescence data are reported 
as means ± S.E.. 
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Table 11.1  
Apparent dissociation constants and hill coefficients of M205C and M205C-
P259R EAAT3 sodium dependence 
 
voltage (mV) 
M205C M205C-P259R 
KD (mM) nH KD (mM) nH 
 
-150 
 
11.7 ± 4 
 
1.9 ± 0.9 
 
50.7 ± 7.7 
 
1.5 ± 0.2 
-100 13.4 ± 4.6 2 ±1.3 63.7 ± 2.4 1.3 ± 0.04 
Table 11.1: Apparent dissociation constants and hill coefficients of M205C and M205C-P259R 
EAAT3 sodium dependence. 
KD’s and nH at different applied voltages were calculated by fitting the fluorescence data with the Hill 
equation. 
 
 
Changes in external [Na+] also modify the time courses of M205C as well as of 
M205C-P259R hEAAT3 fluorescence changes upon voltage steps to -150 mV 
(Figure 11.3B). For M205C hEAAT3, time constants of the fluorescence decrease - 
that report on Na+-binding and binding-associated conformational rearrangements9, 
11, 13 - accelerate with increasing sodium concentrations from about 13 ms to 7 ms 
(Figure 11.3C, left column). For M205C-P259R hEAAT3, the time constants 
decrease from 280 to 180 ms upon increasing [Na+] (Figure 11.3C, right column 
Fluorescence increases upon subsequent voltage steps back to the holding potential 
are due to sodium-dissociation and related conformational changes and can be 
described with a single time constant that changes with [Na+]. M205C hEAAT3 
conformational changes display time constants from around 6 ms to 11 ms (Figure 
11.3C, left column) and P259R M205C hEAAT3 conformational changes display time 
constants between 370 ms to 440 ms with increasing [Na+]. For M205C as well as for 
M205C-P259R EAAT3 we observed a saturating Na+ dependence for fluorescence 
time constants. This deviation from a linear [Na+] dependence indicates that the 
fluorescence signal does not only result from a one step association of Na+ to the 
transporter. The saturation behavior rather suggest that there is an additional 
reaction limiting the overall rate at high [Na+] once all sodium binding sites are 
saturated. 
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Within the EAAT transport cycle two Na+ bind prior to glutamate association and a 
third one to the glutamate-bound transporter5, 12, 18. The data presented so far 
indicate altered Na+-association to the glutamate-unliganded transporter. Since 
glutamate reduces fluorescence signals of M205C and M205C-P259R hEAAT3 
(Figure 11.2), we analyzed current amplitudes upon varying [Na+] in the presence of 
saturating glutamate concentrations in order to test whether P259R also affects this 
third sodium binding step. Under these conditions WT, M205C and M205C-P259R 
hEAAT3 display sodium dependences with similar apparent dissociation constants 
and Hill coefficients that agree well with published data19 (Suppl. Figure 11.6). 
 
 
11.4.3 Kinetic modeling reveals altered sodium-binding to P259R hEAAT3  
We next performed kinetic simulations of P259R hEAAT3 fluorescence data using a 
model we recently developed to describe EAAT3 currents and fluorescence values. 
The scheme is based on the EAAT transport cycle9 and was supplemented with 
additional branching open channel states9, 13, 15 (Figure 11.4A, displayed as grey 
circles). To describe fluorescence signals, four major fluorescence levels were 
assigned to four distinct conformations20-22 (Figure 11.4A, displayed as dotted 
boxes). This model describes well the fluorescence-voltage relationship and the 
current characteristics of cysteine-substituted WT13 hEAAT3 (Table 11.2-4, Figure 
11.4).  
The complexity of this kinetic scheme prevents direct determination of P259R-
modified rate constants by a global fitting procedure. We therefore used an iterative 
approach to quantify possible changes in the transport cycle and/or anion channel 
opening in P259R hEAAT3. We initially tested whether modifying reactions in certain 
parts of the uptake cycle can simulate the effects of P259R on hEAAT3 fluorescence 
signals (Figure 11.2 and Figure 11.3). We found that adjusting reactions 1 and 2 
resulted in most promising preliminary results. Since P290R modifies anion channel 
open probabilities of hEAAT14, we also attempted to describe our data by exclusively 
varying anion channel opening and closing. However, we could neither describe the 
fluorescence-voltage relationship nor the current characteristics of P259R hEAAT3 
by modification of anion channel opening and closing rates alone.  
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We then optimized rate constants of reaction 1 and 2 versus fluorescence data, 
experimentally determined relative current amplitudes at -100 mV and relative 
glutamate uptake currents at -100 mV. Since preservation of detailed balance turned 
out to be impossible under these conditions, and since it appears unlikely that only 
sodium association to the outward-facing, but not to the inward-facing transporter is 
altered by P259R, we also optimized reactions 12 and 13 during the fitting process.  
The resulting kinetic scheme predicts drastic deceleration of binding as well as 
unbinding of the first and second sodium in the outward facing conformation (Table 
11.2). Furthermore, unbinding of the second (reaction 12) from the inward facing 
state of EAAT is enhanced and unbinding of the first sodium (reaction 13) is reduced, 
whereas other rates are just slightly changed (Table 11.2). The reduced sodium 
binding rates are consistent with the experimentally observed deceleration of 
fluorescence time constants. The kinetic scheme does not only reproduce the 
fluorescence-voltage relationship with and without glutamate, the sodium 
dependence and the corresponding apparent fluorescence dissociation constants 
and Hill coefficients of M205C and M205C-P259R EAAT3 (Figure 11.4B-C, Table 
11.2-5), but also the decreased uptake current and increased anion conductance in 
the absence of glutamate by P259R are correctly calculated by the kinetic simulation 
(Figure 11.4D-E). 
 
Figure 11.4 
Kinetic model and simulated conformational changes and currents of M205C 
and M205C-P259R EAAT3 
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Figure 11.4: Kinetic model and simulated conformational changes and currents of M205C and 
M205C-P259R EAAT3.  
A, 15-state model with branching anion channel states (grey circles), grouped into 4 fluorescence 
states (dotted boxes), corresponding to 4 conformations shown as protomers (modified from 20). B, 
voltage dependence of measured (circles) or simulated ﬂuorescence changes (solid lines) without 
(grey) or with glutamate (black). C, simulated fluorescence changes at different [Na
+
] (197, 98.5, 
49.25, 24.625, 10, 0 mM). D,E Comparison of the simulated (grey) and measured (black) glutamate 
uptake (D) and anion currents (E) at -100 mV, normalized to the current amplitudes of M205C. F,G 
time-dependent simulation ﬂuorescence changes (F) and current amplitudes (G) upon the indicated 
voltage steps for M205C or M205C-P259R EAAT3 either in the absence or in the presence of 1 mM 
glutamate. 
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However, assuming identical voltage dependence for Na+ association to M205C and 
M205C-P259R EAAT3, the model failed to predict the slow activation of P259R 
hEAAT3 upon hyperpolarizing voltage steps, but rather predicted time-independent 
current responses. We thus manually optimized the voltage dependence of Na+-
association for P259R hEAAT3 and found that increasing the apparent electrical 
distance zδ of reaction 1 from 0.2 to 0.5 and adjusting zδ of reaction 2 from 0.2 to -
0.1 resulted in an improved agreement of simulated time-dependent fluorescence 
responses and anion currents with experimental data without affecting the predictions 
for other parameters (Figure 11.4F and G). The altered voltage dependence of Na+ 
association also accounts for the different voltage dependences of the time constants 
of fluorescence changes upon hyperpolarizing voltage steps (Figure 11.2). 
 
 
Table 11.2  
Parameters of the EAAT3 model 
 
    changed parameters for P259R 
reaction forward backward z z forward backward 
 
1 
 
1.00 10
+04 
M
-1
s
-1
 
 
2.50 10
+03
 s
-1
 
 
0.20 
 
0.50 
 
80 M
-1
s
-1
 
 
51.73
 
s
-1
 
2 1.00 10
+04
 M
-1
s
-1
 2.50 10
+03
 s
-1
 0.20 -0.10  55 M
-1
s
-1
 78.61 s
-1
 
3 6.80 10
+06
 M
-1
s
-1
 3.00 10
+02
 s
-1
  -0.40    
4 6.00 10
+11
 M
-1
s
-1
 7.00 10
+02
 s
-1
     
5 6.00 10
+11
 M
-1
s
-1
 7.00 10
+02
 s
-1
 0.40    
6 6.80 10
+06
 M
-1
s
-1
 3.00 10
+02
 s
-1
     
7 1.00 10
+04
 M
-1
s
-1
 1.00 10
+03
 s
-1
 0.55    
8 5.50 10
+02
 s
-1
 5.00 10
+02
 s
-1
     
9 8.00 10
+02
 s
-1
 4.00 10
+04
 M
-1
s
-1
 0.45    
10 6.00 10
+03
 s
-1
 9.00 10
+10
 M
-1
s
-1
     
11 3.00 10
+03
 s
-1
 4.00 10
+05
 M
-1
s
-1
     
12 5.00 10
+02
 s
-1
 2.00 10
+05
 M
-1
s
-1
   7.5710
+04
 s
-1
 4.6410
+03
 M
-1
s
-1
 
13 4.00 10
+03
 s
-1
 1.00 10
+06
 M
-1
s
-1
 0.20  2.20 s
-1
 2.3910
+05
 M
-1
s
-1
 
14 1.00 10
+06
 M
-1
s
-1
 1.00 10
+03
 s
-1
     
15 50 s
-1
 5.00 s
-1
 0.40    
16 8.00 10
+02
 s
-1
 1.00 10
+04
 M
-1
s
-1
     
17 0.80 s
-1
 1.00 10
-02
 s
-1
     
Table 11.2: Parameters of the EAAT3 model.  
Rate constants of the transport process and channel opening/closing at -70 mV. Electrogenic 
reactions are defined by z values, which correspond to the product of the charge, and the fraction of 
the electric field the charge is moved across the membrane. Clockwise transitions in the model 
scheme are denoted as “forward reactions”. 
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Table 11.3  
Open probabilities used in the kinetic modeling of cysteine-substituted 
wildtype and mutant EAAT3 
 
 
anion channel state 
branching from: 
open probability 
 
ToNa1 
 
0.7224 
ToNa2 9.9990 10
-05
 
ToNa2G 9.9990 10
-05
 
ToNa2H 9.9990 10
-05
 
ToNa2GH 1.3214 10
-04
 
ToNa3GH 0.9881 
TiNa3GH 0.8264 
TiNa2GH 0.7133 
TiNa2G 1.2749 10
-04
 
TiNa2 1.0081 10
-04
 
TiNa1 0.7652 
TiK 1.3570 10
-04
 
Table 11.3: Open probabilities used in the kinetic modeling of cysteine-substituted wildtype 
and mutant EAAT3. 
 
 
 
 
Table 11.4 
Fluorescence intensities used for simulations of cysteine-substituted wildtype 
and mutant EAAT3 fluorescence voltage relationships 
 
 
fluorescence state M205C M205C-P259R 
 
Foopen 
 
1.00 
 
1.00 
Fooccluded 0.89 1.05 
Fiopen 0.29 0.99 
Fioccluded 2.44 2.81 
Table 11.4: Fluorescence intensities used for simulations of cysteine-substituted wildtype and 
mutant EAAT3 fluorescence voltage relationships.  
Fluorescence intensities of fluorescence states Foopen/occluded and Fiopen/occluded of cysteine-substituted 
and M205C-P259R EAAT3 used to simulate the overall fluorescence voltage relationship were 
normalized to the fluorescence intensity of Foopen. 
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Table 11.5 
Simulated dissociation constants and hill coefficients of M205C and M205C-
P259R EAAT3 sodium dependence 
 
 
voltage (mV) 
M205C M205C-P259R 
KD (mM) nH KD (mM) nH 
 
-150 
 
9.5 ± 0.8 
 
2.8 ± 1.1 
 
27 ± 1.2 
 
1.3 ± 0.06 
-100 17.2 ± 1.6 1.8 ± 0.3 71 ± 1.2 1.2 ± 0.05 
Table 11.5: Simulated dissociation constants and hill coefficients of M205C and M205C-P259R 
EAAT3 sodium dependence.  
KD’s and nH at -150 and -100 mV were calculated by fitting the simulated fluorescence data with the 
Hill equation. 
 
 
 
11.5 Discussion 
EAAT transporters fulfill diverse cellular functions in the central nervous system, in 
sensory organs as well as in the kidney23. The physiological impact of this class of 
glutamate transporters is illustrated by several hereditary diseases caused by 
naturally occurring mutations in the SLC1A gene family that encodes EAAT 
glutamate transporters. Apart from the mutations in SLC1A3 in episodic ataxia2, 3, 
SLC1A2 mutations have been identified in rare hereditary forms of amyotrophic 
lateral sclerosis24, and SLC1A1 mutations associated with human dicarboxylic 
aminoaciduria25. Studying “transporteropathies” does not only provide insights into 
the physiological roles of affected transporters or does not only improve the 
understanding of certain rare human diseases, but also serves as tool to decipher the 
molecular basis of transporter function. Random sequence alterations that are known 
to impair transporter function permit unexpected insights into structure-function 
relationship and thus provide an alternative approach to identify sequence 
determinants of EAAT functions. We here show that a combination of voltage clamp 
fluorometry and kinetic modelling permits identification of the underlying molecular 
mechanism of the EAAT “transporteropathy” episodic ataxia type 6 for one disease-
associated mutation, P290R.  
In these experiments, we used the related isoform hEAAT3 for voltage clamp 
fluorometry experiments since P290R hEAAT1 did not express at levels sufficiently 
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high to allow current and fluorescence measurements. EAAT1 and EAAT3 share 
basic mechanisms of glutamate transport and exhibit similar anion conduction 
properties26-27, 28. The homologous mutations P259R and P290R both reduce 
glutamate uptake currents and increase the amplitudes of EAAT anion currents in the 
absence as well as in the presence of glutamate (Figure 11.1, Suppl. Figure 11.5). 
Moreover, we observed comparable modifications of the time and voltage 
dependence of P259R hEAAT3 and P290R hEAAT1 anion currents (Figure 11.1, 
Suppl. Figure 11.5). These findings indicate that the function of both mutant 
transporters is comparably affected and that voltage clamp fluorometry on P259R 
EAAT3 permits insights into the dysfunction of P290R EAAT1.  
We found that P259R inverts the voltage dependence of EAAT3 fluorescence 
intensities, changes the glutamate-induced fluorescence change and drastically 
decelerates the time dependence of these signals (Figure 11.2 and Figure 11.3). To 
describe the basis of these alterations we optimized a kinetic scheme developed to 
describe fluorescence signals as well as transport and anion currents of M205C 
hEAAT39. By modifying reactions that report on Na+-association/-dissociation to the 
transporter prior to glutamate in the outward or in the inward facing state, we could 
simulate all functional alterations by P259R. The obtained kinetic scheme correctly 
predicts the voltage, substrate and [Na+] dependence of fluorescence signals of 
mutant transporters (Figure 11.4, Table 11.2-5). Moreover, it accounts for decreased 
glutamate uptake and increased anion conduction in the absence of glutamate and 
predicts qualitatively the deceleration in the time course of fluorescence signals and 
anion currents by P259R (Figure 11.4).  
In EAAT3 three putative sodium binding sites have been identified as aspartate 
residues at position D368 (TM7), D440 and D455 (TM8)12, 18, 22, 29. Since P259 is not 
in close proximity to any of those residues (C-distances in the outward facing open 
conformation from P259 to: D368 = 26.3 Å, D440 = 21.2 Å, D455 = 24.4 Å), the 
structural basis for altered sodium binding to P259R hEAAT3 is not clear. Moreover, 
Na+-association should be a diffusion-controlled process, and the dramatic effect we 
observed for P259R on the Na+-association rates is difficult to imagine. We thus 
hypothesize that P259R does not affect the cation association itself, but rather an 
associated conformational change. This interpretation is supported by the saturating 
behaviour in the Na+ concentration dependence of time constants for M205C or 
M205C-P259R EAAT3 fluorescence changes. A possible Na+-associated 
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conformational change affected by P259R might be the opening of HP2 that is 
triggered by association of Na+ to the empty transporter 12.   
Proline often acts as structural disruptor of -helices and -sheets, and the 
conserved proline P259 at the hinge of TM5 might represent the structural 
determinant of the kinked shape of TM5 20. P259R might abolish the TM5 kink and 
cause an overall structural change of the trimerization domain of mutant transporters. 
The resulting change in the orientation of the transport domain towards the 
trimerization domain might impair certain conformational changes within the transport 
domain. Moreover, it possibly could alter the position of Na+ binding sites within the 
electric field. This hypothesis can explain the inversed voltage dependence of 
conformational changes (Figure 11.2) and the increased electrical distances 
simulated for sodium binding (Table 11.2). 
To quantitatively describe our results on P259R hEAAT3 we used a kinetic scheme 
that was developed to describe fluorescence signals as well as transport and anion 
currents of hEAAT3 carrying multiple reporter mutations. WT hEAAT3 as well as 
P259R hEAAT3 anion currents predicted by this scheme do not resemble measured 
currents. A possible explanation for this deviation is the complexity of EAAT transport 
functions and of the used kinetic scheme. For example, anion channel opening is 
coupled to transitions within the uptake cycle that can be directly observed by voltage 
clamp fluorometry9-13. However, it is currently not possible to determine anion 
channel opening and closing reactions experimentally. 
P259R as well as P290R result in dramatically increased EAAT3 and EAAT1 anion 
currents in the absence as well as in the presence of glutamate. For P290R EAAT1, 
we demonstrated that the increased anion current of mutant EAAT1 is accompanied 
by a reduced number of transporters in the surface membrane4. This finding is 
incompatible with noise analysis measurements that reveal an absolute open 
probability larger than 0.5 for WT EAAT14 or the very high absolute open probabilities 
predicted by the kinetic scheme developed here (Suppl. Figure 11.8). The 
approximately fourfold increase of EAAT3 anion currents by P259R will be only 
possible if noise analysis underestimates the number of active EAAT anion channels 
and thus overestimates their absolute open probability. We recently demonstrated a 
similar disagreement for the dual function anion transporter ClC-4, reporting that 
changes in the external [Cl-] alters the apparent number of ClC-4 channels 
determined by noise analysis without modifying the density of ClC-4 proteins in the 
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surface membrane30. We explained this behaviour by proposing two functional states 
of ClC-4, one functioning as transporter and the other one as channel, and transitions 
between these functional modes are mediated by association of Cl-. If the rate 
constant of Cl- binding is much faster than the opening transition of the channel, the 
proportions of ClC-4 without or with bound Cl− will equilibrate into a semi-equilibrium 
distribution, and noise analysis will only report on opening and closing transitions of 
the anion channels. The state diagram proposed for ClC-4 resembles the kinetic 
scheme used to describe hEAAT3. Since Na+-association is very fast for WT 
hEAAT3, noise analysis might provide incorrectly high absolute open probabilities of 
hEAAT3 anion channels via a similar mechanism. 
Gameiro et al.31 recently studied EAAT5 glutamate transport and anion currents. 
They reported that EAAT5 anion currents activate slowly upon membrane 
hyperpolarization and identified slow Na+-association as basis for the slow activation 
time course and the very low glutamate transport rates. Our result that the high 
capacity glutamate transporters EAAT1 or EAAT3 carrying a disease-causing 
mutation functionally resemble the low capacity glutamate transporter EAAT5 
beautifully illustrates the importance of the evolutionary optimization of EAAT isoform 
with distinct functional properties. 
 
 
 
11.6 Methods 
11.6.1 Expression of WT and mutant hEAAT3 transporters in Xenopus laevis 
oocytes or mammalian cells 
Point mutations were introduced into pTLN2-hEAAT324, 32 (kindly provided by Dr. 
Matthias Hediger (University of Bern, Switzerland)) or into pTLN2-hEAAT1 using the 
QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). Capped cRNA was 
synthesized from MluI-/NheI-linearized pTLN2-hEAAT through use of MESSAGE 
machine kits (Ambion, Austin, TX, USA). Collagenase-treated, defolliculated stage 
IV-V oocytes were microinjected with 10 ng of RNA (Nanoliter 2000, World Precision 
Instruments, Sarasota, FL, USA) and incubated at 18°C in ND96 (in mM: 96 NaCl, 2 
KCl, 1.8 CaCl2, 1 MgCl2, 5 Hepes, pH 7.6, supplemented with 2.5 sodium pyruvate 
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and 50 µg/ml gentamycine sulfate). Experiments were performed 3-7 days after 
injection.  
For expression in mammalian cells point mutations were introduced into pcDNA3.1-
hEAAT133 or pcDNA3.1-hEAAT334 and transiently transfected in tsA201 cells using 
the Ca3(PO4)2 technique as described
33. For each construct, two independent 
recombinants from the same transformation were examined and shown to exhibit 
indistinguishable functional properties. 
 
 
11.6.2 Voltage clamp fluorometry  
Current amplitudes were measured under two-electrode voltage clamp using a CA-
1B amplifier (Dagan Corporation, Minneapolis, MN, USA) and digitized at 5 kHz 
using an ITC-18 Computer Interface in combination with Patchmaster (HEKA 
Elektronik, Lambrecht, Germany). For fluorescence experiments, oocytes were 
labeled for 2-3 h with 10 µM of the fluorescent maleimide probe, AlexaFluor546 (Life 
Technologies Corporation, Invitrogen, Carlsbad, CA, USA). Incubation times were 
optimized for each construct as described13. A short arc mercury lamp (HBO 103W/2, 
Osram, München, Germany) combined with a Uniblitz shutter (VS25S2ZMOR1-24 
shutter, VCM-D1 shutter driver, Uniblitz, Vincent Associates, Rochester, NY, USA) 
was used as light source. Fluorescence was monitored under voltage clamp by a 
photodiode (PIN020-A, AMS Technologies AG, Martinsried, Germany) and a 
rhodamine filter cube (HQ535/50x, Q565LP,  HQ610/75m, Chroma Technology 
Corp., Bellows Falls, VT, USA) attached to an inverted fluorescence microscope 
(IX71, Olympus, Hamburg, Germany). Fluorescence signals were amplified with a 
DLPCA-200 amplifier (Femto Messtechnik, Berlin, Germany) and low pass-filtered at 
2 kHz (LPF-8, Low Pass Bessel Filter, Warner Instruments, Hamden, CT, USA). 
Experiments were performed under constant perfusion  using a PF-8 8-Channel 
Perfusion System (Abimek-Zech electronic, Göttingen, Germany) with Ringer’s 
solution (in mM: 98.5 Choline-Cl or NaCl/NO3/gluconate, 1.8 CaCl2/gluconate, and 1 
MgCl2/gluconate, 5 Hepes pH 7.5,  1 glutamate). Oocytes were held at 0 mV for at 
least 2 s between voltage steps, and representative fluorescence recordings were 
obtained by averaging ten consecutive measurements. 
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To permit site-directed fluorescence labeling of EAAT3, we introduced a single 
cysteine into hEAAT3 and expressed WT and cysteine-substituted transporters in 
Xenopus oocytes. We chose a mutation for fluorophore attachment localized in 
TM4c, M205C and additionally mutated the endogenous C158 to serine to prevent 
possible modifications by fluorophore application (for simplification further not 
nominated). Oocytes expressing M205C or M205C-P259R hEAAT3 exhibited higher 
fluorescence intensities than uninjected oocytes or oocytes expressing 
corresponding hEAAT3 without the reporter mutation (data not shown). Moreover, 
the fluorescence changes display characteristic voltage or substrate dependences13 
and could be inhibited by the EAAT-specific transporter-blocker DL-threo-
benzyloxyaspartate (TBOA) in the absence and in the presence of glutamate by 
about 90%13. These data strongly supports the notion that the studied fluorescence 
signals are specific for WT or mutant hEAAT3. 
 
 
11.6.3 Electrophysiology 
Standard whole-cell patch clamp recordings were performed using an Axopatch 
200B amplifier (Molecular Devices, Sunnyvale, CA). We routinely compensated at 
least 80% of the series resistance by an analogue procedure to reduce voltage 
errors, filtered currents at 5 kHz and digitized with a sampling rate of 20 KHz using a 
Digidata AD/DA converter (Molecular Devices, Sunnyvale, CA). Borosilicate pipettes 
were pulled with resistances of 1.5–2.5 MΩ and cells with currents more than 10 nA 
were excluded from the analysis. We used an internal solution containing (mM) 115 
KNO3, 2 MgCl2, 5 EGTA, 10 HEPES (pH = 7.4) and an external solution of (mM) 140 
NaNO3, 4 KCl, 2 CaCl2, 1 MgCl2, 5 HEPES (pH = 7.4) to study the effect of 1 mM 
external applied L-glutamate on WT EAAT1 and EAAT3 and mutant transporter-
mediated currents. The pH of the internal and external solution was adjusted to 7.4, 
with KOH or NMDG, respectively. 
 
 
11.6.4 Data analysis  
Electrophysiological and fluorescence data were analyzed with a combination of 
Patchmaster (HEKA Elektronik, Lambrecht,), pClamp10 (Molecular Devices, 
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Sunnyvale, CA, USA), MATLAB (The MathWorks, Natick, MA, USA) and SigmaPlot 
(Jandel Scientific, San Rafael, CA, USA). For statistical evaluations, Student’s t-test 
and paired t-test with p ≤ 0.05 (*) as the level of significance were used (p ≤ 0.01 (**), 
p ≤ 0.001 (***)). The data are given as the means ± S.E.. Apparent dissociation 
constants and hill coefficients were calculated by fitting the data with the Hill equation 
(F/F+150mV =y0+a*[Na
+]nH/(KD
nH+[Na+]nH). 
 
 
11.6.5 Kinetic modeling  
We recently established a kinetic scheme for WT hEAAT3 based on voltage- and 
substrate-dependent fluorescence signals, as well as on uptake currents and 
glutamate-sensitive relative current amplitudes13.  Based on the idea of four major 
conformations (inward/outward facing and substrate-bound/-unbound), all states 
were grouped into four different subsets with distinct relative fluorescence intensities 
for each construct. The first conformation corresponds to an empty transporter 
residing in an outward facing state with HP2 being open and the substrate binding 
sites exposed to the extracellular space (Foopen: ToK, To). Binding of sodium and 
glutamate causes closure of HP2 (Fooccluded: ToNa1, ToNa2, ToNa2G, ToNa2H, 
ToNa2GH, ToNa3GH) which is followed by the large movement of the whole 
transport domain (Fioccluded: TiNa3GH, TiNa2GH, TiNa2G, TiNa2, TiNa1). Opening of 
HP1 leads to substrate release and exposure of the binding sites to the intracellular 
solution (Fiopen: Ti, TiK). Whereas the first three conformations have been 
characterized at a structural level, the inward facing open state is at present only 
hypothetical. The overall fluorescence was calculated as sum of the products of 
relative fluorescence and probability of occupation for every state. Parameters for 
channel gating (open probabilities for leaving the cycle into the conducting state) 
were estimated by optimizing the model against WT steady-state fluorescence data 
using the genetic algorithm as implemented in MATLAB (The MathWorks, Natick, 
MA, USA). The so-determined model was then adapted to the P259R mutant by 
modifying sodium-binding rates (reactions 1, 2 and 12, 13) and electrical distances 
z. In all cases, detailed balance was preserved, and fitting parameters were 
simultaneously optimized against experimentally determined relative glutamate 
uptake and relative glutamate-induced current amplitudes at -100 mV. For kinetic 
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modeling we assumed intracellular concentrations of [Na+] = 10 mM, [K+] = 70 mM, 
[glu] = 12 mM and a pH = 7.327, extracellular concentrations were set to experimental 
conditions. 
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11.9 Supplemental Figures and Information  
P259R results in altered residence probabilities for hEAAT3 transport states 
Modification of the rate constants of reaction 1, 2 12 and 13 produces a shift of the 
residence probability of EAAT uptake cycle states by P259R (Suppl. Figure 11.7). In 
the absence of glutamate, mutant transporters reside with higher likelihood in To than 
WT, and sodium-bound states are slightly less occupied, consequently resulting from 
a weaker sodium binding to P259R EAAT3. Furthermore there is a low probability of 
the occupation of the state TiNa1. In the presence of glutamate, M205C EAAT3 
resides mostly in the glutamate-bound outward facing states and to a lesser extent in 
the inward facing states. M205C-P259R hEAAT3 transporters are almost not 
occupying the inward facing states, except of TiNa1, explaining the lower transport 
capability of mutant EAAT3.  Instead of residing in the inward facing states, To and to 
a lesser extent the outward facing sodium- and glutamate-bound states are occupied. 
 
Suppl. Figure 11.5  
P290R alters EAAT1 glutamate-activated anion currents and uptake currents in 
mammalian cells and oocytes similar to P259R in EAAT3 
 
 
Suppl. Figure 11.5: P290R alters EAAT1 glutamate-activated anion currents and uptake 
currents in mammalian cells and oocytes similar to P259R in EAAT3. 
A, representative current recordings from tsA201 cells expressing WT or P290R EAAT1 with standard 
KNO3-based internal solution and a NaNO3-based external solution before (light grey, top) and after 
application of 1mM glutamate (black, bottom). B, averaged uptake currents at -100 mV of oocytes 
expressing WT or P290R EAAT3. Uptake currents were calculated as difference of current amplitudes 
with and without glutamate measured in a chloride-free solution. Student’s t-test and paired t-test with 
p ≤ 0.05 (*) as the level of significance were used (p ≤ 0.01 (**), p ≤ 0.001 (***)). The data are given as 
the means ± S.E.; n ≥ 8. 
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Suppl. Figure 11.6  
Sodium dependence of WT, M205C and M205C-P259R EAAT3 
 
 
Suppl. Figure 11.6: Sodium dependence of WT, M205C and M205C-P259R EAAT3.  
A, B and C, dose-response curves of late current amplitudes versus the sodium concentration of WT, 
M205C or M205C-P259R EAAT3. Apparent dissociation constants (KD) (in mM) and hill coefficients 
(nH) were calculated by fitting the data with the Hill equation. Current amplitudes are normalized to the 
current in 197 mM sodium. Fluorescence data from at least 7 oocytes are reported as means ± S.E.. 
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Suppl. Figure 11.7 
Simulated conformational changes, uptake and anion currents of M205C and 
M205C-P259R EAAT3 
 
Suppl. Figure 11.7: Residence probability of each state of EAAT3 transport cycle. 
A, B simulated residence probability of each state for M205C (A) or M205C-P259R  EAAT3 (B) without 
(top) or in presence of glutamate (bottom) at -150 mV (black line), 0 mV (blue line) or +150 mV (red 
line). 
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Suppl. Figure 11.8 
Simulated open probabilities of M205C and M205C-P259R EAAT3 anion 
channels  
 
Suppl. Figure 11.8: Simulated open probabilities of M205C and M205C-P259R EAAT3 anion 
channels. 
A, B simulated open probabilities for M205C (A) and M205C-P259R (B) EAAT3 in the absence of 
glutamate (grey lines) or in the presence of 1 mM glutamate (black lines) at voltages between -150 mV 
and +150 mV. 
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12 Abbreviations 
 
Amino acids  
  
A  (Ala) alanine 
C  (Cys) cysteine 
D (Asp) aspartic acid  
E (Glu) glutamic acid 
F (Phe) phenylalanine  
G (Gly) glycine   
H (His) histidine   
I (Ile) isoleucine   
K (Lys) lysine  
L (Leu) leucine   
M (Met) methionine  
N (Asn) asparagine   
P (Pro) proline   
Q (Gln) glutamine   
R (Arg) arginine   
S (Ser) serine   
T (Thr) threonine   
V (Val) valine  
W (Try) tryptophan  
Y (Tyr) tyrosine 
  
  
  
General abbreviations 
 
AMPA 

amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
ATP adenosine triphosphate 
BN blue native 
CFP cyan fluorescence protein 
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CNS central nervous system 
DTT dithiothreitol 
EA episodic ataxia 
EAAC1 excitatory amino-acid carrier 1 
EAAT excitatory amino acid transporter 
EDTA ethylene-diamine-tetra-acetic acid 
2-FAA β-2-fluorenyl-aspartylamide 
GABA γ-aminobutyric acid 
GFP green fluorescence protein 
GLAST glutamate aspartate transporter 
GLT1 glial glutamate transporter 1 
GltPh glutamate transporter in Pyrococcus horikoshii 
HEK human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HP hairpin 
MDCK Madin Darby canine kidney 
MES 2-(N-morpholino)ethanesulfonic acid 
mGluR metabotropic glutamate receptor 
NMDA N-methyl-D-aspartic acid 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
SDS sodium dodecylsufate 
SLC solute carrier  
TBOA threo--benzyloxyaspartate  
TM transmembrane domain 
tsA201 HEK cell line 
VCF voltage clamp fluorometry 
VGLUT vesicular glutamate transporter 
WT wildtype 
YFP yellow fluorescence protein 
ZNS Zentrales Nervensystem 
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